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Abstract 
A series of novel europium(III) based anion receptors [Eu.1-8] for nucleoside 
polyphosphate anions have been designed and synthesized. A study of their binding 
abilities was carried out in buffered aqueous media against a range of biologically relevant 
anions. It was demonstrated that certain probes could be used in biological applications 
such as real-time monitoring of enzymatic activity and real-time monitoring of ATP 
concentrations in living cells. Chapter 2 describes the synthesis of the 8 cationic Eu(III) 
complexes, each  based on a cyclen macrocyclic scaffold and two quinoline arms in a trans 
relationship, which serve as antennae for the sensitisation of the central Eu(III) ion. 
Modifications in the structure of the complexes included varying the hydrogen bond donor 
groups on the quinoline arms (hydrogen, amide or an urea moiety) and the nature of the 
ligand donor groups to vary the local charge at the Eu(III) metal centre.  The photophysical 
properties of all 8 complexes were characterised and the two urea bearing compounds 
proved unsuited for anion sensing as they do not possess a coordinated water molecule in 
the absence of added anion, preventing the displacement of water by an anion.  Chapter 3 
focuses on the behaviour of the 6 remaining Eu(III) complexes towards numerous 
biologically relevant anions in buffered water. The probes bearing the hydrogen moieties 
showed very little selectivity and low affinity towards the target anion ATP. On the other 
hand, probes bearing the amide moiety proved selective towards polyphosphate anions 
with high affinities. Additionally, polyphosphate anions when displacing the bound water 
molecule of such probes induced significant spectral changes and a large increase (up to 
14-fold) in the emission intensity. In Chapter 4, discovery was made that in presence of 
magnesium the probe [Eu.5]
+
 could bind to Mg-ATP
4-
 and the induced change in emission 
spectra was even stronger than in water. The real time monitoring of the apyrase enzyme 
reaction was carried out (which converts ATP to ADP) showing that the probe could 
correlate rate of reaction to the amount of enzyme added.  Multiple different enzymes were 
studied using [Eu.2]
+
 and a short summary of the most exciting results is provided at the 
end of Chapter 4. The probe [Eu.5]
+
 was shown to bind weakly to proteins contrary to 
[Eu.2]
+
, and was therefore suitable for visualising ATP concentrations in living cells. 
viii 
 
Chapter 5 describes the application of [Eu.5]
+
 to successfully monitor elevated and 
depleted ATP levels in living cells.   
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 Introduction Chapter 1:
 
1.1. Adenosine triphosphate and polyphosphate anions 
 
1.1.1. Biological anions 
 
In the human body multiple anions are present; they can be classified in two main 
categories. First the ‘simple’ inorganic anions such as Cl-, OH-, HCO3
-
, H2PO4
–
, P2O7
4-
 and 
SO4
2-
. This category represents the largest composition of anions in the body and they 
correspond to different biological functions and play numerous biological roles. For 
example, chloride is important in maintaining hydration, balancing cations and maintaining 
the electrical neutrality of the extracellular fluid.
1
 Bicarbonate is a by–product of the 
metabolic glycolysis and the Krebs cycle, it is believed to play a key role in the respiration 
of the cell as it allows it to modulate it according to the availability of the nutrients.
2
 A 
major constituent of intracellular fluid, phosphate is important in the regulation of 
metabolic processes and also acts as a buffering agent in cells.
3
 Dysregulation of the levels 
of these anions leads to disease, for example, hyperchloremia and cystic fibrosis occur as a 
result of dysregulated chloride levels.
4
 
Organic anions, the second category comprise a wide range of anions such as 
lactate, citrate, urate, ascorbate and nucleoside polyphosphate anions (Figure 1.1). Lactate 
plays a key role in the regulation of oxygen levels in muscle during exercise.
5
 Citrate is 
responsible for binding to calcium to avoid crystallisation of calcium salts.
6
 Dysregulation 
of citrate levels leads to the formation of urinary stones.
7
 Urate is a useful diagnostic tool 
as it is the final step of most purine metabolism.
8
 Abnormal urate levels can be used to help 
diagnose multiple diseases such as familial nephritis, neurological abnormalities for 
example.
9
 Phosphate oxyanions including adenosine triphosphate (ATP) or guanosine 
triphosphate (GTP) are key metabolites and their detection and quantification in biological 
2 
 
fluids and cellular compartments can be used to understand biological signalling 
mechanisms.
10
 
 
Figure 1.1: Structures of organic anions 
 
1.1.2. Nucleoside phosphate anions  
 
Nucleoside phosphate anions are composed of one, two or three phosphate groups 
attached to the 5’–position of a ribose or deoxyribose sugar, which is attached to a 
nucleotide base at the 1’ carbon atom (Figure 1.2). Nucleoside phosphates are based on 
adenine, thymine, uracil, cytosine and guanidine, which comprise the five bases used to 
form DNA and RNA.  
Nucleoside triphosphate (NTP) anions serve as a source of energy for most cellular 
chemistry. Upon conversion of the ribose unit of NTPs to a deoxyribose, the deoxy 
nucleoside triphosphates (dNTP) are formed, which are utilised by polymerase enzymes 
for DNA synthesis.  
Cytidine triphosphate (CTP) is a coenzyme in metabolic reactions, such as the 
synthesis of glycerophospholipids and glycosylation of proteins.
11
 GTP is essential for 
signal transduction,
12
 in particular with G–proteins located at the cell membrane and in 
second–messenger mechanisms, where it is converted to guanosine diphosphate (GDP), 
through the action of GTPases. Extracellular uridine triphosphate (UTP) stimulates 
vasodilatation, indicating that UTP may be important in cardiac regulation. 
13
 
  
3 
 
 
Figure 1.2: Nucleoside phosphate anions 
The nucleoside phosphates can be separated into two families: purines and 
pyrimidines. Members within a family are closely interconnected and nature has many 
pathways for transformation of one member into another.
14
 Most of these processes are 
catalysed by specific enzymes. There is a close relation in chemical structure and shape 
between these molecules. Variations in the concentration of one nucleoside phosphate has 
an impact on the relative concentrations of the related anions.  
Table 1.1 shows the average concentration of the most common nucleotides in the 
human body.
14
 This concentration has been calculated by taking the average of over a 
hundred different papers and reviews using a range of common measurement methods. 
These concentrations should be taken with caution, as methods to reliably measure these 
anion concentrations in cells are limited. In the measurement process, the cells are killed 
which may induce a variation in the concentrations of certain molecules. The concentration 
of nucleotides may also vary significantly dependent on the cell type or the sub–
compartment of the cell.
15
 However, these values can give us a guideline regarding the 
relative concentrations of the different nucleotides. The most abundant species are the 
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nucleotide triphosphates, with ATP being approximately 7 times more abundant compared 
to its analogues. This difference in concentration renders the detection of ATP possible as 
competing molecules are present in comparatively small amounts. 
Table 1.1: Average concentrations (expressed in µM) of various purines and 
pyrimidines in the average human cell
14
 
Adenine Adenosine AMP ADP ATP dATP 
0.4 0.5 82 137 2102 2.4 
Guanine Guanosine GMP GDP GTP dGTP 
97 0.9 32 36 305 2.7 
Cytosine Cytidine CMP CDP CTP dCTP 
1.5 0.6 67 0.8 91 4.5 
Uracil Uridine UMP UDP UTP dUTP 
1.3 5.2 / 3.5 253 0.7 
 
1.1.3. Adenosine triphosphate and its derivatives 
 
Adenosine triphosphate (ATP) is the main energy currency for most biological 
functions. This molecule stores chemical energy, generated from respiration, and is able to 
release it.
16
 ATPase enzymes catalyse the hydrolysis of ATP and release 31 kJ mol
–1
 of 
energy upon cleavage of a single phosphate group.
17
 In protein phosphorylation, ATP is 
transformed into adenosine diphosphate (ADP) by kinase enzymes (Figure 1.3), 
transferring the terminal phosphate group of ATP to an amino acid residue (usually serine, 
threonine or tyrosine) on a protein. This phosphorylation process is essential for signal 
transduction, regulation of enzyme activity, and switching protein function ‘on’ and ‘off’.18 
5 
 
 
Figure 1.3: Common transformations of ATP by different enzymes. 
ATP can also be transformed by the enzyme, adenylate cyclase, into cyclic 
adenosine monophosphate (cAMP), a key regulator of the cellular energy levels. For 
example, cAMP is involved in regulation of the amount of adrenaline and glucagon in the 
cell, and is also required for controlling the action of ion channels.
19
 ATP is also utilised in 
RNA transcription, a process catalysed by RNA polymerase, and in DNA synthesis by 
DNA polymerase. In this process, the ribose sugar of ATP must first be converted into 
deoxyribose, catalysed by ribonucleotide reductase.
20,21
 
 
1.1.4. Recognition of ATP by synthetic receptors 
 
The selective recognition of ATP by synthetic receptors is an active area of 
research within supramolecular and bio-active chemistry.
22–31
 The ability to determine the 
concentrations of ATP in the different compartments of living cells could provide a better 
understanding of the way in which energy is produced, transported and consumed within 
the cell, allowing a comparison of metabolism in diseased versus healthy cells.
32
 
Additionally, the ability to detect and measure ATP concentrations rapidly in biological 
samples has a number of applications in biomedical research.
33
 A synthetic receptor for 
ATP could be used to monitor the enzymatic consumption of ATP as a function of time. 
For example, it may be possible to monitor the activity of kinase enzymes, which convert 
ATP to ADP during protein phosphorylation.
34
 The ability to measure enzyme activity in 
real-time could allow the determination of enzyme kinetics and mechanism, or facilitate 
the screening of enzyme inhibitors in drug discovery programmes. 
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1.2. Synthetic receptors for anions 
 
The chemistry of anion recognition has expanded significantly over the last two 
decades and has involved the synthesis of many selective anion receptors.
35–37
 To date, a 
large number of receptors have been developed based on many different molecular hosts 
for a range of different anions. Selective anion recognition is achieved by hydrogen–
bonding interactions, electrostatic interactions, metal–ligand coordination, π–π stacking 
and hydrophobic interactions.
38
 This host–guest complementarity can lead to high 
selectivity for a particular anion.
39–41
 
The field of anion receptor chemistry is very large, and several excellent reviews 
and books have emerged in this area.
42–46
 Further discussion within this thesis will focus on 
receptors for nucleoside phosphate anions. 
An anion receptor that can signal the presence of a particular anion by a measurable 
change is known as a chemosensor (or probe).
47
 The most common method used to signal 
anion binding involves the attachment of a signalling subunit (or indicator) close to the 
anion binding site of the receptor via a spacer (Scheme 1.1).
42
 Anion binding is signalled to 
the observer, often in the form of a colour change,
48
 modulation of fluorescence 
emission
49,50
 or an electrochemical shift of the redox potential.
51
 
 
Scheme 1.1: General design of a chemosensor (or probe) for anions 
A colorimetric signalling unit has the advantage of providing a signal that is visible 
by the ‘naked eye’.52 This allows the rapid detection of anions, and does not require 
expensive instrumentation. A fluorescent signalling unit, which provides a measurable 
change in the fluorescence emission, has the advantage of being highly sensitive and 
allows quantitative measurements of the binding affinity. Other signalling methods include 
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monitoring changes in redox potential (e.g. using ferrocene)
36
 or the chemical shift of an 
nuclear magnetic resonance (NMR) signal (e.g. 
1
H, 
19
F).
42,53
  
 
Figure 1.4: Bromide-selective probe by Steed et. al.
54
 
For example, 
1
H NMR spectroscopy was used by Steed and co-workers to assess 
the binding affinity of the bromide-selective probe 1.1 shown in Figure 1.4.
54
 It was found 
to bind bromide very strongly to due to its capacity to form a capsule in which the bromide 
ion could sit. Another example is the use of the probe shown in Figure 1.5 by Paul Beer’s 
research group, they synthesised a number of redox active ferrocene probes using halogen 
bonding to detect various anions. 
55,56,57
 
 
 
Figure 1.5: An example redox potential sensor for halogens by Beer & al.
58
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During the past 20 years several probes for the detection of ATP have been 
developed and a brief overview of progress in this field is provided in the following 
section. However, to develop an effective probe for detecting ATP, several issues must be 
addressed: 
 
1.2.1. Affinity 
 
The affinity of the probe for ATP in aqueous solution is of key importance. Anions 
are highly solvated in water,
59
 and the probe must bind to ATP with sufficient affinity to 
overcome the high hydration energy (see Table 1.2).
35
 Some very interesting probes have 
been synthesised with high affinity to ATP; with the range of detection in the micro to 
nanomolar range.
24,31,43,60–64
 However, such probes may not be useful for measuring 
cellular ATP levels, as the expected cellular ATP concentration (1 – 5 mM)65 is much 
higher, potentially leading to saturation of the optical signal. The exact nature of the 
medium under investigation defines the affinity needed between the probe and the anion. 
 
1.2.2. Selectivity 
 
It is important that the probe binds to ATP with a higher affinity than structurally 
similar phosphate anions, such as ADP, AMP, pyrophosphate (PPi) and inorganic 
phosphate (PO4
3–
).
35
 In many existing probes for ATP, other anions such as PPi and ADP, 
can bind to the probe and induce similar responses to that of ATP, hence the selectivity is 
rather poor.
61,62
 Other potentially competing anions include the nucleoside triphosphates 
(UTP, CTP and GTP, Figure 1.2). It should be noted that a probe does not necessarily 
have to bind most strongly to ATP for the probe to exhibit discrimination between 
structurally similar anions. The key to a functional probe is to provide a spectral response 
for the target anion that is distinct from those observed for structurally related anions.  
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1.2.3. Compatibility with physiological conditions 
 
A number of probes have been developed that function in organic media,
66–70
 
however, the transferability between organic and aqueous media in terms of probe stability 
and function, is often minimal or even non–existent.49 In order for the probe to have any 
biological application, it must be soluble in water, and show high affinity and selectivity 
for ATP at physiological pH. For use in cells it must also be non–toxic. Additionally a 
fluorescent probe must resist quenching by endogenous proteins and operate over a wide 
pH range.
71
 
Water has a high dielectric constant and interacts intermolecularly via a network of 
hydrogen bonds.
45
 As a consequence, anions that are highly polar are strongly solvated. 
Thus the binding between a synthetic probe and a guest anion has to be strong in order to 
overcome the high hydration energies (Table 1.2).
35
 A property of water that must also be 
considered is that non–polar molecules tend to aggregate, a hallmark of the hydrophobic 
effect.
72
 This process is driven by entropy; the release of ordered water molecules as two 
non–polar molecules come together.73 
Table 1.2: Free energies of hydration of some common anions.
51
 
Anion F
-
 Cl
-
 OH
-
 NO3
-
 HCO3
-
 H2PO4
-
 SO4
2-
 
Hydration 
energy 
(kJ/mol) 
465 340 430 300 335 465 1080 
 
Cellular media is not comparable to bulk water. In addition to the issues associated 
with the detection of anions in water, cells contain high concentrations of macromolecules 
(e.g. proteins), and competitive anions and cations, and small molecules (e.g. glutathione). 
When designing a probe, it is thus necessary to have a complete understanding of the 
media in which it is hoped to work. Anion structures and properties can be pH dependent 
(e.g. phosphates and hydrogen carbonates) or dependent on the composition of the aqueous 
10 
 
solution of interest. For example, in the presence of magnesium(II) ions, ATP exists 
largely in the form ATP-Mg
2-
.
74,75
  
On a more practical note, other parameters are important for a probe to be applied 
for biological measurements. The probe needs to be thermodynamically stable at 
physiological pH and kinetically inert. Its photostability is also crucial as most biological 
processes require time (minutes to hours) to occur and the probe needs to show minimal 
photobleaching over an appropriate time frame.
76
 Finally, the probe should have minimal 
cytotoxicity; if the probe induces changes in the cell or induces apoptosis the 
measurements are not reliable. 
1.2.4. Providing a robust, reliable response 
The majority of existing ATP probes signal the presence of ATP using an ‘off/on’ 
or ‘on/off’ spectral response (Figure 1.6 (a)).27,60,63,77–79 The variation in the relative 
intensity of a fluorimetric or colorimetric signal is used to detect the amount of ATP 
present. However, this method has a drawback, because the relative intensity of the probe 
signal is dependent on the amount of probe present, not just on the amount of anion 
present. In a cellular environment, where the probe concentration may vary considerably 
from one sub–cellular compartment to another, unreliable readouts may be given.  
  
 
Figure 1.6: Example of different spectral responses: a) an ‘off/on’ spectral 
response. b) a ratiometric spectral response 
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 It is more appropriate to design a probe that can provide a ratiometric response 
(Figure 1.6 (b)). A ratiometric response involves measuring the change in emission 
intensity at two different wavelengths, to determine the ratio of intensities. This has two 
advantages: firstly, the intensity ratio is independent of probe concentration. Secondly, 
other potential interfering anions may not interfere with both of the response wavelengths, 
leading to higher level of discrimination for the target anion.
80
 
 
1.3. Examples of ATP probes 
 
1.3.1. Recognition of ATP by enzymes 
 
Enzymes, such as kinases and adenylate cyclase, have developed highly efficient 
methods to bind to ATP with high selectivity, by utilizing a number of cooperative non–
covalent interactions.
81
 A number of kinases (e.g. Spleen tyrosine kinase (SYK),  Leucine–
rich repeat kinase 2 (LRRK2)) form two hydrogen bonding interactions with the adenine 
moiety of ATP, by providing one hydrogen donor and one hydrogen acceptor.
82
 In addition 
several other interactions are used to ensure selective recognition of ATP, such as the 
creation of a hydrophobic pocket around the adenosine moiety. The geometric 
conformation of the kinase creates a hydrophobic cleft, in which ATP can bind. Finally, the 
triphosphate fragment of ATP may engage in electrostatic interactions with positively 
charged amino acid residues (e.g. lysine, arginine) on the protein. In the human cell, free 
ATP levels are low, the majority of ATP is bound to magnesium(II).
14,83,84
 Magnesium(II) 
plays a role in the binding as it stabilises the negative charge of ATP, reducing free ATP
4–
 
down in charge to ATP–Mg2–. All of these interactions combined lead to a very stable 
ATP–bound complex.29,85 
A number of research groups have tried to adapt peptides to ATP sensing, creating 
metal-free host molecules.
23,29,48,60,86
 Schmuck and co–workers studied the X-ray crystal 
structures of some phosphate binding proteins and discovered that two thirds of them do 
12 
 
not contain a metal ion in the binding domain.
29
 Instead, positively charged amino acids, in 
particular lysine and arginine, are used for ATP binding. They reported, in 2017, a probe 
using a naphthalimide sensing moiety on a synthetic peptide. Two freely moving arms 
extend from the central fluorophore and contain multiple binding sites, such as 
guanidinium groups, for binding to the phosphate and tryptophan moieties for π-π stacking 
with the base (Figure 1.7). The peptide-based probe can adopt different conformations, 
wrapping around ATP and turning on the fluorescence (λem = 540 nm), with a 4-fold 
increase in emission intensity in the presence of 10 µM ATP. The selectivity reported by 
the binding affinity is modest compared to all the phosphate nucleotides (e.g. ATP, ADP, 
GTP, CTP, UTP, TTP and PPi all bind with the same order of magnitude in HEPES buffer 
pH 7.4), but the change in emission intensity is more significant for ATP than for other 
polyphosphate anions (4 times increase for ATP compared to 2–3 times for all other 
anions). A cellular study was conducted and showed that the probe could be used to detect 
ATP in cells. It crosses the cell membrane, it was shown to be non–toxic and fluorescent. 
However, the probe exhibits short-lived fluorescence that may be obscured by other 
endogenous fluorescent molecules (e.g. proteins). Additionally, the fluorescence signal is 
not ratiometric, and the competition study with other anions was rather small to conclude 
that the increase in emission in cells is coming from ATP alone. 
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Figure 1.7: Binding model and chemical structure of the synthetic peptide probe 
designed by Schmuck & al.
29
 
 
1.3.2. Use of metal complexes for the detection of anions 
 
Synthetic anion receptors that utilise hydrogen bonding alone usually only work in 
aprotic solvents (e.g. DMSO, chloroform) because the energies of dissolution are much 
14 
 
lower.
87
 To overcome this limitation, strong electrostatic or metal ligand interactions can 
be used, which are stronger than other non–covalent interactions in water.35 For example 
the interaction of zinc(II) with phosphate derivatives is the only driving force used by 
Kimura et al.
88
 in their phosphate-selective probe 1.4 (Figure 1.8). 
 
Figure 1.8: Kimura's probe using metal–ligand interactions 
Butler and Parker
35
 distinguished 2 types of approach to synthetic probe design: i) 
without direct metal ion coordination (only relying on weak interactions such as hydrogen 
bonding and hydrophobic effect) and ii) with metal ion coordination where the anion 
displaces bound water molecules or a weakly bound ligand. Metal ions often display a 
geometrical preference for anion binding compared to other strong interactions such as 
pure electrostatic interactions. In aqueous media, a metal–ligand interaction is strong; it is 
the combination of electrostatic interactions and ligand field stabilization.  
As described previously, binding between a probe and anion needs to induce 
modulation of some parameter that can be measured. Ideally, this should be independent of 
the local probe concentration and be tuned to respond within the target anion concentration 
range. Emissive metal complexes can be very sensitive, the response time is fast and 
spatial resolution is optimal, allowing their use in cellular imaging.
89–94
 Finally, metal ions 
possess an extensive excited state chemistry.
95
 Emission is dependent on a number of 
parameters and may be ligand centred, using singlet, triplet, charge transfer and metal–
centred emissive processes. Modification of the ligand can vary any of these parameters 
giving a wide range of leverage for a chemist to tailor the probe to their application. 
Hamachi and co–workers reported some of the first metal complexes for the 
detection of ATP, using zinc(II) as the metal ion.
61
 Their initial probe 1.5 (Figure 1.9) was 
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based on a substituted anthracene fluorophore, linked to two zinc(II) dipicolylamine groups 
(Dpa•Zn). These Dpa•Zn probes have been used widely for the detection of phosphate 
species, including hydrogen phosphate
66
, pyrophosphate
96–98
 and phosphorylated 
peptides/proteins.
99
 
 
Figure 1.9: One of the first ATP sensors based on Dpa•Zn ligands.61  
The association constant between ATP and probe 1.5 was found to be log Ka = 6.3
 
in 10 mM HEPES buffer (pH 7.2). This molecule did not bind to non–phosphorylated 
anions (e.g. HCO3
-
) but showed minimal selectivity between the different phosphate 
derivatives, binding strongly to ADP (log Ka = 5.3) and AMP (log Ka = 4.8). The probe 
relies on a relative change in fluorescence intensity (centred at 450 nm) to signal anion 
binding and does not provide a ratiometric response. Furthermore, the study was performed 
using micromolar concentrations of ATP (0 – 20 µM); much lower than the ATP levels 
typically present in cells (1 – 5 mM), which would induce saturation of the fluorescence 
signal. 
Later they reported a new probe for ATP,
100
 also based on the Dpa•Zn binding 
motif, using a xanthone fluorophore (Probe 1.6, Figure 1.10). The selectivity and affinity 
of this probe for ATP are similar to the previously reported compound but the signalling 
method has changed as this probe provides a ratiometric repsonse. Two bands appear and 
move differentially upon binding to ATP (centred at 320 and 370 nm). 
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Figure 1.10: Hamachi’s Dpa•Zn probes based on a xanthone fluorophore.30,100 
The next improvement implemented by the Hamachi group was reported in 2012.
30
 
They reported the synthesis of a similar ATP probe but with an attached lipid anchor, for 
extracellular imaging (Probe 1.7, Figure 1.10). Thanks to the lipid anchor which localized 
in the plasma membrane, they were able to detect extracellular ATP and to monitor its 
level upon addition of ATP to the media. Unfortunately, the ability to perform ratiometric 
analysis in pH 7.4 water was not transferred to the cells.  
 
1.3.3. Use of electrostatic interactions 
 
In 2009, Yoon and co-workers reported a probe, comprising two arms linked via an 
aromatic ring; each arm possesses a pyrene group at the end and a bis-methyl imidazolium 
group (Figure 1.11).
86
 The imidazolium groups bind to the phosphate fragment of ATP by 
electrostatic interactions and the pyrene groups engage in π–π interactions with the adenine 
moiety of ATP. 
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Figure 1.11: ATP probe with two imidazolium arms
86
 
 
The reported affinity constant of probe 1.8 for ATP was Ka = 1.3 x 10
4
 M
–1
 in 
buffered water at pH 7.4. The probe showed a good response to micromolar concentrations 
of ATP (0–10 µM). However, the emission signal is saturated for ATP concentrations 
higher than 200 µM. Upon the addition of ATP, a unique emission band at 350 – 400 nm is 
observed, whereas other anions such as GTP or pyrophosphate only showed emission 
centred at 500 nm.  The fact that this detection system is ratiometric makes this compound 
one of the more promising ATP selective probes developed over the last decade. However, 
binding affinities for ADP and AMP were not reported, and the potential interference of 
these anions was not assessed in vitro.  
 
1.3.4. Use of hydrogen bonding for ATP detection 
 
Some probes for ATP have been designed that only utilise hydrogen bonding. 
Compounds based on a tri–serine or tri–lactone scaffold, on which there are three thioureas 
or sulfonamide moieties, were reported by Anzenbacher (Figure 1.12).
101
 These moieties 
are well known strong hydrogen bond donors, and can detect ATP levels in serum using 
the fluorescence of a dimethylaminonaphthyl group, which is quenched in the presence of 
ATP for the sulfonamides and enhanced for the thioureas. However, anion titration 
18 
 
experiments were conducted in acetonitrile, indicating poor solubility of the compounds in 
water and the response is a simple on/off or off/on system and not ratiometric. 
 
Figure 1.12: Anzenbacher’s design for hydrogen bonding ATP probes.101 
 
1.3.5. Other methods for ATP detection  
 
It should be noted that other methods exist to assess ATP levels without using 
synthetic receptors or binding interactions. For example, historically many groups used 
radiolabelled ATP for kinase assays.
102
 Protein kinase activity results in the incorporation 
of radiolabelled phosphate from [γ–32P]ATP into a peptide or protein substrate. The 
measurement of the amount of radiolabelled phosphate incorporated into a substrate and 
allows enzyme activity to be quantified and the level of ATP utilized to be assessed. 
However, radiolabelled substrates require very careful handling and disposal procedures, 
and this method does not provide real-time measurements of ATP levels  
The current commercial kits for the detection of ATP levels used by biologists are 
based on the enzyme, luciferase and its substrate luciferin.
103
 Upon addition of ATP the 
enzyme breaks down luciferin resulting in bioluminescence. The process is very sensitive 
and works in the range 0.1 nM – 1µM.104 However, this is a destructive method as ATP is 
consumed in the process.  
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1.4. Lanthanide complexes 
 
In the past twenty years, lanthanide complexes have been used widely for the 
detection of anions.
35,105–108
 The unique properties of lanthanide ions provide a versatile 
tool kit for the chemist, biologist, and the imaging scientist to exploit. The classical design 
is to have the lanthanide ion encapsulated in a ligand, usually comprising a macrocycle and 
a chromophore that can sensitise emission of the Ln(III) ion. The ligand provides a number 
of coordination sites for the metal (usually 7 or 8) with at least one coordination site 
available for water. Stable europium(III) and terbium(III) complexes present several 
advantages over classic fluorescent molecules such as a large separation between the 
excitation and emission spectra, long emission lifetimes and sharp emission bands. These 
features are discussed in more detail below. 
 
1.4.1. Designing luminescent macrocyclic lanthanide complexes 
 
 
Figure 1.13: The general design of macrocyclic lanthanide complexes 
Designing a responsive macrocyclic lanthanide complex can be challenging 
because of the number of parameters that can be modified. This section will present the 
modifications that can be made to different moieties of the probe and their effects. 
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1.4.1.1. Hydration state 
The most classic design of macrocyclic lanthanide complexes for sensing is to 
modulate the hydration state upon binding a target analyte. When bound to a water 
molecule the emission of europium(III) is quenched because of energy transfer to O–H 
oscillations (Figure 1.15). Displacement of bound water molecules by an anion thus allows 
the luminescence to be ‘switched on’. 
An example of a europium based sensor for carboxylate groups in proteins has been 
developed recently (Figure 1.14);
109
 the design is simple as it is made of a macrocycle 
cyclen which provides four coordination sites to europium(III). Three of the cyclen 
nitrogen atoms are functionalised with carboxylate moieties, which provide three more 
oxygen donor atoms. The fourth cyclen nitrogen atom is functionalised with the 
fluorophore, which acts as an ‘antenna’, absorbing light energy and transferring it to the 
Eu(III) ion. The carboxylate groups present in proteins binds to the europium(III) ion, 
displacing the bound water, providing an increase in luminescence.  
 
Figure 1.14: Simple europium probe for the detection of carboxylates.
109
 
 The hydration state, q, represents the number of bound water molecules that can be 
displaced upon binding of the anion of interest. Experimentally the hydration state can be 
calculated using the luminescence lifetime of the probe in water and deuterated water, 
using the equation:
110
 
q =  A ∗ ( 
1
τ(H2O)
−
1
τ(D2O)
) − 𝐶 
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Where A and C are intrinsic properties of the lanthanide ion, for europium A = 1.2 
ms and C = 0.25 + 0.075x where x is the number of proximal N–H oscillators. For terbium, 
A= 5 ms and C= 0. Care should be taken in the interpretation of calculated q values since 
errors are often significant (± 0.5).
110
 
 
Figure 1.15: Cartoon representing the anion sensing mechanism of an Eu(III) 
probe: when one water molecule is bound the emission is quenched, but when the 
anion displaces it the luminescence is enhanced. 
1.4.1.2. Macrocyclic chelates 
 
The macrocycle must form a complex that stabilises the Ln(III) coordination sphere 
over a wide pH range. Both 1,4,7–triazacyclononane (9N3) and 1,4,7,10–
tetraazacyclododecane (cyclen) (Figure 1.16) provide excellent scaffolds for the 
development of Ln(III) based probes, giving complexes with high stability and kinetic 
inertness.
111–115
 The presence of the chelating ligand is necessary, especially for 
bioimaging, as the toxicity of the free lanthanide ions is high.
116–118
  The scaffold also 
needs to shield surrounding solvent from the lanthanide ion to prevent energy dissipation. 
 
Figure 1.16: Macrocycles commonly used for Ln(III) complexes 
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The lanthanide ions have a preferred coordination number usually between 8 and 9, 
hence the macrocyclic nitrogen atoms are functionalised with other side arms to provide 
additional stabilisation through coordination to the Ln(III) metal. Due to its hard nature, the 
lanthanide ion prefers to have hard bases as ligands (usually carboxylic acids, amides, 
phosphonates and pyridines).
119
 
1.4.1.3. Sensitizing Antennae 
A chromophore is needed in the Ln(III) probe because f–f transitions are Laporte 
forbidden and hence are very weak. This renders direct excitation of the lanthanide ions 
very inefficient and only practicable with a sensitising chromophore (antenna). In most 
systems the antenna is included in the ligand, but it can also be provided by the anion.
42
 
Numerous properties should be given by the antenna. Firstly, it should have a high 
molar absorptivity (ε) to avoid the use of lasers and other powerful excitation lamps. The 
ideal excitation wavelength should be above 340 nm to allow quartz optics to be used and 
also to prevent interference with biological chromophores (e.g. tryptophan residues in 
proteins, DNA etc.).
120
 The energy of the antenna triplet state needs to be at around 1700 
cm
–1
 above the energy of the accepting lanthanide energy level (20400 cm
–1 
for 
terbium(III) and 17200 cm
–1
 for europium(III)). If it is too high the energy transfer 
efficiency is poor, whereas if it is too low, thermally activated back energy transfer can 
occur. The significant issue with a number of cyclen-based Ln(III) agents is their low 
brightness, which is defined by the product of the quantum yield ϕ and the extinction 
coefficient ε, B(λ)=ε(λ)ϕ. The antennae are often derivatives of commercially available 
organic chromophores with known fluorescence profiles that possess suitable energy 
requirements (Figure 1.17).
80,119,121–127
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Figure 1.17: Examples of sensitizing organic molecules derived from organic 
fluorophores with favourable properties for sensitization.
80,119,121–127
  
Pendant antennae are generally understood to sensitize the lanthanide ions mainly 
through Förster resonance energy transfer (FRET) but also display some Dexter energy 
transfer.
80
 The efficiency of FRET is proportional to 1/r
6
, where r is the distance between 
the lanthanide and the antenna, whereas the efficiency of the Dexter mechanism is 
proportional to 1/e
r
.
128
 In both cases the closer the metal to the antenna the stronger the 
energy transfer, so there has been focus on decreasing the linker length or to coordinate the 
antennae directly to the metal centre, to enable efficient energy transfer. In addition to 
decreasing the distance, the overall energy transfer efficiency can be improved by 
increasing the number of pendant antennae attached to the single chelate. Parker and co–
workers used three antennae to make some of the brightest Eu(III) complexes reported in 
water to date (Figure 1.18)
76
 
 
Figure 1.18: One of the brightest lanthanide complexes in water reported to date
76
 
1.4.1.4. Other design strategies 
Other design strategies have been reported over the years, for example some 
bimetallic systems have been reported which proved to be very bright.
129
 The q modulation 
can be adapted intramolecularly, where a side arm of the antenna can reversibly coordinate 
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to the metal centre.  In this case the presence of an analyte such as potassium
130
 or a change 
in the environment (e.g. pH)
131
 can affect the ability of the arm to sensitize the Ln(III) ion. 
 
1.4.2. Signalling mechanisms of lanthanide complexes 
 
The process described in Scheme 1.2 presents the energy transfer processes that 
occur when a lanthanide probe is excited by light at an appropriate wavelength.
35
 
Lanthanide luminescence begins with the excitation of the sensitizer via absorption of 
light. The sensitizer, in the singlet excited state can return to the ground state by 
fluorescing or by non–radiative decay. Alternatively, it can transfer energy to its triplet 
excited state by intersystem crossing (ISC), assisted by the presence of the heavy metal 
ion. Again, some non–radiative decay can occur. The energy gap between the triplet 
excited state of the chromophore and the excited state of the lanthanide ion needs to be 
close (see above) rendering the energy transfer possible. The excited state of the lanthanide 
ion becomes populated, which can expel the energy via luminescence, leading to a series of 
line–like emission bands. However, back energy transfer can also occur from the excited 
lanthanide to the triplet excited state of the chromophore. Non–radiative decay can also 
occur, the most important of which is the energy transfer to higher harmonics of solvent 
and ligand oscillators, particularly O–H and N–H bonds. This means that when water 
molecules are bound to the lanthanide ion, the luminescence of the complex is quenched 
significantly.
80
 
The overall quantum yield reflects the efficiency of each of the three main steps 
involved in the process: i) formation of the triplet state (KISC); ii) the energy transfer step 
(KeT), maximised by a short distance between the chromophore and the lanthanide and a 
small energy gap; iii) the emissive quantum yield of the lanthanide ion itself (klum). The 
emitted photon always possesses a lower energy than the absorbed photon (λabs< λem), this 
difference is called pseudo Stokes’ shift. In the case of the lanthanide luminescence the 
pseudo Stokes’ shift is particularly large (hundreds of nanometres).132 
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Scheme 1.2: Photophysical processes occurring during sensitized lanthanide 
emission (eT: energy transfer, ET electron transfer)
35
 
 
1.4.3. Europium and terbium complexes for anion sensing 
 
 
Figure 1.19: Jablonski diagram of europium luminescence 
Europium(III) and terbium(III) possess several properties which make them most 
suitable for biological applications. First, their emission wavelengths are the visible region. 
The emission bands of europium(III) are centred at 580 nm, 590 nm, 613 nm, 650 nm, 690 
nm, 710 nm, in red region of the visible region (Figure 1.19). Terbium(III) also possesses 
bands in the green region of visible region making them the two main lanthanide ions used. 
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The emission spectral form of Eu(III) is simplified by the absence of degeneration in the 
emissive 
5
D0 excited state. Second, the emission band at 590 nm is usually unaffected by 
any coordination changes but the band at 613 nm is strongly affected, which allows 
ratiometric analyses of anion binding and removal of the dependence on probe 
concentration.
105
 Another method of obtaining ratiometric response is by using a mixture 
of Eu(III)/Tb(III) complexes, analysing the change in the red/green emission ratio.
133
 
Additionally, Eu(III) and Tb(III) both have long luminescence lifetimes in the order of 
milliseconds, whereas Yb(III) and Nd(III) are within the microsecond timescale. This 
allows the implementation of time–gated procedures allowing the Eu(III) and Tb(III) 
luminescence to be distinguished from the short–lived background fluorescence present in 
most biological moelcules (e.g. from tryptophan and tyrosine residues in proteins). This 
increases signal to noise significantly.  
The most common europium(III) complex design used in anion sensing has the 
sensitizer integrated within the complex and a water molecule that can be displaced by the 
anion.
134
 In the case of europium(III), the spectral form varies significantly as the local 
field varies.
135
 Upon binding, the coordination around the metal complex may be changed, 
affecting certain emission bands. 
 
1.5. Detection of polyphosphates using lanthanide-based 
probes 
 
Although Ln complexes have been used successfully for a detecting a number of 
anions (e.g. bicarbonate and lactate),
120,136
 only a few examples exist for the detection of 
polyphosphate species.  
In work by Yuan and co-workers., a short series of β–diketonate–Eu(III) complexes 
capable of binding pyrophosphate in micellar solution (pH 7.2) by displacement of a 
coordinated antenna from the lanthanide centre was developed.
137
 When the antenna is 
dissociated from the complex, the europium(III) ion can no longer be excited, thus 
emission is switched off. The compound showed some selectivity between phosphate 
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species, as the only anion capable of displacing the bound antenna was pyrophosphate. In 
the absence of the micellar environment, the europium emission is much weaker and anion 
affinity is lower. Consequently, the sensor is unable to operate with a useful level of 
sensitivity or selectivity in homogenous aqueous solution. 
One of the earliest examples of the use of lanthanide probe for ATP was reported 
by Schäferling in 2007.
138
 An already reported europium tetracycline probe was screened 
against ATP, ADP, AMP, cAMP and PPi.
139
 It was observed that only ATP caused 
significant (75%) quenching of the signal, whereas AMP and PPi showed a smaller (25%) 
quenching effect and AMP and ADP showed no significant effect. They used this property 
of their probe to monitor, in real time, enzymatic transformation of ATP to ADP, cAMP 
and PPi by luminescence spectroscopy. the probe is limited by its low specificity and 
cannot be applied to any complex media or enzymatic reactions requiring more anions 
present. Indeed because the weakness between the europium(III) and the tetracycline an 
excess of sensitizer is added causing the compound structure to be poorly defined and 
causes a strong potential interference with the local media.
140
  
In 2014 the same group synthesised three new probes (Figure 1.20). They are 
europium complexes with varying charges (–1 or 0) and number of bound water molecule 
(2, 3 and 4). The negatively charged compound did not bind to anions. They screened the 
other two complexes and obtained a different response depending on the anion. No affinity 
constants were reported but they showed that the response for ATP was stronger than for 
ADP and AMP and similar for PPi. Unfortunately, they lost this difference in the emission 
intensity when complicating the media. In the presence of 5 µmol of magnesium(II) the 
emission is quenched 3 times and the difference between ATP and ADP is reduced to 
around 20% where it used to be more than 100% in the absence of magnesium(II). Beside 
these drawbacks, they tested the probe for real time monitoring of ATPase enzyme and 
showed that different concentrations of enzyme lead to different speed of decrease of the 
signal. 
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Figure 1.20: Probes used in enzymes assays by Schafferling et al.
140
 
 
A more recent example was reported in 2013 by Pierre’s group.28 Two probes were 
developed, based on a cyclen scaffold with one phenanthridine arm to serve as the antenna 
(Figure 1.21). The europium(III) complex is based on DOTA whereas the terbium(III) 
complex is DOTAm causing a difference in the overall charge of the molecule from 0 to 
+3 respectively. This causes the negatively charge nucleotide phosphates to bind only with 
the positively charged terbium(III) complex and confers selectivity between the mono, di 
and tri phosphate anions. Upon binding, the base of the nucleotide engages in π–π stacking 
with the phenanthridine. The metal emission is then quenched by photoinduced electron 
transfer (PeT). By then using both complexes simultaneously during kinase assays they 
were able to monitor, in real time, the conversion from ATP to ADP. This is impressive 
considering the relatively small selectivity between ATP, ADP and AMP, indeed the 
Stern–Volmer constant are respectively of 1.28, 0.85 and 0.397 showing that there is very 
little difference in the quenching constant between them. 
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Figure 1.21: Terbium and Europium probe for ratiometric real time enzyme 
monitoring
28
 
Parker’s group developed a probe in 2018 that could detect ATP/ADP ratios by 
using the polarisation of their luminescence emission.
141
 In micromolar amounts, ATP and 
ADP when bound to their probe (Figure 1.22) showed circularly polarised emission of 
opposite signs. This allowed them to plot the circularly polarised emission at 592 nm 
against the ratio of ATP and ADP. Unfortunately, they did not obtain a linear relationship 
between ATP/ADP ratio and emission response, and did not pursue the experiment further 
by monitoring enzyme activity.  
 
Figure 1.22: Probe used by Parker & co-workers. for simulating enzyme 
activity.
141
 
The real–time monitoring of ATP levels in cells would allow variations of energy 
in the cell to be monitored depending on stress, diseases or different type of cells.
142
 
Thanks to their unique photophysical properties lanthanide complexes are being 
intensively used in cellular imaging. With the development of time–gated confocal 
microscopy the number of reported Ln(III) complexes has increased significantly.
119
 But to 
the best of our knowledge, no lanthanide–based probe for imaging of ATP in cells has been 
reported previously. The current methods have significant drawbacks, being affected by 
small variations in pH and requiring enzymes (luciferinase) which consume ATP in the 
process of measurement. Therefore, it is necessary to develop better methods and discrete 
europium complexes could be designed for this purpose.
142
 The large Stoke shift, the long 
emission lifetimes, the capacity to tune the ligand to target a specific anion and direct the 
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probe to specific compartments of the cell, makes them excellent candidates for cellular 
imaging of ATP.  
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1.6. Aims of the project 
 
The work described by Butler in 2015 reports the synthesis of two europium 
complexes [Eu.1]
+
 and [Eu.2]
+
 (Figure 1.23).
143
 These two complexes have shown 
capabilities of binding anions (e.g. fluoride) in water and thus their potential as anion 
sensors was demonstrated. This work aims to explore the use of such complexes in the 
recognition of nucleoside polyphosphate anions. The use of these complexes for ATP 
detection would permit us to follow enzymatic reactions involving ATP in real–time, to 
study enzyme kinetics and aid the discovery of new kinases inhibitors. This class of 
complex could also permit real time monitoring of ATP inside the cell and its organelles. 
The aim of this thesis was to synthesise, characterise and study europium(III) complexes 
with these anion binding and imaging applications in mind. 
 
Figure 1.23: Structure of europium(III) target compounds. 
In the design of these new molecules we implement two different strategies. As 
shown by Butler with [Eu.1]
+
 and [Eu.2]
+
 the incorporation of hydrogen bonding groups in 
the quinoline units is critical for selectivity and high affinity for anions.
143
 [Eu.1]
+
 and 
[Eu.2]
+
 respectively have a hydrogen and an acetamide group in the 7-position of the 
quinoline unit. Following this logic, [Eu.3]
+
 is designed to increase the hydrogen bonding 
strength by the incorporation of urea groups, which are well studied strong hydrogen 
donors.
46
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The second strategy is to modulate the local charge at the europium(III) centre with 
the aim of varying anion affinity (and selectivity), by changing the electrostatic interactions 
between them. With this in mind, [Eu.4–6]+ were designed as mirror images of [Eu.1–3]+ 
but with a modification of the side chain represented by X (Figure 1.23). The new design 
replaces the two carboxylate donor groups with neutral amide groups linked via ethylene 
spacer to a terminal carboxylate. In the case of [Eu.1–3]+ the local charge at the europium 
centre is +1 but with this new modification [Eu.4–6]+ will have a local charge of +3 which 
could increase affinity towards more negatively charged nucleosides phosphates. In 
addition, this strategy pushes the carboxylate groups to the periphery which will help with 
the solubility of the probes in aqueous media. The overall charge of the complexes is not 
modified and each complex remains at +1 charge overall. 
It is envisaged that polyphosphate anions will bind to the complexes via the 
terminal phosphate, displacing the bound water molecule. This metal-phosphate interaction 
may be strengthened by hydrogen bonding to the amide or urea groups of the quinoline 
arms .
143
 We wished to investigate how changing the relationship of the two quinoline units 
to a cis configuration will affect the binding and change the selectivity. Hence, we aimed to 
prepare complex [Eu.cisL2]
+
 also. Other moieties will be tested for their binding 
properties such as boronic acids, which are well known to interact with diols and could 
provide an extra element of selectivity for nucleoside phosphates. Different synthetic 
strategies will be pursued and an anion binding will be assessed using luminescence 
titrations, NMR structural studies and X-ray crystallography, where possible. The most 
promising probes will be further developed for in vitro applications, including enzyme 
activity monitoring and live cell imaging. 
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 Synthesis of the europium(III) complexes Chapter 2:
 
Scheme 2.1: Retrosynthesis of the europium complexes 
The retrosynthetic strategy followed for the synthesis of the new europium 
complexes [Eu.1–6]+ is shown in Scheme 2.1. First, two sets of building blocks will be 
synthesised: the quinoline arms, bearing different moieties at the R position and the cyclen 
scaffold also possessing different moieties, providing either a carboxylate donor or an 
amide donor for coordination to the europium(III) ion. Two of those building blocks will 
then be combined to form ligands 1–6 which will then be complexed with Eu(III) to form 
the final compounds [Eu.1–6]+. 
2.1. Synthesis of the sensitizing antennae and the cyclen 
scaffolds 
2.1.1. Synthesis of the 7-substituted quinoline building block 
The capacity of Eu(III) to absorb light is not very efficient,
144
 therefore a suitable 
sensitizer is necessary to compensate. Azaaromatics such as quinolines have been widely 
used in the past 20 years for fluorescence applications.
145,146
 Although their standard state 
is not fluorescent; they can be made fluorescent if their singlet excited state is perturbed. 
From the excited state, the quinoline will engage in intramolecular energy transfer to the 
excited state of Eu(III), resulting in luminescence.
147
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The literature provides a number of examples where quinolines are substituted in 
different positions, which leads to modulation of the photophysical properties.
27,42 
Here, the 
focus is on position 7 of the quinoline framework (See Scheme 2.2, compound 2.4). 
Functionalisation of positions 6 and 8 with hydrogen bond donor (urea) groups have been 
tested towards binding with anions on a tripodal zinc(II) scaffold, but only position 7 
provided the spatial geometry to allow the necessary hydrogen bonding to occur (Figure 
2.1).
27
 
 
Figure 2.1: Tripodal zinc complex for the detection of ATP by Butler, each 
quinoline is functionalised with urea groups at the 7-position.
27
 
2.1.1.1. Synthesis of the key building block 2.8 
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Scheme 2.2: Synthesis of the quinoline building block 2.8 
The synthesis of quinoline derivative 2.8 described in Scheme 2.2 is an 
optimization of the synthesis used previously by Butler.
27
 An improvement in the yield of 
the first step, the Skraup–Doebner–Von Miller quinoline synthesis, from 15% to 33% was 
due to a simplification of the purification system. The crude material was put in an ice bath 
to give a precipitate, which was then decanted, instead of a filtration with multiple washes. 
The compound behaved like a non-Newtonian liquid and thus filtration was problematic. A 
column was still needed to remove impurities and particularly the 5-bromo regioisomer of 
2.4, which explains the poor yield of this step. According to mass spectrometry and NMR 
spectroscopy the amount of regioisomer produced was around 5% but due to high 
similarity with product 2.4 the purification was difficult. In terms of synthetic strategy, it 
was not considered problematic that the first step was low yielding. First, the starting 
materials crotonaldehyde and 3–bromoaniline are cheap and readily available. Second, 
literature does not propose many other possibilities for the same synthesis and the reported 
yields are similar to those observed here.
148–152
 
The second step, an Ullman–like coupling, was also difficult even following the 
protocol by Ma.
153
 Several problems can occur that lower the yield; the reaction must be 
performed under oxygen free conditions to avoid the oxidation of copper(I) and the 
temperature needs to be carefully controlled. Coupling of the L–proline amine was also 
observed as a competing reaction was occurring, even when the equivalence of L–proline 
was of 5% compared to ammonium hydroxide. The third step was a simple Boc protection 
to give compound 2.6 followed by an allylic oxidation using selenium dioxide, to give 
compound 2.7. The last step of the synthesis of this key building block was the reduction 
of aldehyde 2.7 to the alcohol 2.8. 
Overall, the synthesis of 2.8 has been improved compared to the previously 
reported procedure,
143
 mainly due to a simplification in the purification procedures, 
specifically, reducing the aqueous workup and focus on column chromatography, allowed 
the yields to improve two-fold overall. Extra care was taken to ensure high purity, as 
judged by 
1
H and 
13
C NMR spectroscopy and LC–MS analysis. 
36 
 
2.1.1.2. Attempts at direct functionalisation of key building block 2.8 
The purpose of this work is to synthesize different anion receptors, in which the 
nature of the hydrogen bond donor groups and local charge at the Eu(III) metal centre is 
varied, to modulate affinity and selectivity between adenosine polyphosphate anions. With 
this in mind, we created a range of functionalized quinolines, to be added to our different 
scaffolds.  
Ureas and thioureas have been used extensively in anion sensing for their hydrogen 
donor ability.
66,154
 They provide stronger hydrogen bonds between the urea and the oxygen 
atoms of various anions (including phosphate derivatives) compared to amides.
155
 This 
stronger hydrogen bonding could lead to a higher affinity towards ATP. 
 
Scheme 2.3: Deprotection of the Boc–protected quinolylamine and attempt to 
functionalize compound 2.9 selectively with phenyl isocyanate 
For further functionalisation building block 2.8 was deprotected using HCl in 
dioxane. From compound 2.9 the first idea was to have the primary amine react selectively 
with phenyl isocyanate (Scheme 2.3). The amine was hoped to be more reactive than the 
primary alcohol under the conditions of the formation of a urea function. However, despite 
several attempts, using different conditions, selectivity was never obtained. The formation 
of 2.11 is a speculation as we analysed the reaction mixtures by LCMS and the carbamate 
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has the same mass as the desired urea. It was soon decided that protection of the primary 
alcohol was necessary, prior to urea formation. 
Acetamides are another good hydrogen–bond donor group.43 Considering that the 
solubility in general organic solvents are better compared to aryl urea groups, we reasoned 
that they should be less difficult to handle. Therefore, the synthesis of an amide quinoline 
moiety 2.12 was pursued (Scheme 2.4). 
 
 
 
Scheme 2.4: Preparation of acetylated quinolines. 
 
In order improve the synthesis by reducing the number of steps, N–acetylation was 
initially carried out on quinolyl amine 2.5 rather than compound 2.9, to avoid the need for 
protection of the primary alcohol of 2.9. The acetylation using acetic anhydride was 
successful, leading to compound 2.13 in good yield (83%). Unfortunately, the allylic 
oxidation using selenium dioxide can occur on either side of the quinoline (Scheme 2.4) 
and no regiocontrol was achieved, so an alternative route was needed. 
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2.1.2. Synthesis of the amide and phenyl urea quinoline arms 
 
 
Scheme 2.5: Preparation of quinolines functionalised with aryl urea groups, via 
TBDMS protection of the alcohol. 
Given that the reaction between 2.9 and phenyl isocyanate was not regioselective, 
another possibility was to selectively protect the alcohol function of compound 2.9 
(Scheme 2.5) as a silyl ether (e.g. TBDMS). Subsequent functionalisation of the amine 
would then be allowed. This route is less economical in terms of number of 
protection/deprotection steps but nevertheless led to the desired product 2.11 in good 
yields. 
The reaction of compound 2.9 with tert–butyldimethylsilyl chloride (TBDMSCl) 
lead to selective protection of the alcohol in 83% yield. The reaction of phenyl isocyanate 
with quinolyl amine 2.15 gave compound 2.16 in a good yield and confirmed that the 
TBDMS protecting group was able withstand the conditions of the urea formation, which 
results in an acidic solution being generated. The solubility of the urea–containing 
compound 2.15 in acetonitrile was poor and required high dilution (1 mg/mL). 
Tetrabutylammonium fluoride (TBAF) in tetrahydrofuran was used to remove the silyl 
protecting group of 2.16, giving the free alcohol 2.11 in 86% yield. 
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Scheme 2.6: Preparation of amide–functionalised quinoline 2.12 via TBDMS 
protection of the alcohol 
A similar route using the TBDMS protected quinoline alcohol 2.15 was used to 
synthesise the quinoline amide 2.12. Addition of acetic anhydride in presence of 
triethylamine gave compound 2.17 in 90% yield. Deprotection of the silyl ether using 
TBAF gave the free alcohol in 82% yield. 
 
 
Scheme 2.7: Activation of the alcohol group 
To combine the building blocks with the desired macrocyclic amine, the quinoline 
alcohol groups need to be activated. The mesylation of the urea–functionalised quinoline 
2.11 (Scheme 2.7) was carried out using the same conditions proposed for the activation of 
quinoline alcohol 2.12, using only one equivalent of mesyl chloride to avoid workup 
procedures, which was complicated by solubility issues. 
1
H NMR spectroscopy revealed 
high conversion to the product, as determined by a clear shift in the methylene signal from 
4.9 ppm to 5.5 ppm, and very little mesyl chloride remaining, so we proceeded to the next 
step without further purification. The acetamide quinoline 2.12 did not have the same 
solubility issues to those observed for its urea counterpart, so following the reaction a 
dichloromethane/brine extraction was carried out and overall the mesylation worked 
perfectly (quantitative yield). 
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2.1.3. Synthesis of the cyclen scaffolds 
 
Over the last 15 years, a variety of europium(III) and terbium(III) complexes have 
been developed for use in luminescence sensing of anions,
35,106
 a large proportion of these 
utilising a macrocyclic scaffold. The 1,4,7,10-tetraazacyclododecane (cyclen) scaffold used 
in [Eu.1]
+
 and [Eu.2]
+
 was synthesised using the method described previously as shown in 
Scheme 2.8.
143
 Cyclen was dissolved in water and 1,4-dioxane and the pH was adjusted to 
2.5. This allowed control of the extent (and regioselectivity) of the alkylation in the first 
step. At pH 2.5, two of the trans-related nitrogen atoms were protonated. Addition of 
Na2HPO4 guaranteed the stability of the pH over the alkylation reaction. Beside these 
precautions, a certain amount of impurities appeared including mono-, tri-, tetra- 
functionalised cyclen presenting a challenge to purify the desired compound 2.21. Cbz–
protected compound 2.21 was alkylated with tert-butyl bromoacetate, in the presence of 
cesium carbonate at 80 °C, giving compound 2.22. Deprotection of the Cbz groups using 
hydrogen gas and palladium hydroxide on carbon gave the desired cyclen scaffold 2.23 in 
relatively high yield.  
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Scheme 2.8: Synthesis of compound 2.23, the scaffold for complexes [Eu.1–3]+  
 
 
Figure 2.2: [Eu.1]
+
 with local Eu(III) charge of +1 and [Eu.4]
+
 with local Eu(III) 
charge of +3. 
 
To increase the electropositive nature of the europium(III) centre (in complex 
[Eu.4]
+
, Figure 2.2) we needed a new arm which could provide a neutral donor to the 
europium(III) ion. By positioning a negatively charged carboxylate group further along the 
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arm we envisaged that this arm would provide better solubility of the Eu(III) complex in 
water. The first step of the synthesis was to make the new arm itself. An alkylation of 
bromoacetyl bromide onto β–alanine ethyl ester with base gave compound 2.24 (Scheme 
2.9). 
156
 
 
Scheme 2.9: Synthesis of a new amide donor arm. 
 
 
 
Scheme 2.10: Synthesis of cyclen scaffold 2.26 bearing two amide donor arms 
 
Cbz–protected cyclen 2.21 was alkylated with the arm 2.24, in presence of base at 
60 °C, giving compound 2.25. Deprotection of the Cbz groups using hydrogen gas and 
palladium hydroxide on carbon gave the desired cyclen scaffold 2.26 (Scheme 2.10). 
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Figure 2.3: Cyclen scaffold 2.23, bearing two carboxylic acid donor arms, and its 
constitutional isomer 2.27. 
The cyclen scaffold bearing two shorter carboxylic acid donor arms (Figure 2.3) 
was synthesised using the procedure described in scheme 2.8 above. The third scaffold 
2.27 is a regioisomer of scaffold 2.23. The symmetry has been changed so that the 
quinoline binding arms will be adjacent (cis) to each another in the final Eu(III) complex. 
We wished to evaluate the effect of changing the relative positions of the binding arms on 
the affinity, selectivity and response of the Eu(III) complexes towards NPP anions. 
Macrocycle 2.27 was formed in one–step (carried out by a colleague Thomas Berki), 
following the protocol by C. Li,
157
 where 2 equivalents of tert-butyl bromoacetate were 
added to cyclen in presence of base. 
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2.2. Synthesis of the ligands and Eu(III) complexations 
2.2.1. Synthesis of ligands L1–3 
 
 
Scheme 2.11: Synthesis of ligands L1–3 
The quinoline mesylate esters 2.18 and 2.19, as well as commercially available 2-
(chloromethyl)quinoline (2.28), were alkylated onto the cyclen scaffold 2.23 (Scheme 
2.23). The optimal number of equivalents of mesylate ester was found to be 2.3 and the 
reaction was followed by LCMS. The compounds were then purified by column 
chromatography to obtain pure compounds 2.29-2.31 in yields ranging from 60% to 80%. 
The tert-butyl groups were then hydrolysed using trifluoroacetic acid in dichloromethane 
50/50 (v/v). The newly formed acids were purified by reverse phase HPLC and yielded 
pure ligands L1–3 in good yields. 
2.2.2. Synthesis of ligands L4–6 
Ligands L4–6 were synthesised using a similar method to that described above, 
using the cyclen scaffold bearing two ethyl ester protected carboxylic acid arms (Scheme 
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2.12). The alkylation step to form compounds 2.32–2.34 was the same as for the shorter 
side arm compounds above, although the yields were slightly lower, ranging between 40% 
and 65%. Formation of the ligands L4–6 differs as the ethyl esters were hydrolysed using 2 
mM KOH in water, followed by purification by reverse phase HPLC yielding the desired 
ligands in 60 to 75%. 
 
 
Scheme 2.12: Synthesis of ligands L4–6, involving alkylation of compound 2.26 
with mesylate ester 2.19 and 2.20 and quinoline chloride 2.28 
 
 
 
46 
 
2.2.3. Synthesis of ligands cis–L2 
 
 
 
Scheme 2.13: Synthesis of cis–L2 
The synthetic strategy used for ligand cis-L2 was very similar to that described 
above for L2: the cyclen scaffold 2.27 was reacted with 2.3 equivalents of the mesylate 
ester 2.19 to form 2.35, followed by removal of the tert-butyl ester protecting groups using 
TFA to form ligand cis–L2. 
2.2.4. Complexation with europium(III) 
Preliminary tests of the complexation of ligands with Eu(III) to form the final 
Eu(III) complexes proved to be difficult in certain cases.
143
 A study of different conditions 
was carried out with a representative example of the synthesis of [Eu.5]
+
.  
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Table 2.1: Optimisation of the complexation of L5 with EuCl3 to form [Eu.5]
+
. 
Conditions: 18 hours, 1.05 equivalents of EuCl3, 2 mg scale. 
Entry 
Solvent pH Temperature °C 
Ratio of Eu(III) luminescence (615 
nm) to ligand fluorescence (410 nm)  
1 NH4HCO3
-
  (50 
mM) 
8.5 60 20:80 
2 Water 6.5 60 23:77 
3 Water 7.5 60 45:55 
4 Water 8.5 60 62:38 
5 Methanol/Water 
50/50 
8.5 60 96:4 
6 Methanol/Water 
50/50 
8.5 85 96:4 
7 Methanol/Water 
25/75 
8.5 60 84:16 
8 Methanol/Water 
75/25 
8.5 60 92:8 
9 Acetonitrile/ 
water 50/50 
8.5 60 78:22 
 
Table 2.1 shows the different conditions used for Eu(III) complexation and the 
corresponding ratio of Eu(III) luminescence/ligand fluorescence observed after 18 hours. 
The emission intensity ratio was measured by recording an emission spectrum from 350 to 
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720 nm (excitation at 330 nm) and comparing the overall intensity of the ligand 
fluorescence (350–550nm) and Eu(III) luminescence (550-720 nm). First, pH was 
assessed, if the pH is too low the protonation of the cyclen nitrogen will hinder 
complexation (entry 2), on the other hand if the pH is too high precipitation of 
europium(III) hydroxide occurs. In pure water, the optimal Eu(III) luminescence was 
obtained at pH 8.5 (entry 4), which was then used for further optimisation. Changing 
solvent and temperature revealed that optimal conditions for [Eu.5]
+
 complexation were a 
mixture of water/methanol (50/50) at 60 °C at pH 8.5 (entry 5). The final conditions were 
used for the larger scale synthesis of [Eu.5]
+
 (around 50 mg scale), using 1.05 equivalents 
of Eu.Cl3 and stirring for 15 hours (Scheme 2.14). 
 
Scheme 2.14: Addition of europium(III) to ligand L5 to form [Eu.5]
+ 
The same protocol was followed to form europium(III) complexes [Eu.1]
+
, [Eu.2]
+
 
and [Eu.4]
+
. However, the urea compounds L3 and L6 did not show any complexation 
under similar conditions, probably because of their poor solubility in methanol/water 
mixtures. Consequently, the Eu(III) complexation of ligands L3 and L6 was performed in 
methanol using Eu.Tf3 and microwave heating at 60 °C for 2 hours. 
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2.2.5. Complexation with terbium(III) 
 
Scheme 2.15: Complexation of L2 with terbium(III) 
From the optimised complexation conditions it was then straight forward to form 
the terbium(III) complex [Tb.2]
+
, by treating ligand L2 with TbCl3.6H2O under the same 
conditions as described for the formation of [Eu.2]
+
 (Scheme 2.15). This was performed to 
assess the ability of the quinolylamide units to sensitise Tb(III) emission.  
 
2.3. Divergent synthesis for rapid functionalisation of 
europium complexes 
 
With the synthetic strategy developed for compounds [Eu.1–6]+ a convergent route 
was used with all the building blocks being synthesised prior to combining them in the 
final few synthetic steps. In this approach, any combination of arm or macrocyclic scaffold 
could be prepared relatively quickly. An alternative method is to opt for a divergent 
strategy, synthesizing a ligand bearing arms that can be modified readily to obtain several 
new complexes. Scheme 2.16 describes the synthesis of the precursor complex [Eu.7]
+ 
for 
this purpose. The synthesis is similar to the method used previously, but utilises a Boc 
protected quinoline derivative rather than the different hydrogen bonding moieties on the 
quinoline units. The Boc groups are deprotected at the same time as the t-butyl ester groups 
on the ‘non-binding’ arms, using trifluoracetic acid. Complexation of ligand L7 with 
europium gives the europium complex [Eu.7]
+
 bearing two aromatic amine groups, which 
can be further functionalised with anion binding motifs. 
50 
 
 
Scheme 2.16: Synthesis of [Eu.7]
+
 allowing divergent synthesis of new anion-
receptors. 
. 
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Scheme 2.17: Synthesis of [Eu.8]
+
, bearing phenylboronic acid groups, from 
precursor [Eu.7]
+
. 
Scheme 2.17 shows the first attempt to use the newly formed complex [Eu.7]
+
 for 
the synthesis of a new europium (III) complex for polyphosphate detection. The design 
principle behind complex [Eu.8]
+
 was to use the well-known reversible interaction 
between boronic acids and sugars (diols) to introduce additional recognition of the ribose 
component of NPP anions. Indeed, [Eu.8]
+
 was designed so that upon binding of ATP, in 
addition to the electrostatic and hydrogen bonding interactions present in the other 
synthesised probes, the B(OH)2 moiety would interact with the ribose moiety of ATP. It 
was hypothesised that by changing the distance between the boronic acid and the 
europium(III) ion, selectivity could be tuned for mono-, di- or tri-phosphates.  
The compound was prepared by the acylation of a benzoic acid derivative bearing a 
meta boronic ester. The acid chloride was then reacted with complex [Eu.7]
+
 to give 
[Eu.8]
+
 in a very modest yield after HPLC purification (6%) but in only two steps. The low 
yielding reaction is due to the low reactivity of the quinoline amine in the 7 position (in 
conjugation with the electron-deficient pyridine component), the low solubility of the 
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different components of the reaction, and the difficulty of purification by reverse phase 
HPLC. However, this proof of concept study confirms that there is the potential for 
divergent synthesis of functionalised Eu(III) complexes, but further optimisation of the 
reaction conditions is necessary to increase the yield of reactions involving a precursor 
complex such as [Eu.7]
+
. 
 
2.4. Photophysical properties of the europium(III) 
complexes 
 
With complexes [Eu.1-8]
+ 
and [Eu.cis2]
+ 
in hand, photophysical studies were 
conducted, including the measurement of absorption spectra, total Eu(III) emission spectra, 
determination of quantum yield, excited state lifetimes and number of coordinated water 
molecules, q, allowing full characterisation of the lanthanide(III) complexes. 
 
2.4.1. Absorption and emission properties 
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Figure 2.5: Structure of the europium complexes [Eu.1–8]+and [Eu.cis2]+ 
2.4.1.1. Absorption and emission 
Table 2.2: Maximum absorbance wavelength of the synthesised complexes, 
measured in 10 mM HEPES, pH 7.0, 25 °C. 
Complex [Eu.1]
+ 
[Eu.2]
+ 
[Eu.3]
+ 
[Eu.4]
+ 
[Eu.5]
+ 
[Eu.6]
+ 
[Eu.8]
+
 [Eu.cis2]
+ 
λmax / nm 318 332 342 318 330 344 333 328 
The absorption maximum of the 8 Eu(III) complexes is presented above. The 
macrocyclic scaffold has a limited effect on the absorbance of the quinoline derivative. The 
quinoline substitution, on the other hand, changes the absorption maximum in an 
interesting manner. The effect of the R group at the 7–position on the magnitude of λmax 
follows the trend: H < amide < urea. This can be explained by the increasing electron 
donating effect of those groups changing the electronic properties of the quinoline group 
such that the HOMO-LUMO gap is smallest for the urea analogue, leading to a longer 
absorption wavelength.
158
 This result is significant as it is generally advised for the λmax of 
a given probe to be 350 nm or higher for application in cellular imaging, to avoid 
absorption of endogenous biomolecules in cells.
80
 
All 7 complexes show similar emission profiles in buffered aqueous solution, in the 
absence of added anion. They possess 5 characteristic europium bands with at least three 
components in the ΔJ = 1 band and at least two components in hypersensitive ΔJ = 2 band, 
this is a sign of the complexes adopting low symmetry in water. Each complex displayed 
very sharp and well-defined emission bands usually bearing a maximum around 615 nm. 
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[Eu.5]
+
 showed a distinctive emission spectrum, specifically the intensity of the ΔJ = 2 
band is much greater compared to the other bands, unlike the other complexes. The 
absorption and emission spectra of complexes [Eu.2]
+
 and [Eu.5]
+
 are shown for 
comparison in Figure 2.6, each measured at pH 7.0 in 10 mM HEPES buffer. In each case, 
a residual fluorescence emission is present in addition to the Eu(III) luminescence. Their 
minimal intensity shows the efficiency of the sensitization of the of Eu(III) excited state by 
the quinoline units. 
 
Figure 2.6: Absorption and Emission spectra of [Eu.2]
+
 (blue) and [Eu.5]
+
 (red), 
in 10 mM HEPES buffer at pH 7.0, λexc = 330 nm, 25 °C. 
2.4.1.2. Extinction coefficient and quantum yield 
 
Table 2.3: Extinction coefficients and quantum yields of synthesised Eu(III) 
complexes, measured in 10 mM HEPES buffer, pH 7.0, 25 °C. Errors in quantum 
yield and lifetimes are ± 20% and errors for hydration states are ± 0.5. 
Complex [Eu.1]
+ 
[Eu.2]
+ 
[Eu.3]
+ 
[Eu.4]
+ 
[Eu.5]
+ 
[Eu.6]
+ 
[Eu.8]
+
 [Eu.cis2]
+ 
ε / M–1cm–1 11800 12500 5900 21000 7700 n.d n.d 14000 
em / % 23 7 15.5 18 6.5 n.d 4.6 9.5 
0.0
1.0
2.0
3.0
4.0
5.0
0
0.1
0.2
0.3
0.4
0.5
0.6
260 360 460 560 660
In
te
n
s
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y
 
A
 
Wavelength / nm 
[Eu.2]+
[Eu.5]+
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The extinction coefficient of the complexes, which shows their capacity to absorb 
light, is a key factor when evaluating their overall brightness, defined by the product of the 
quantum yield ϕ and the extinction coefficient ε, B = ε × ϕ.76 All Eu(III) complexes studied 
have extinction coefficients in the same range (5900–21000 M-1cm-1), showing that their 
capacity to absorb light is similar. Examples of the calculation of the extinction 
coefficients are provided in Figures 9.1–9.4 of the appendix. 
 
The quantum yield represents the proportion of absorbed light that is emitted as 
light. Quantum yields were measured in 10 mM HEPES buffer (pH 7) by comparison to a 
previously reported bis-azaxanthone europium(III) complex, [Eu.L1(OH2)] (Figure 2.7), 
as a standard (em = 0.018). Quantum yield values have an error of ±20%.
109
 The quantum 
yields ranged between 7 and 23% and seemed to follow a trend. Particularly, Eu(III) 
complexes [Eu.1]
+
 and [Eu.4]
+
, containing non–substituted quinolines, have a noticeably 
larger quantum yield. The data could suggest that electron donating groups modulate the 
energy of the triplet excited state, such that energy transfer to the europium(III) excited 
state is less efficient. However, the relatively high quantum yield of [Eu.3]
+
 is not 
consistent with this theory. An alternative explanation may be that the emission intensity of 
complexes [Eu.1]
+
, [Eu.3]
+
 and [Eu.4]
+ 
are less quenched by proximal O–H oscillators of 
surrounding water molecules. 
 
Figure 2.7: Structure of the complex [Eu.L1(OH2)] used as the reference for 
measuring the quantum yields. 
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2.4.2. Excited state emission lifetimes and estimation of complex 
hydration state. 
Table 2.4: Excited state lifetimes and hydration state of the newly synthesised 
complexes. 
Complex [Eu.1]
+
 [Eu.2]
+
 [Eu.3]
+
 [Eu.4]
+
 [Eu.5]
+
 [Eu.6]
+
 [Eu.8]
+
 [Eu.cis2]
+
 
τ (H2O) / ms 0.51 0.49 1.08 0.60 0.56 1.16 0.632 0.66 
τ (D2O) / ms 1.37 1.38 1.72 1.29 1.22 3.03 2.182 1.39 
q 1.1 1.2 0.0 0.7 0.8 0.2 1.0 0.7 
 
To determine the hydration state of the complexes, the excited state lifetimes of the 
europium(III) complexes were measured in H2O and D2O, with each complex showing an 
increase in emission lifetime in D2O compared to H2O, as expected. The transfer of excited 
state energy of the europium(III) ion to O–H oscillators of water occurs very efficiently 
hence why O–H oscillators quench the emission of lanthanides.35 The corresponding O–D 
oscillators possess lower stretching frequencies and any energy matching is only possible 
with higher vibrational states, which is less probable. This means that in water the 
diminution of the emission intensity over time occurs faster than in deuterated water. Using 
the equation in section 1.4.1.1, the number of bound water molecules was determined for 
each complex. 
The lifetime of each complex in water is relatively long, around 0.6 ms. This is an 
advantageous feature of the compounds, because it allows time gated measurements to be 
used, removing any residual fluorescence of the probe and the fluorescence of the 
biological media.
159
 This result was expected for the target europium complexes.  
On a more surprising note the number of bound water molecules varied between the 
complexes studied. For [Eu.1–2]+ and [Eu.4–5]+ and [Eu.8]+ there is one bound water 
molecule in accordance with the original probe design. However, the urea compounds 
[Eu.3]
+
 and [Eu.6]
+
 do not appear to have any bound water. This explains the higher 
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quantum yield of [Eu.3]
+
 (16%); no bound water molecule reduces energy loss to O–H 
oscillators. In terms of sensing anions, this is likely to be an issue for these two complexes, 
as the increase of luminescence intensity will be limited, because there is no water 
molecule for the anion to displace.  
 
2.4.3. Photophysical properties of terbium(III) complex [Tb.2]+ 
 
Figure 2.8: Structure of terbium complex [Tb.2]
+
. 
The absorbance maximum (λmax) of complex [Tb.2]
+
 was 328 nm, the same as for 
[Eu.2]
+ 
as expected. [Tb.2]
+
 has 4 characteristic Tb(III) emission bands in the green region 
of the visible spectrum, and showed a relatively high ligand fluorescence compared to its 
europium counterpart, a sign of a non-optimal energy matching between the triplet excited 
state of the quinoline chromophore and the excited state of terbium (Figure 2.9). As 
described in the previous chapter: the energy of the antenna triplet state needs to be around 
1700 cm
–1
 above the energy of the accepting lanthanide energy level (often the emission 
state, 20400 cm
–1 
for terbium(III) and 17200 cm
–1
 for europium(III)). 
58 
 
 
Figure 2.9: Absorption (blue) and emission (green) spectra of [Tb.2]
+
 (5 µM) in 10 
mM HEPES buffer at pH 7.0, λex = 330 nm, 25 °C. 
Due to the limited amount of Tb(III) complex obtained, the extinction coefficient of 
[Tb.2]
+
 could not be measured with confidence. The quantum yield was also not measured 
, but is expected to be low, due to an intrinsic property of terbium complexes being very 
oxygen sensitive. Figure 2.10 shows the emission response of [Tb.2]
+
 to dissolved oxygen 
in buffered aqueous solution. In an aerated aqueous solution the luminescence is weak and 
decreases even further if the solution is gently bubbled with oxygen. On the other hand, 
replacing the oxygen source with nitrogen enhances the emission intensity significantly. 
The actual increase is difficult to quantify because of the overlap of quinoline fluorescence, 
however, analysis of the band between 570–600 nm showed that the air-equilibrated 
sample intensity decreased by a factor of two upon oxygenation and increased by a factor 
of 4 upon bubbling with nitrogen. 
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Figure 2.10: Change in emission spectra of [Tb.2]
+
 (5 μM) as a function of oxygen 
content in the solution. Conditions: HEPES buffer (10 mM), pH 7.0, λexc 330 nm, 25°C. 
 
2.4.4. Photophysical properties of complex [Eu.8]+ 
 
Complex [Eu.7]
+
 has no Eu(III) luminescence as seen Figure 2.11. This can be 
explained by the change in energy of the excited state of the quinoline due to the presence 
of an electron donating amine group at the 7 position, making the energy match between 
the triplet excited state of the quinoline and the excited state of the europium no longer 
optimal. This is consistent with the significantly larger absorption maximum (360 nm) of 
[Eu.7]
+
, indicating a lower energy singlet excited state compared to the other Eu(III) 
complexes. 
0
0.5
1
1.5
2
2.5
3
350 400 450 500 550 600 650 700
In
te
n
s
it
y
 
Wavelength / nm 
Aired
Oxygenated
Deoxygenated
60 
 
 
Figure 2.11: Absorption (blue) and emission (green) spectra of [Eu.7]
+
 (5 µM) in 
10 mM HEPES buffer at pH 7.0, λex = 355 nm, 25 °C. 
 
2.5. Conclusion 
 
The synthesis of nine related Ln(III) complexes designed for the detection of 
polyphosphate anions has been discussed. A convergent strategy was followed for the 
preparation of complexes [Eu1–6]+: a number of 7-substituted quinoline building blocks 
were synthesised presenting different moieties aimed to strengthen the interaction with 
ATP via hydrogen bonding. A Skraup–Doebner–Von Miller strategy was utilised and the 
7-position was functionalised with amide and phenyl urea groups, whereas the 2 position 
was functionalised with a mesylate ester and prepared for alkylation. In addition, different 
cyclen scaffolds were constructed presenting different Ln(III) donor groups aimed for 
strengthening the interaction or modifying the physiological properties such as water 
solubility and biological availability. 
The building blocks were then combined to create ligands L1–6 and cisL2, each 
bearing two quinoline arms at different positions on the macrocyclic scaffold. After 
optimisation, the ligands thus obtained were complexed with europium(III) to give 
complexes [Eu.1–6]+ and [Eu.cis2]+ as well as with terbium to form [Tb.2]+. The efficient 
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synthesis of these 8 complexes via a convergent method allowed the relatively rapid 
fabrication of a small library of compounds. A divergent strategy was also pursued, which 
would allow faster access to a new compound, which could be studied and the results 
obtained could inform the design of modified structures in a very short time. The 
disadvantage to this approach is that it only enables modifications to be made at the 
quinoline moieties (their relative positions cannot be changed), but it is a rapid method 
using a feedback loop to produce optimised compounds. With this approach in mind, 
complex [Eu.7]
+
 was prepared presenting two NH2 moieties in the 7 position of the 
quinoline units. A one-step synthesis allowed functionalisation of these amines with a 
phenylboronic acid moieties, targeting the ribose component of nucleoside polyphosphate 
anions. 
The photophysical properties of those complex were studied, all proved to be 
effective europium(III) emitters but with differences in the capacity of anion detection. 
[Eu.3]
+
 and [Eu.6]
+
 present the most interesting absorption wavelength for biological 
applications as they are close to the region were endogenous biological emission will be 
less likely to interfere. Complexes [Eu.1]
+
 and [Eu.4]
+
 proved to have the highest 
extinction coefficient, likely due to the non-substitution of the quinoline group. They also 
have the highest quantum yield representing the proportion of light emitted compared to 
the light absorbed, making them overall relatively bright europium complexes.  
All these complexes exhibit long emission lifetimes (0.5 to 1 ms in water) with a 
particular mention for [Eu.3]
+
 and [Eu.6]
+
 (1.08 and 1.16 ms, respectively). The excited 
state lifetime was also measured in deuterated water, enabling the determination of the 
hydration state of each complex. We discovered that the explanation for the particularly 
long lifetime for urea bearing complexes [Eu.3]
+
 and [Eu.6]
+
 is due to the lack of a bound 
water molecule, which is necessary in the sensing. All the other probes were found to have 
a bound water molecule, which could then be displaced in the event of binding to ATP. 
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 Anion sensing in water Chapter 3:
 
Figure 3.1: Structure of europium(III) target compounds. 
The newly synthesised complexes [Eu.1–6]+, with different binding moieties and 
photophysical properties, are potential candidates for the application of anion sensing. The 
first step was to assess their sensing capacities in 100% aqueous media. Water is a highly 
competitive medium for sensing because of the high hydration energies of ions in water 
(see section 1.2.3). As a result, several sensors do not possess the properties to bind anions 
effectively in water and only provide responses in organic solvents, which solvate anions 
in a much weaker manner.
160
 Analysing anion binding in buffered water at physiological 
pH is a good media to rule out the complexes which do not possess the desired 
characteristics. 
3.1. pH titrations 
A first step when analysing a new anion receptor in water is to test its behaviour 
towards changes in pH. Indeed, upon addition of an anion to a buffer, there might be a 
small variation in the pH. It is thus necessary to assess if these small variations influence 
the emission intensity and spectral shape of the Eu(III) complexes. 
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Figure 3.2: Examples of the change in emission spectra of [Eu.3]
+
 (a) and [Eu.5]
+
 
(c) (5 μM) as a function of pH in aqueous solution. The plot shows the variation of 
the total emission intensity of the ΔJ = 2 band (605–630 nm) of [Eu.3]+ (b) and 
[Eu.5]
+
 (d). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
Figure 3.2 shows the pH titrations of complexes [Eu.3]
+
 and [Eu.5]
+
. Complex 
[Eu.3]
+
 (Figure 3.2 (a)) shows little change in its emission spectrum over the range of pH 5 
to pH 8 showing that at physiological pH a small variation in pH will not significantly 
affect the emission.  The plot in Figure 3.2 (b) shows the total emission intensity of the ΔJ 
= 2 band (605–630 nm) as a function of pH. More care needs to be taken when using 
[Eu.5]
+
 (Figure 3.2 (a) and (c)) as the Eu(III) complex is only non-pH responsive between 
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pH 5 and pH 7.5, however as the subsequent measurements presented were conducted at 
pH 7.0 this is not problematic. 
 
  
Figure 3.3: Change in emission spectra of [Eu.8]
+
 (5 μM) in the absence (a) and 
presence of 20 mM glucose (b) as a function of pH. The plots show the variation of 
the total emission intensity of the ΔJ = 2 band (605–630 nm). Conditions: HEPES 
buffer (10 mM), λexc 330 nm, 25 °C. 
In the case of the boronic acid containing complex [Eu.8]
+ 
the influence of pH was 
studied under different conditions. First, under the same conditions to those used for Eu.1–
6 (Figure 3.3 (a) and (b), the complex was not pH responsive in the pH range 5–8, above 
which further increase in the pH resulted in an increase in the emission intensity of the ΔJ 
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= 2 band (605–630 nm). The second set of data (Figure 3.3 (c) and (d)) was recorded in the 
presence of 20 mM glucose. Depending on the pH the boronic acid moieties could be in the 
form B(OH)2 or B(OH)3
-
 (pKa = 8.8) which could influence the emission of the 
complex.
161
 In the presence of 20 mM glucose, it was expected that the interaction between 
glucose and the boronic acid moieties would affect the pH response of this moiety and 
potentially the emission response of the complex. This was not the case as the data in the 
presence and absence of 20 mM of glucose are similar, showing a stable emission spectrum 
from pH 5 to 8 and an increase thereafter. This indicates that the boronic acid moiety is too 
distant from the Eu(III) centre to have any significant influence on its luminescence.  
3.2. Measurement of apparent binding constants 
The affinity constant quantifies the strength of the binding; it is usually measured 
by calculating the apparent binding constant of a probe towards an analyte by titrating the 
probe with anion and measuring the change in emission intensity (which is correlated to 
host-anion complex concentration). Luminescence titration experiments were conducted 
for all the synthesised Eu(III) complexes in 10 mM HEPES buffer at pH 7.0. All probes 
tested showed an increase in emission intensity upon binding to polyphosphate anions, 
with a particularly strong variation in the intensity of the ΔJ = 2 (605–630 nm) band. 
Figure 3.4 shows an example of the ATP titration with [Eu.5]
+
, up to 180 µM of ATP was 
added causing an increase in emission intensity of about 17-fold at 614 nm. No major 
change in the emission spectral form was observed, suggesting that very little 
conformational change has occurred and that the water was displaced without significant 
rearrangement of the ligand.
162
 The lifetime of [Eu.5]
+
 was measured in H2O and D2O in 
the presence of ATP and showed that upon addition of ATP the hydration state goes from 
0.8 to zero (See Table 9.1 of the appendices) indicating that the coordinated water 
molecule is being displaced, inducing the large increase in emission intensity. Similarly 
[Eu.1]
+
, [Eu.2]
+
 and [Eu.4]
+
 also showed displacement of a water molecule upon binding 
to ATP. 
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Figure 3.4: a) Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. b)  shows the fit to the experimental data, for 
log Ka = 5.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
The binding constant was measured by plotting the ratio of the intensity of the ΔJ = 
2 band (605–630 nm) by the ΔJ = 0 band (575–582 nm) against the concentration in ATP. 
The obtained curve is fitted by a non–linear, least squares curve fitting procedure to a 1:1 
binding model, to give log Ka = 5.8 (± 0.1). This represents strong binding to ATP in water 
and is comparable to the affinities observed for certain binuclear zinc(II) complexes 
developed by Hamachi.
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Figure 3.5: a) Change in emission spectra of [Eu.4]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. b) shows the fit to the experimental data, for log 
Ka = 3.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 °C. 
Another example of an ATP titration is provided in Figure 3.5 above; upon addition 
of up to 1 mM of ATP to [Eu.4]
+
 we were able to plot the ratio of the intensity of the ΔJ = 
2/ΔJ = 1 band against the concentration in ATP. Two differences can be noted compared to 
[Eu.5]
+
: firstly, the overall increase in emission intensity is much smaller compared to that 
of [Eu.5]
+
, secondly the calculated apparent binding constant is log Ka = 3.8 (± 0.1). This 
is 100 times lower than the binding between ATP and [Eu.5]
+
. This result gave an early 
indication that changes in the structure of the ligand of the Eu(III) complex can 
dramatically influence the anion affinity and the magnitude of the luminescence response 
of these new anion receptors. 
3.3. 1:1 binding model 
To calculate the apparent binding constants, we used the assumption that anion 
binding would occur in a 1:1 manner. Having only one bound water molecule and knowing 
that previously reported europium(III) probes with a similar binding pocket showed a 1:1 
binding with fluoride, it is a reasonable assumption.
143
 The 1:1 binding mode was 
confirmed by Job plots, an example of Job plot is showed in Figure 3.6. The emission 
intensity of different molar ratios of [Eu.5]
+
 and ATP were recorded and the molar fraction 
of ATP with [Eu.5]
+
 reaches its maximum for 0.5, consistent with a 1:1 binding model.  
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Figure 3.6: Job plot of [Eu.5]
+
 with ATP, Conditions: HEPES buffer (10 mM), λexc 
330 nm, 25 °C. 
The 1:1 binding mode of selected Eu(III) complexes with anions is also suggested 
by mass spectrometry. Figure 3.7 shows the high-resolution mass spectra (ESI) obtained 
when injecting a mixture of [Eu.5]
+
 with ATP (top) as well as the calculated mass for the 
1:1 adduct (bottom). We observed a mass of 742.6596 corresponding to the doubly charged 
species [Eu.5+ATP+5H]
2+
 where the calculated value was 742.6603. In addition, major 
signals were observed for the adducts [Eu.5+GTP+5H]
2+
, [Eu.4+ATP+5H]
2+
, 
[Eu.4+GTP+5H]
2+
 and the figures are available in the appendix (Figures 9.36–9.38). 
Equivalent mass spectral work was conducted on [Eu.2]
+
 with ATP and ADP by Dr. Sarah 
Hewitt and is available in Figure 9.39.  
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Figure 3.7: High resolution mass spectral data for [Eu.5+ATP+5H]
2+
 
(EuC52H68N15O21P3). 
3.4. Urea complexes [Eu.3]+ and [Eu.6]+ 
The phenyl urea containing complexes [Eu.3]
+
 and [Eu.6]
+
 displayed poor 
solubility in water and lifetime studies indicated that they did not possess a water molecule 
bound to the Eu(III) metal centre (section 2.4.2).
163
 As such, their quantum yield is higher 
(around 16%) compared to the other Eu(III) complexes studied. Upon addition of ATP the 
increase in emission is only 2-fold for the ΔJ = 2 (605–630 nm) band for [Eu.3]+. 
Compared to the 10-fold increase for the amide containing complex [Eu.5]
+
 this is much 
less significant. The apparent affinity constant is also much smaller for [Eu.3]
+
 and ATP, 
with log Ka = 3.2 (± 0.2) whereas the affinity constant for [Eu.5]
+
 and ATP was 
determined to be log Ka = 5.7 (± 0.1): this is 100-fold stronger binding. Additionally, for 
[Eu.3]
+
 the binding constant for ADP is log Ka = 3.2 (± 0.2) (Figure 3.8 (c) and (d)) and for 
AMP (Figure 3.8 (e) and (f)) an unexpected decrease in emission intensity was observed, 
giving a binding constant of log Ka = 3.2 as well. Thus [Eu.3]
+
 showed essentially no 
selectivity between ATP, ADP and AMP, potentially as a result of some complex 
interactions occurring in water, such as aggregation of the complex. These results could be 
consistent with an anion being displaced such as bicarbonate, but all solutions used 
throughout this thesis were buffered and bubbled under nitrogen before titration 
experiments to prevent bicarbonate accumulating in the solutions of interest. 
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The poor solubility and low selectivity of the two phenyl urea bearing compounds 
[Eu.3]
+
 and [Eu.6]
+
, as well as the fact that they do not appear to have a bound water 
molecule, meant that no further anion binding studies were conducted for these 
compounds. 
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Figure 3.8: Change in emission spectra of [Eu.3]
+
 (5 μM) as a function of added a) 
ATP c) ADP d) AMP in aqueous solution at pH 7.0. The right hand plots shows the 
fit to the experimental data, for b) ATP and d) ADP and e) a decrease in emission 
for AMP. Conditions: HEPES buffer (10 mM), λexc 340 nm, 25 °C. 
3.5. Selectivity study of [Eu.1 and 2]+ , [Eu.4 and 5]+ and 
[Eu.cis2]+ 
 
An anion screening experiment is often the first selectivity test carried out on a 
chemical sensor.  The measurement of the emission spectra of a probe before and after the 
addition of an anion is recorded and the variation in emission intensity used to compare a 
probe response with another and to compare different anions for the same probe. It gives 
initial insight of what the probe capacity will be for sensing a given anion in a media 
containing others but does not provide quantitative results on the strength of the binding. 
Complexes [Eu.1, 2, 4 and 5]
+
 were screened against a wide range of anions (1 mM each) 
and their emission spectra were recorded in buffered water at pH 7.0 (10 mM HEPES).  
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Figure 3.9: Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = probe intensity (605–630 nm) in the absence of 
anions) of [Eu.1,2,4 and 5]
+
 (5 μM) in the presence of different anions (1 mM 
sodium salts). Conditions: 10 mM HEPES buffer, pH 7.0, λexc = 330 nm. 
[Eu.1]
+
 and [Eu.4]
+
 were designed as control compounds to investigate the 
function of hydrogen bond donor groups for the detection of polyphosphate anions. They 
lack the hydrogen bond donor moiety on the quinoline units, which is expected to 
strengthen binding to the negatively charged phosphates of ATP. Figure 3.9 above shows 
the anion screening conducted in buffered water at pH 7.0 for the four compounds [Eu.1]
+
, 
[Eu.2]
+
, [Eu.4]
+
 and [Eu.5]
+
. At first glance the effect of the hydrogen bond donor groups 
is apparent. Probes [Eu.2]
+
 and [Eu.5]
+
 bearing quinoline amide groups show and 
enhancement in emission intensity of the ΔJ = 2 band of about 10-fold following the 
addition of 1 mM ATP.  Whereas [Eu.1]
+
 and [Eu.4] show an approximate 2-fold 
enhancement in emission intensity of the ΔJ = 2 band. A similar trend is observed with 
ADP where the control probes display an enhancement of around 2 times whereas for 
[Eu.2]
+
 and [Eu.5]
+
 ADP enhances the emission intensity by about 14 times. The level of 
discrimination showed by [Eu.1]
+
 and [Eu.4]
+
 between the different anions studied is not 
high enough for these control complexes to be pursued further. Yet, they do provide 
evidence to suggest that the hydrogen bond donor groups (amides) are an important feature 
for polyphosphate recognition and sensing.  
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Figure 3.10: Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = Intensity (605–630 nm) of [Eu.2]
+
 and [Eu.5]
+
 
in the absence of anions) of [Eu.2]
+
 and [Eu.5]
+
 (5 μM) in the presence of different 
ions (1 mM sodium or chloride salts). Conditions: 10 mM HEPES buffer, pH 7.0, 
λexc = 330 nm. 
A more thorough selectivity study was conducted for the hydrogen bond donating 
probes [Eu.2]
+
 and [Eu.5]
+
 (Figure 3.10). First, it can be seen that overall ADP gave the 
largest increase in emission, followed by ATP. Both complexes showed a much smaller 
increase in emission intensity for AMP (4 times and 2 times, respectively) and other 
monophosphates such as cyclic AMP and phosphorylated amino acids (pSer, pTyr, pThr) 
induced no significant change in the emission intensity. Other biologically relevant ions 
such as chloride, sulfate, lactate, acetate, glutathione, sodium, potassium, zinc, magnesium 
and calcium induced negligible change in the emission intensity. Citrate and bicarbonate 
were the only two non–nucleotide phosphate anions to show a significant response: the 
emission of [Eu.5]
+
 was increased 4 and 6 times respectively and [Eu.2]
+
 did not respond 
to 1 mM bicarbonate but displayed a 4-fold increase in emission intensity of the ΔJ = 2 
band for citrate.  
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Figure 3.11: Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = Intensity (605–630 nm) of [Eu.2 and 5]
+
 in the 
absence of anions) of [Eu.2 and 5]
+
 (5 μM) in the presence of different nucleotide 
phosphates (1 mM sodium salts). Conditions: 10 mM HEPES buffer, pH 7.0, λexc = 
330 nm. 
The other purine nucleosides based on guanosine were tested in the same manner. 
GTP, GDP and GMP showed a similar trend in response to that observed with their 
adenosine counterparts (Figure 3.11). The only notable difference is with [Eu.5]
+
 which 
showed the strongest response for GDP, with an 18-fold increase in emission, whereas 
[Eu.2]
+
 displayed only a 12-fold increase.  
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Figure 3.12: Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = Intensity (605–630 nm) of [Eu.cis2]
+
 in the 
absence of anions) of [Eu.cis2]
+
 (5 μM) in the presence of different nucleotide 
phosphates (1 mM sodium salts). Conditions: 10 mM HEPES buffer, pH 7.0, λexc = 
330 nm. 
The anion screening study of [Eu.cis2]
+
 is presented Figure 3.12. The sensing 
selectivity of [Eu.2]
+
 is not conserved when changing the quinoline configuration to cis as 
the Eu(III) complex shows little discrimination between anions. Where the increase in the 
emission intensity is 14-fold for [Eu.2]
+ 
in the presence of ADP, it is only 3-fold for 
[Eu.cis2]
+
. This is an indication that the trans relationiship of the quinoline arms is 
necessary for achieving high levels of discrimination between anions.  
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Figure 3.13: Comparison of the ΔJ = 4 emission band of complexes [Eu.1]+, 
[Eu.2]
+
, [Eu.4]
+
 and [Eu.5]
+
 in presence of different anions, measured in 10 mM 
HEPES buffer, pH 7.0. . λexc = 318 nm for [Eu.1]
+
, 332 nm for [Eu.2]
+
, 318 nm for 
[Eu.4]
+
 and 330 nm for [Eu.5]
+
, [anions] = 1 mM. 
 
One advantage of using Eu(III) complexes for sensing is the line-like emission 
spectra that can lead to distinctive spectral patterns that allow certain anions to be 
distinguished, like a fingerprint. Figure 3.13 shows the difference in response of the ΔJ = 4 
(680-710 nm) band for four Eu(III) complexes towards ATP, ADP, AMP and HPO4
2-
. 
[Eu.1]
+
 and [Eu.2]
+
 show little change in spectral form and [Eu.1]
+
 shows a very small 
change in intensity, compared to the large increase in emission for [Eu.2]
+
 with nucleoside 
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polyphosphates. However, probes [Eu.4]
+
 and [Eu.5]
+
 displayed significant changes in 
spectral form of the ΔJ = 4 band. For [Eu.4]+ the intensity change is not significant but 
changes in the spectral form can be noted. In the absence of anions or in the presence of 
phosphate the ΔJ = 4 band is characterised by 4 peaks centred at 682, 687, 697 and 700 nm 
(Figure 3.13 (c)). Upon addition of AMP the bands start to merge two by two but stay 
visible, probably due to a weaker binding and the presence of unbound probe. With ADP, 
the biggest increase in intensity for this probe, only two peaks are observed, 689 nm and 
697 nm corresponding to the merging of the peaks observed in the absence of anions. ATP 
shows a similar response but with lower intensity. For [Eu.5]
+
 ATP and ADP caused a 
large but similar change in spectral form and intensity whereas phosphate and AMP caused 
much smaller changes. All the anion-bound species display two main bands but they are 
centred at different wavelengths dependent on the bound anion. It is also interesting to note 
that the ΔJ = 4 band globally shifts to longer wavelengths for probes bearing a hydrogen 
bond donating group. Indeed, where for [Eu.1]
+
 and [Eu.4]
+
 the band starts at 
approximately 675 nm for [Eu.2]
+
 and [Eu.5]
+
 it starts at 685 nm, indicating a change in 
the binding mode. 
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Figure 3.14: Comparison of emission spectra of complexes [Eu.1, 2, 4 and 5]
+
 (5 
µM) in presence of different anions, measured in 10 mM HEPES buffer, pH 7.0. λexc 
= 318 nm for [Eu.1]
+
, 332 nm for [Eu.2]
+
, 318 nm for [Eu.4]
+
 and 330 nm for 
[Eu.5]
+
, [anions] = 1 mM. 
 
Next we compared the change of the ΔJ = 4 band (680-710 nm) upon addition of 
ATP, ADP or AMP to each of the probes (Figure 3.14). For ATP, the increase in emission 
is much smaller for [Eu.1]
+
 and [Eu.2]
+
 than for [Eu.4]
+
 and [Eu.5]
+
 but importantly none 
of them have the same spectral form. [Eu.4]
+
 and [Eu.5]
+
 have two components, for 
[Eu.2]
+
 three are discernible and for [Eu.1]
+
 four of them can be seen. For ADP, the 
observed results are similar, we can note the relative simplicity of [Eu.4]
+
 and [Eu.5]
+
 with 
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only two clearly discernible bands and just an increase in intensity. AMP is interesting as it 
causes very little change between [Eu.4]
+
 and [Eu.5]
+
 indicating a very similar binding 
mode. [Eu.1]
+
 and [Eu.2]
+
 both show stronger intensity and display the same 4 and 3 
components, respectively. This study indicates that each of these 4 probes have a unique 
binding mode to nucleotide phosphate anions and that the response is characteristic for a 
particular probe. 
 
3.6. Apparent affinity constants of [Eu.1 and 2]+ and [Eu.4 
and 5]+ 
 
Table 3.1: Apparent binding constants (log Ka) of probes [Eu.1]
+
 , [Eu.2]
+
 , 
[Eu.4]
+
 and [Eu.5]
+
  and various anions, Conditions: HEPES buffer (10 mM), λexc 
330 nm, 25 °C. Each value represents the average of at least two duplicate titration 
experiments. Errors in measurements were ± 0.1 with the statistical error 
associated with the fit of the data <0.05.
*
Work carried out initially by Jonathan 
Parris (MChem student).  
Anion [Eu.1]
+ 
[Eu.2]
+ 
[Eu.4]
+ 
[Eu.5]
+ 
ATP 3.0
*
 4.4
* 
3.8 5.8 
ADP 3.3
*
 4.6
* 
3.8 5.7 
AMP 3.3
*
 3.4
* 
3.5 4.8 
PPi 2.4
* 
3.5
* 
3.4 4.7 
HPO4
2–
 n.d 2.1 n.d 2.7 
HCO3
–
 n.d 3.0
*
 n.d 3.0 
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The apparent association constants were determined for [Eu.1]
+
, [Eu.2]
+
, [Eu.4]
+
, 
[Eu.5]
+
 and different phosphate species, using the procedure described in section 3.2. 
Table 3.1 shows the apparent binding constants for ATP, ADP, AMP, PPi, HPO4
2- 
and 
HCO3
-
 in buffered water (HEPES 10 mM) at pH 7.0. The titration data are provided in the 
experimental section (Figure 9.5–9.35 of the appendix). Firstly, [Eu.1]+ and [Eu.4]+ 
confirmed the previously observed properties; they do not discriminate between the 
different phosphate species, having a log Ka value of around 3.5 for ATP, ADP, AMP and 
PPi. Because of this lack of selectivity and low signal intensity changes, binding constants 
for other NPPs were not determinined. 
Between the two amide bearing probes [Eu.2]
+
 and [Eu.5]
+
, the change in the local 
charge density at the metal centre was shown to improve the affinity by about one order of 
magnitude. The probe [Eu.5]
+
 binds most strongly to ATP and ADP with log Ka values of 
5.8 and 5.7 respectively. The selectivity of [Eu.5]
+
 was found to similar to that of [Eu.2]
+
, 
with one order of magnitude difference in binding strength between ATP/ADP and 
AMP/PPi and two orders of magnitude difference over HPO4
2- 
and HCO3
-
. Importantly, the 
binding constants determined for [Eu.2]
+
 were approximately 10 times lower than those 
determined for [Eu.5]
+
. This highlights the influence of changing the structure of the 
surrounding ligand from two carboxylate donors to neutral carbonyl amide donor groups.   
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Table 3.2: Apparent binding constants (log Ka) of probes [Eu.2]
+
 and [Eu.5]
+ 
and 
various anions, Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. Errors in 
measurements were ± 0.1 with the statistical error associated with the fit of the 
data <0.05.
 *
Work initially done by Jonathan Parris. Each value represents the 
average of at least two duplicate titration experiments. 
Anion [Eu.2]
+
 [Eu.5]
+
 
GTP 4.4
* 
5.3 
GDP 4.6
* 
5.2 
GMP 3.4 3.9 
UTP 3.6
* 
4.9 
UDP 4.2
* 
5.4 
UMP 2.7
* 
4.3 
 
The two complexes [Eu.2]
+
 and [Eu.5]
+
 bind more strongly to di- and triphosphate 
nucleotides than monophosphate anions, this is attributed to their larger negative charge, 
the complexes have an overall charge of +1 and bind stronger with anions bearing  -3 or -4 
charges. ATP and ADP also could potentially have additional stabilisation via hydrogen 
bonding interactions between the non-directly coordinated phosphate and the amide N–H 
moiety on the quinoline units. For monophosphate anions this interaction is not possible, 
hence the stronger affinity of [Eu.2]
+
 and [Eu.5]
+
 for ATP and ADP. This is supported by 
[Eu.1]
+
 and [Eu.4]
+
, lacking amide groups, which showed weaker binding to nucleoside 
polyphosphate anions and no selectivity between mono-, di- and triphosphate anions. 
No selectivity was observed between the different nucleotide bases for [Eu.2]
+
 and 
[Eu.5]
+
 (Table 3.2), they all showed similar selectivity with log Ka values for NTPs and 
NDPs being approximately one order of magnitude higher than NMPs. No obvious 
correlation between the specific nucleotide (adenine, guanine, uracil) and the binding 
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affinity/selectivity could be drawn, but their presence did seem to impact binding overall. 
Indeed, where NMPs bind relatively strongly to the [Eu.5]
+
 (log Ka from 4.3 to 4.8) 
hydrogen phosphate alone shows a lower affinity of log Ka = 2.7, implying that the 
nucleoside component is somehow involved in the binding. Applying the same logic 
between NDPs and PPi  is consistent with this result: NDPs bind to [Eu.5]
+
 with a log Ka 
from 5.2 to 5.7 whereas binding to PPi is 10 times weaker, once gain indicating that the 
nucleoside component contributes to binding. This is tentatively ascribed to a favourable 
hydrophobic interaction between the Eu(III) complexes and the nucleoside phosphates, but 
further studies (e.g. isothermal titration calorimetry) would be needed to confirm this 
effect. 
The binding of [Eu.cis2]
+ 
to ATP and ADP is weaker compared to [Eu.2]
+
: the 
binding constants are one order of magnitude lower (log Ka = 3.5 (± 0.2) vs log Ka = 4.4 (± 
0.2) for ATP and log Ka = 3.3 (± 0.2) vs log Ka = 4.6 (± 0.2) for ADP) and the change in 
the increase in emission is much smaller. This is a very good indication that a trans 
relationship of the quinoline arms on the macrocycle is favourable to bind to nucleoside 
polyphosphate anions. This complex and any other cis derivatives were thus ruled out as 
effective sensors for NPPs. This compound is still interesting from a structural point of 
view. Understanding why the binding is weaker with the cis geometry could lead to a 
better understanding of key properties that the ligand must possess in order to obtain 
strong, selective anion binding. 
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3.7. Terbium complex [Tb.2]+ 
 
Figure 3.15: Selectivity experiments showing the relative change in emission 
intensity, I(450–650)/I0 (where I0 = probe intensity (450–650 nm) in the absence of 
anions) of [Tb.2]
+
 (5 μM) in the presence of different anions (1 mM sodium salts). 
Conditions: 10 mM HEPES buffer, pH 7.0, λexc = 330 nm. 
The selectivity study of [Tb.2]
+
 (Figure 3.15) showed that the Tb(III) complex did 
not display a large variation in the emission intensity upon addition of most anions. ATP, 
ADP, CTP, CDP, UTP and UDP induced a small intensity increase, but this was not 
significant compared to [Eu.2]
+
. Additionally, this change is primarily due to an increase 
in the ligand fluorescence and not to a change in terbium(III) luminescence as shown 
Figure 3.16. Upon addition of AMP no real change is observed but upon addition of ADP 
or ATP a rise in the baseline fluorescence is observed with very minimal change in terms 
of Tb(III) luminescence. This indicated that if the quinoline fluorescence was removed, by 
using time-resolved luminescence measurements, the probe would not respond to any 
nucleoside polyphosphate anion under study. This property could be very useful as it can 
allow ratiometric detection of a target anion in complex media. Indeed, if [Eu.2]
+
 and 
[Tb.2]
+
 are used in conjunction the time-resolved emission signal of [Tb.2]
+
 should not 
fluctuate whereas the emission intensity of [Eu.2]
+
 will depend on the concentration of a 
target anion. The combination of both Eu/Tb signals can be used to generate a ratiometric 
signal that is intrinsically normalised. For the application in cells, it is considered that the 
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uptake and localisation behaviour will be identical for both probes as the ligand is identical 
and the properties of the lanthanide ion are similar, but this would need to be tested. 
 
Figure 3.16: Change in emission spectra of [Tb.2]
+
 (5 μM) as a function the added 
anion. Conditions: [anion] = 1 mM, HEPES buffer (10 mM), pH 7.0, λexc 330 nm, 
25 °C. 
To test the principle of ratiometric detection, ATP was titrated into a solution 
containing [Eu.2]
+
 and [Tb.2]
+
 (Figure 3.17). Upon addition of ATP the signals 
corresponding to the Eu(III) emission increased similarly to [Eu.2]
+
 alone while signals 
corresponding to [Tb.2]
+
 showed very little change in emission intentsity (due only to a 
rise in the ligand fluorescence intensity). Unfortunately, it was not possible to record time-
gated luminescence measurements using our spectrometer, but it was hypothesised that if it 
was possible the emission intensity of [Tb.2]
+ 
would be constant in the presence of ATP, 
providing an internal reference of the probe concentration. 
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Figure 3.17: Change in emission spectra of  [Eu.2]
+
and [Tb.2]
+
 (5 μM) as a 
function of added ATP. Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
 
3.8. Boronic acid complex [Eu.8]+ 
 
Figure 3.18: Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = probe intensity (605–630 nm) in the absence of 
anions) of [Eu.8]
+
 (5 μM) in the presence of different anions (1 mM sodium salts). 
Conditions: 10 mM HEPES buffer, pH 7.0, λexc = 330 nm. 
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For [Eu.8]
+
 bearing phenylboronic acid groups, anion screening was performed 
with different anions compared to the other complexes as the main goal was to test whether 
the presence or absence of sugar groups in different anions impacts the binding via the 
boronic acid moiety. The first result showed that AMP, dAMP, phosphoglucose and UDP-
glucose do not provoke any significant change in the luminescence intensity (Figure 3.18). 
Whereas the addition of ATP, ADP, dATP and dADP to the probe induced some changes 
to the intensity of the ΔJ = 2 band (605–630 nm) but the results were not quite as expected.  
Figure 3.19 shows that the addition of dATP and dADP, which do not possess the 
ribose diol moiety, result in a larger increase in the emission intensity than their ribose 
counterparts, ATP and ADP. One explanation for this phenomenon could be that upon 
addition of ATP, interaction with the boronic acid group reduces the binding interaction 
between the triphosphate component and Eu(III), rather than reinforcing it, hence the 
increase emission intensity is less pronounced. This implies that the flexibility and length 
of ATP or ADP is not sufficient to put the normally bound phosphates into close proximity 
to Eu(III). Other designs with different lengths of linkers between the quinoline and the 
boronic acid could be tested to validate or disprove this theory. 
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Figure 3.19: Change in emission spectra of [Eu.8]
+
 (5 μM) as a function of added 
a) ADP and c) dADP. The plots show the fit to the experimental data. Conditions: 
HEPES buffer (10 mM), pH 7.0λexc 330 nm, 25 °C. 
The titrations of ADP and dADP with [Eu.8]
+
 are consistent with this hypothesis. 
In the case of ADP, the plot of the intensity of the ΔJ = 2 band (605–630 nm) showed a 
complex binding isotherm suggesting that more than one binding event is occurring 
(Figure 3.19b), whereas in the case of dADP (Figure 3.19d) a more classical binding 
isotherm was produced, corresponding to a binding interaction similar to that observed 
with the previously studied probes. Further work is needed to understand the anion binding 
mechanism for this complex, however, time constraints and insufficient amounts of 
material prevented further investigation. 
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3.9. Structural study of europium complexes [Eu.2]+ and 
[Eu.cis2]+ 
 
Figure 3.20: Structure of ATP 
To gain a better understanding of the binding mode of the Eu(III) probes to specific 
anions an NMR study was conducted in collaboration with Dr Alan Kenwright (Durham 
University). To [Eu.2]
+
 and [Eu.cis2]
+
 was added aliquots of ATP and ADP and the 
1
H 
and 
31
P NMR spectra were recorded. Europium(III) is paramagnetic which causes a shift in 
the 
1
H NMR signals from the range 0 – 10 ppm to the range -40 – 50 ppm. In general, the 
closer to the europium(III) centre the proton is, the more it will be shifted.
164
 The same 
logic can be applied to the 
31
P NMR spectra where usually the unbound phosphates of 
polyphosphate anions range from -30 to 0 ppm but when bound to a europium complex the 
range changes to around -80 to -30 ppm.  
 
Figure 3.21: Change in 
1
H NMR spectra of [Eu.2]
+
 (5 mM) as a function of added 
ATP in D2O at pD 7.4, 400 MHz. 
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Figure 3.21 shows the variation of the 
1
H NMR spectra of [Eu.2]
+
 as a function of 
added ATP. The complex alone (0 eq of ATP) has sharp peaks consistent with one stable 
conformation. Upon addition of ATP the peaks get broader, and the shape and chemical 
shifts of the peaks vary. These two observations are consistent with the formation of at 
least one new conformation of the complex and with a rapid exchange between those 
conformations. The titration of ADP (Figure 3.22) gave similar results, providing limited 
information about the geometry of the host-anion interaction, but suggesting that the bound 
and unbound species are in fast exchange and that anion binding changes the overall 
conformation of the Eu(III) complex. 
 
Figure 3.22: Change in 
1
H NMR spectra of [Eu.2]
+
 (5 mM) as a function of added 
ADP in D2O at pD 7.4,400 MHz. 
Analysis of the
 31
P NMR spectra proved to be more informative. Figure 3.23 
displays the change in the 
31
P NMR spectra upon addition of increasing amounts of ATP 
(a) and ADP (b). Upon addition of 1 equivalent of ATP six peaks are observable; three 
peaks at -5, -10 and -20 ppm consistent with the peaks of unbound ATP in water at pH 7  
and three peaks at -37, -60 and -71 ppm. These three peaks are attributed to the peaks of 
bound ATP. For ADP (Figure 3.23b) upon addition of 0.5 equivalents of ADP only one 
bound conformation is observed (broad signal around -80 ppm) but upon addition of 1 or 2 
equivalents of ADP two distinct signals appear in the same area, corresponding to the two 
phosphates of bound ADP. Additionally, signals for unbound ADP are observed at -5 and -
0.5 eq of ADP 
1 eq of ADP 
2 eq of ADP 
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10 ppm (along with a signal corresponding to inorganic phosphate impurity at 4 ppm). This 
data confirms that upon binding ATP or ADP a stable complex is formed that is observable 
on the 
31
P NMR timescale.  
 
 
 
Figure 3.23: a) Change in 
31
P NMR spectra of [Eu.2]
+
 (5 mM) as a function of 
added ATP in D2O at pD 7.4,400 MHz. b) Change in 
31
P NMR spectra of [Eu.2]
+
 
(5 μM) as a function of added ADP in D2O at pD 7.4,160 MHz. 
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As a comparison [Eu.cis2]
+
 was studied with NMR spectroscopy under the same 
conditions (Figure 3.24). On the contrary to [Eu.2]
+
, [Eu.cis2]
+
 appears to have more than 
one conformation in the absence of added anions, but upon binding to ATP the peaks 
sharpen, and a more prominent conformation appears. The 
31
P NMR spectra is similar to 
[Eu.2]
+
, upon addition of one and two equivalents of ATP it is clear to see the bound and 
unbound ATP at similar chemical shift to that observed for [Eu.2]
+
. The NMR data alone 
does not show any significant difference in the binding mode. 
 
 
Figure 3.24: a) Change in 
1
H NMR spectra of [Eu.cis2]
+
 (5 mM) as a function of 
added ATP in D2O at pD 7.4,400 MHz. b) Change in 
31
P NMR spectra of 
[Eu.cis2]
+
 (5 μM) as a function of added ATP in D2O at pD 7.4,160 MHz. 
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In the 
31
P NMR spectrum, the three phosphate signals of unbound ATP appear at -5 
ppm for γ-phosphorus, -10 ppm for α-phosphorus and -20 ppm for β-phosphors. To gain a 
better understanding of the binding mode it is useful to identify the phosphates of ATP in 
the bound species. Therefore, the 
31
P NMR spectrum of [Eu.2]
+
 and ATP (1 equiv.) was 
recorded with both bound and unbound ATP present. Each bound ATP signal was then 
suppressed systematically by pulsing at the appropriate frequency, causing suppression of 
the corresponding unbound phosphate due to the binding equilibrium. Table 3.3 displays 
the variation of the integral (Δ) of each peak upon pulsing. Upon pulsing the peak at - 35 
ppm there is a decrease in the intensity of the signal for the β-phosphorous peak at - 20 
ppm indicating that the peak at -35 ppm is the bound β-phosphate of ATP. The same logic 
was applied to the other two bound peaks indicating that the peak at - 60 ppm corresponds 
to the γ-phosphate of bound ATP and the peak at -70 ppm corresponds to the α-phosphate 
of bound ATP. The NMR spectra from which this table was made are available in the 
experimental section as well as a 
31
P NOESY corroborating these results (Figure 9.41-
9.44). The 
31
P NOESY NMR shows a correlation signal for the β-phosphorus at the 
crossing of -20 and -35 ppm and for the γ-phosphorus the crossing is at -5 and -60 ppm. 
The α-phosphorus did not resolve in this experiment, but by the process of elimination it is 
possible to deduce the final peak as the α-phosphate, confirmed by the selective inversion 
experiment described above. 
Table 3.3: Study of the variation of the integral (Δ) of each signal upon selective 
inversion of the 
31
P signals of [Eu.2]
+
-ATP. Conditions: D2O at pD 7.4,160 MHz. 
Pulsed 
wavelength 
Integral  at 
-5 ppm 
Integral at 
-10 ppm 
Integral  at 
-20 ppm 
Integral  at 
-35 ppm 
Integral at 
-60 ppm 
Integral  at 
-70 ppm 
None 1.0 1.0 0.6 0.7 0.5 0.5 
 -35 ppm 
1.0 1.1 0.4 0.3 0.6 0.5 
Δ  = 0.0 Δ = 0.1 Δ = - 0.2 Δ = - 0.4 Δ = 0.1 Δ = 0.0 
 -60 ppm 
0.6 1.0 0.6 0.7 0.2 0.4 
Δ = - 0.4 Δ = 0.0 Δ = 0.0 Δ = 0.0 Δ = - 0.3 Δ = - 0.1 
 -70 ppm 
1.0 0.8 0.6 0.5 0.6 0.3 
Δ = 0.0 Δ = - 0.2 Δ = 0.0 Δ = - 0.2 Δ = 0.1 Δ = - 0.2 
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This result is surprising, it was hypothesised that ATP binding was taking place 
primarily between the γ-phosphate and the europium(III) ion and the β-phosphate was 
hydrogen bonding to the quinoline amide arms. The NMR study of the shift between the 
corresponding peaks of bound and unbound ATP indicates that the α- and γ-phosphates are 
closest to the europium(III) ion and that the β-phosphate is further away. 
In order to model this binding mode, a computational study was performed by Rhys 
Francis (MSc student) and Dr Felix Plasser (Loughborough), using DFT calculations. 
Calculating the stability of the different modes of binding (γ-bound versus α,γ-bound,  
Figure 3.25), it was found that the γ-phosphate bound to the europium(III) ion is the most 
favourable (lowest energy) binding mode. This is consistent with our initial hypothesis but 
not with the new insight given by the NMR study. 
   
a) b) 
γ phosphate of ATP 
bound to europium 
α-γ phosphate of ATP 
bound to europium 
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Figure 3.25: Energy minimised structures of the possible binding between ATP and 
[Eu.2]
+
 with interaction of the Eu(III) ion with a) the γ-phosphate, b) the α- and γ- 
phosphates and both of the quinolines and c) the α- and γ- phosphates but only one of the 
quinolines. 
A more in-depth study of the most favourable configuration where only the gamma 
phosphate is bound shows an interesting binding mode. One of the quinoline arms is 
further away than the other (2.6 and 2.8 Å respectively). The oxygen atoms of the γ-
phosphate also interact with the ligand with distances between quinoline amide N-H of 1.8 
and 1.7 Å. After the discovery of a potential α,γ- binding two scenarios were studied. First, 
in order to keep the coordination number of 9 for the ATP-bound species, one of the 
quinoline arms is moved away and leaves space for ATP to bind in a chelation mode. This 
is represented in Figure 3.25 (b), the configuration appears unstable: the bond between the 
europium ion and  to coordinated quinoline N atom is lengthened (2.8 Å) and no additional 
hydrogen bonding seems to take place. The second scenario is where the original geometry 
(in absence of bound anion) is maintained (Figure 3.25 c). In this model, one of the 
quinoline arms is pushed away anyway (Eu-N bonds are 3.5 Å for 2.8 Å respectively) but 
other stabilising interactions are maintained or created. For example, one quinoline amide 
N-H is 1.5 Å away from one of the oxygen atoms of the β-phosphate. Additionally, the 
c) 
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quinoline amide carbonyl oxygen is in close proximity to both ribose O-H groups (2.2 and 
1.8 Å). These modelling studies indicate that an α,γ- binding is both plausible and 
potentially benefits from additional stabilisation from multiple hydrogen-bonding 
interactions between the ligand and anion. 
To gain more information regarding the geometry of anion binding we attempted to 
obtain crystal structures. Unfortunately, we were unable to obtain crystal structures of a 
bound nucleoside polyphosphate anion (e.g. ATP), but we were able to obtain a crystal 
structure of [Eu.2]
+
 with formate bound to the Eu(III) ion (Figure 3.25). The cyrstals were 
grown from a mixture of methanol/water (1:1). This structure was resolved by Dr. Mark 
Elsegood (Loughborough). The compound crystallised in the high symmetry orthorhombic 
space group Fddd (See Figure 9.40 of the appendices). The europium(III) ion is bound to 
the ligand in the expected 8-coordinate manner, with the two quinoline arms positioned on 
the same face of the molecule. The formate ion is disordered with C(19) and O(5) 
modelled as disordered over two, equally-occupied, sets of positions determined by the 
symmetry. Notably, there are supramolecular contacts via quinoline N–H∙∙∙O hydrogen 
bonds to the terminal formate O(5) atom, indicating the ability of the quinoline amide arms 
to strengthen anion binding via hydrogen bonds. 
Looking beyond a single molecule, one unique water molecule was well-behaved 
and located in a general position with H atoms located. Another water molecule was 
located on a special position but H atoms could not be located. Atom O(5) of the bound 
formate accepts two H bonds, one intramolecular and one intermolecular. Neighbouring 
pairs of embraced molecule also form two pairs of rather ungainly π∙∙∙π interactions 
between their aromatic ring systems. These are not quite parallel so the inter-atom 
separations vary between ca. 3.38 Å at the short end between C(10) and C(11’), to values 
greater than 4 Å where the ring systems diverge. Pairs of embraced molecules are then 
linked into layers and these are linked via channels/zones of largely disordered water 
molecules, which H-bond with each other and suitably located donors and acceptors on the 
Eu(III) complexes (Figure 9.40 of the appendix). 
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Figure 3.26: Crystal structure of the complex [Eu.2]
+
 bound to formate.  
 
3.10. Conclusion 
 
The anion binding capabilities of six europium complexes were studied in buffered 
aqueous solution at pH 7.0. Urea containing complexes [Eu.3]
+
 and [Eu.6]
+
 were ruled out 
at early stages as anion-responsive probes for biological applications, because of their poor 
solubility in water and lack of a bound water molecule, which prevents the desired anion 
binding and signalling mechanism from taking place. 
An anion screening study was conducted using complexes [Eu.1]
+
, [Eu.2]
+
, 
[Eu.4]
+
, [Eu.5]
+
. Quinoline amide containing complexes [Eu.2]
+
 and [Eu.5]
+
 showed high 
potential for sensing ATP and ADP as the increase in emission intensity observed for these 
anions was much higher compared to other anions. [Eu.1]
+
 and [Eu.4]
+
, lacking hydrogen 
bond donor groups, did not show any discrimination between anions, nor did they display a 
strong enhancement in the emission intensity for any given anion, confirming the 
requirement for some functionality at the 7-position on the quinoline ring. 
The binding of our probes to different phosphate anions was assessed in aqueous 
buffer by luminescence titration experiments and the data was shown to fit to a 1:1 binding 
model, allowing apparent binding constants to be determined. Complexes [Eu.1]
+
 and 
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[Eu.4]
+
 showed no binding selectivity and low affinities, ruling them out for any further 
biological sensing applications.  
Complexes [Eu.2]
+
 and [Eu.5]
+
 were the most promising candidates for further 
study, as they showed high affinities and moderate selectivities for nucleoside di- and 
triphosphate anions over all other anions studied. They showed large enhancements in 
emission intensity in the presence of ATP and ADP (between 10 to 14-fold increases), they 
are soluble and stable in water over the physiological pH range. As such these complexes 
were identified as potential candidates for biological applications such as monitoring 
enzyme activity in real-time and imaging of target polyphosphate anions in living cells. 
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 Monitoring enzyme activity Chapter 4:
 
One of the primary objectives of this PhD study was to be able to monitor enzyme 
activity in real-time using luminescent Eu(III) complexes. Enzymes are the engines of the 
body;
165
 they regulate and control most biological processes. Monitoring enzyme activity is 
a key step for gaining a deeper understanding of complex biological processes and the 
progression of diseases. The phosphorylation of proteins by kinases (which converts ATP 
into ADP) regulates a range of biological mechanisms, including intracellular signal 
transduction,
166,167
 gene expression,
168
 hormonal signalling
169
 and neural processes.
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Misregulation of kinase activity is associated with a range of different cancers. Indeed, 
kinases represent one of the two largest classes of drug target in cancer therapy.
171
  
Besides kinases, ATP is a substrate for a range of other enzyme classes, including 
adenylate cyclases, DNA polymerases and ATPases. The hydrolysis of ATP to ADP by 
ATPases releases energy to power most cellular chemistry. Monitoring the consumption of 
ATP during these processes using a luminescent probe could be used to monitor the 
activity of these enzymes in real-time. Chapter 3 identified two probes, [Eu.2]
+
 and 
[Eu.5]
+ 
capable of binding and sensing ATP under physiological conditions. This chapter 
will study their capacity to monitor enzyme reactions in which ATP is converted to ADP.  
4.1. Real time monitoring of enzyme activity using [Eu.5]+ 
The first probe studied was [Eu.5]
+
, its selectivity between phosphoanions was 
shown to be very similar to [Eu.2]
+
, however, its binding affinity to ATP (and ADP) is 
approximately one order of magnitude larger and it is more soluble in water due to the two 
side arms bearing terminal carboxylic acid groups. Before any studies in the presence of an 
enzyme could be considered, the probe must be tested in an aqueous medium containing 
high (mM) concentrations of magnesium(II) ions. 
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4.1.1. Effect of the presence of magnesium(II) ion on probe [Eu.5]+ 
 
Most enzymes that use ATP as a substrate, such as ATPases and kinases, need 
magnesium(II) to stabilize the binding interaction between the enzyme and ATP.
172
 For our 
study it is important to note that the interaction between magnesium(II) and ADP is 50 
times weaker than with ATP, with log Ka (Mg-ATP) = 4.2 and log Ka (Mg-ADP) = 3.6,
173
 
the presence of magnesium(II) ions is thus expected to modulate the selectivity and 
apparent affinities obtained between the probes and ATP/ADP.
174
 
  
Figure 4.1: a) Selectivity experiments showing the relative change in emission 
intensity, I(605–630)/I0 (where I0 = Intensity (605–630 nm) of [Eu.5]
+
 in the 
absence of anions) of [Eu.5]
+
 (5 μM) in the presence of different anions (2 mM 
sodium salts). b) Spectral response of [Eu.5]
+
 in the presence of 5 mM Mg
2+
and 
different anions (2 mM sodium salts). Conditions: 0 or 5 mM Mg
2+
, 10 mM HEPES 
buffer, pH 7.0, λexc = 330 nm. 
Figure 4.1a) shows the emission response (605–630 nm) of [Eu.5]+ towards 
different phosphoanions in the presence and absence of 5 mM magnesium chloride. As 
expected, the luminescence response in the presence of magnesium(II) is different to that 
without. Interestingly, whilst a number of reported probes display a general decrease in 
emission for each phosphoanion in the presence of Mg(II), the response of [Eu.5]
+
 is more 
complex and varies with different anions.
175
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the presence of ATP: the intensity of the ΔJ = 2 (605–630 nm) band increases from 10-fold 
in water to 14-fold in the presence of Mg(II) ions.  On the other hand, the emission 
response for ADP decreases in the presence of Mg(II) ions (intensity of the ΔJ = 2 band 
decreases from 14-fold in water to 11-fold), reversing the sensing selectivity observed in 
the absence of MgCl2. Figure 4.1b shows the emission spectral change of [Eu.5]
+
 in the 
presence of 2 mM anions, in a background of 5 mM magnesium(II) chloride. It is clear to 
see that ATP now induces the largest response, with an 18-fold increase observed at 614 
nm. AMP and phosphate did not show any significant change: they respond weakly in the 
presence of magnesium(II) ions. 
 
Figure 4.2: a) Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ATP in a fixed background of 5 mM MgCl2. b) Isotherm for the ATP titration. Data 
could not be fit to a 1:1 binding model due to multiple equilibria in solution. 
Conditions: HEPES buffer (10 mM), pH 7.0, MgCl2 (5 mM), λexc 330 nm, 25 °C. 
Figure 4.2a shows the titration of ATP with [Eu.5]
+
 in a fixed background of 5 mM 
of MgCl2. The isotherm (Figure 4.2b) showing variation of the ΔJ = 2 (605–630 nm) band 
as a function of added ATP (0–4 mM) could not be fitted using a 1:1 binding model. The 
isotherm shows signs of two different binding events occurring, indicating multiple 
equilibria in solution. This could be explained by the initial binding of ATP to the probe at 
low ATP concentrations. As the concentration of ATP increases, the proportion of the 
ATP-Mg
2-
 increases also, and this species may bind to the probe leading to a further 
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enhancement in emission intensity. Notably, the two binding interactions do not result in 
any significant change in the spectral form, suggesting that the two species (ATP and ATP-
Mg
2-
) bind in a similar manner to [Eu.5]
+
. Unfortunately, despite several attempts to fit the 
data (including independent treatment of binding events), no binding affinities could be 
determined from this isotherm. To support our hypothesis that the Eu(III) complex forms a 
ternary adduct with ATP and magnesium(II), high resolution mass spectrometric analysis 
was conducted (Figure 4.3). A major signal for the ternary adduct [Eu.5+Mg+ATP+3H]
2+
 
was observed, and the calculated mass was in excellent agreement, indicating that this 
adduct is stable and exists in aqueous solution. 
 
Figure 4.3: High resolution mass spectral data for [Eu.5+Mg+ATP+3H]
2+
 
(EuC52H67N15O21P3Mg). 
One could argue that the changes in luminescence shown in Figure 4.2 are not 
arising from the magnesium(II) ion in particular but from the intrinsic additional ionic 
strength brought by it. Figure 4.4 shows the ATP titration in a background of 100 mM 
NaCl, which provides the same additional ionic strength as 5 mM MgCl2. The data fits 
very well to a 1:1 binding model, and the apparent affinity constant obtained is log Ka = 
4.3 ± 0.1, corresponding to a decrease in affinity compared to buffered water (log Ka = 5.8 
± 0.1). This means that the behaviour with magnesium(II) ion is due to a specific 
interaction between [Eu.5]
+
, ATP and Mg(II) and not only due to increased ionic strength. 
The unique capacity of ATP to increase the luminescence signal of [Eu.5]
+
 in presence of 
Calculated 
Observed 
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magnesium(II) ion is an unexpected result which was exploited for enzyme monitoring in 
the next step. 
 
 
Figure 4.4: a) Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ATP in a fixed background of 100 mM NaCl. b)  fit to the experimental data, for log 
Ka = 4.3 (± 0.1). Conditions: HEPES buffer (10 mM), NaCl (100 mM), λexc 330 nm, 
25 °C. 
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Figure 4.5: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added a) 
ADP and c) AMP in a fixed background of 5 mM MgCl2. The plots show the fit to 
the experimental data, for b) log Ka (ADP) = 4.6 (± 0.1) and d) log Ka (AMP) = 3.8 
(± 0.1). Conditions: HEPES buffer (10 mM), pH 7.0, MgCl2 (5 mM), λexc 330 nm, 
25 °C. 
Titrations of ADP and AMP in the presence of 5 mM Mg
2+
 are shown in Figure 
4.5, the fits for both sets of data were not problematic, showing again the specificity of the 
binding between ATP and [Eu.5]
+
 in the presence of magnesium(II) ion. The apparent 
affinity constants obtained are log Ka = 4.6 (± 0.1) for ADP and log Ka = 3.8 (± 0.1) for 
AMP, each one order of magnitude lower than those determined in buffered water. Having 
shown that ATP and ADP can be distinguished by [Eu.5]
+
 in the presence of 5 mM MgCl2 
we set to work on developing a proof-of-concept assay for enzyme monitoring.  
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Figure 4.6: Proposed binding mode for the ternary adduct [Eu.5-ATP-Mg]
-
. 
 
4.1.2. Simulation of the monitoring of enzyme activity 
 
Before undertaking costly experiments with enzymes, it was decided to try 
simulating the activity of an enzyme called apyrase. Apyrase is a membrane protein from 
the class of the ATPases, which hydrolyse ATP into phosphate and ADP, releasing energy. 
Figure 4.7 shows the simulation of an apyrase reaction. The emission intensity of [Eu.5]
+
 
in the presence of different ratios of ATP and ADP was recorded and plotted in the graph 
below.  
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Figure 4.7: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of the ratio 
of ATP/ADP in a fixed background of 5 mM MgCl2. Conditions: Total [ATP + 
ADP] = 2 mM, HEPES buffer (10 mM), pH 7.0, MgCl2 (5 mM), λexc 330 nm, 25 °C. 
Starting from 100% of ATP (2 mM) to reach finally 100% of ADP (2 mM), the 
graph Figure 4.7 shows that the ΔJ = 0 band was not affected by the change in ATP/ADP 
ratio, but for the ΔJ = 1 band the emission increased at 594 nm, whereas the emission 
intensity of the ΔJ = 2 component centred at 614 nm decreased when going from high ratio 
of ATP to high ratio of ADP. The changes are significant for such competitive conditions 
and the different behaviour observed at different wavelengths could be used to provide 
ratiometric measurements. Different wavelength bands (e.g. ΔJ = 2/ΔJ = 1) and points 
were selected, and the best plot was obtained using the 614/594 nm intensity ratio. A linear 
plot was obtained (Figure 4.8) with an almost a 3-fold decrease in the 614/594 nm ratio 
upon simulated conversion of ATP to ADP. This plot was encouraging and indicated that 
[Eu.5]
+
 could be used to monitor apyrase activity in real-time. 
 
Figure 4.8: Change in the emission intensity ratio of [Eu.5]
+
 at 614/594 nm (5 μM) 
as a function of the ratio of ATP/ADP in a fixed background of 5 mM MgCl2. 
Conditions: [ATP + ADP] = 2 mM, HEPES buffer (10 mM), pH 7.0, MgCl2 (5 
mM), λexc 330 nm, 25 °C. 
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4.1.3. Real time monitoring of apyrase activity 
Apyrase uses either Ca
2+
 or Mg
2+
 as cofactor; its role is mainly to hydrolyse 
extracellular ATP into ADP. Apyrase will be used as our model enzyme for this study. To 
an aqueous solution of HEPES (10 mM) containing 2 mM ATP, 5 mM MgCl2 and 5 µM 
[Eu.5]
+
 was added apyrase with a very high (10:1) ratio of ATPase/ADPase (ensuring that 
ADP hydrolysis is minimised). Pleasingly, the enzyme reaction could be monitored upon 
conversion of ATP into ADP (and some AMP) the emission intensity of [Eu.5]
+
 increased 
at 594 nm and decreased at 614 nm (Figure 4.9), confirming the validity of our calibration 
plot obtained from the enzyme simulation.  
 
Figure 4.9: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of time (0 – 
45 min) in a fixed background of 5 mM MgCl2. Conditions: Apyrase (0.16 U), 
[ATP]0 = 2 mM, HEPES buffer (10 mM), pH 7.0, MgCl2 (5 mM), λexc 330 nm, 25 
°C. 
The experiment was repeated at different concentrations of apyrase, ranging from 0 
to 160 mU (Figure 4.10). The green plot in Figure 4.10a shows the variation in the 
intensity ratio at 614/594 nm in the absence of enzyme, showing very little variation over 
the recorded time, confirming that photobleaching and background ATP hydrolysis is 
minimal in this experiment. During the initial stage of the enzyme reaction the ratiometric 
change in emission is linear (Figure 4.10b), allowing qualitative comparison of the rate of 
reaction, which was proportional to the amount of enzyme added. For example, addition of 
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160 mU of enzyme gave a linear plot with a gradient of around 0.4 and for 80 mU enzyme 
the gradient reduced to 0.2.  
  
Figure 4.10: a) Change in ratio of the emission intensity of [Eu.5]
+
 at 614/594 nm  
(5 μM) as a function of time in a fixed background of 5 mM MgCl2. b) linear 
change at initial stages of reaction. Conditions: Apyrase (0-160 mU), [ATP]0 = 2 
mM, HEPES buffer (10 mM), pH 7.0, MgCl2 (5 mM), λexc 330 nm, 25 °C. 
One could suggest that the probe could influence the rate of reaction as it binds to 
ATP, potentially reducing the amount of ATP available, however, the binding of the probe 
with ATP (and ADP) is a rapid and reversible process (as demonstrated by the simulation 
study) and the concentration of probe used to monitor the enzymatic process (5 µM) is 
much lower compared to the amount of ATP (2 mM). This ensures that the rate of the 
enzyme reaction is not significantly affected by the sensing process. Additionally, the fact 
that we observe changes in reaction rate at different enzyme concentrations indicates that 
the enzyme reaction is rate limiting, not the host-anion binding process. 
 
4.1.4. Monitoring Apyrase with a ATPase/ADPase ratio of 1:1 
 
We wished to see whether [Eu.5]
+
 could be used to monitor an apyrase enzyme 
with a different ATPase/ADPase ratio of 1:1. This means that the transformation of ATP 
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into ADP happens at the same rate as the transformation of ADP into AMP. A simulation 
was setup where the initial amount of ATP (2 mM) was reduced and the corresponding 
amounts of ADP was produced and then consumed to form AMP (Figure 4.10 and Table 
4.1). The intensity at 594 nm initially increases (similar to the previous simulation), 
however, when a significant amount of AMP and phosphate is produced it reduces again 
making it difficult to consider this wavelength as a good indicator of the status of the 
enzyme reaction. At 614 nm the emission intensity is quenched significantly as ATP is 
transformed into ADP, when the concentration of ATP is low (0.2 mM, Table 4.1), a 
smaller reduction in emission intensity is observed from ADP to AMP. Finally, at 620 nm 
the emission inititally increases as the concentration of ADP increases, but as AMP 
dominates, a decrease in intensity occurs, as well as the appearance of a peak at longer 
wavelength (625 nm). These changes are consistent with the results observed for the 
individual titrations of these anions in 5 mM MgCl2 (Figure 4.4 and 4.5) and the limiting 
spectra presented in Figure 4.1b.  
 
 Figure 4.11: Change in intensity of [Eu.5]
+
 as a function of the concentration of 
different molar ratios of ATP, ADP and AMP in aqueous solution at pH 7.0. 
Conditions: Apyrase (0.33 U), HEPES buffer (10 mM), MgCl2 (5 mM), λexc 330 nm, 
25 °C, varying amounts ATP, ADP, AMP and phosphate. 
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Table 4.1: Table of the variation of the concentration of anions used in the apyrase 
simulation (Total adenosine concentration is constant at 2 mM). 
Anion Concentration (mM) 
ATP 2.0 1.8 1.6 1.4 1.2 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.3 0.2 0.2 0.1 0.1 0.0 0.0 
ADP 0.0 0.2 0.4 0.5 0.7 0.7 0.9 0.9 0.9 0.8 0.8 0.7 0.7 0.6 0.6 0.5 0.4 0.2 0.1 0.0 
AMP 0.0 0.0 0.0 0.1 0.1 0.3 0.2 0.3 0.4 0.6 0.7 0.9 1.0 1.1 1.2 1.4 1.5 1.7 2.0 2.0 
HPO4
2-
 0.0 0.2 0.4 0.7 0.9 1.3 1.3 1.5 1.7 2.0 2.2 2.5 2.7 2.9 3.0 3.2 3.4 3.7 4.0 4.0 
 
 
To 2 mM of ATP in HEPES (10 mM, pH 7.0), [Eu.5]
+ 
(5 µM) and 5 mM Mg
2+
 was 
added apyrase (ATPase/ADPase ratio of 1:1) and emission intensity was recorded over 
time (Figure 4.12). At initial stages of the reaction, no intensity increase at 594 or 620 nm 
occurs, however the decrease centred at 614 nm starts slow and then accelerates. These 
observations suggest that a small amount of ADP is binding to the probe at any given time, 
indicating that the enzyme is actually hydrolysing ADP much faster than ATP and that we 
essentially observe a transition from ATP to AMP. This is consistent with the fact that the 
shoulder observed around 620 nm becomes a peak as more AMP and phosphate are bound, 
as observed in the simulation. Also, the maximum intensity at 614 nm decreases regularly 
over time instead of going down in a stepwise manner, consistent with a scenario where 
very little ADP is present during the reaction. Conducting a second simulation, going 
straight from ATP to AMP and phosphate could be the next step towards verifying this 
hypothesis and allowing real–time monitoring of apyrase with an ATPase/ADPase ratio of 
1:1.  
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Figure 4.12: a) Change in emission spectra of [Eu.5]
+
 as a function of time. 
Conditions: HEPES buffer (10 mM), MgCl2 (5 mM), ATP (2 mM), Apyrase (0.33 
U), λexc 330 nm, 25 °C. b) Change in intensity of the ΔJ = 2 band of [Eu.5]
+
 as a 
function of time in aqueous solution at pH 7.0. Conditions: HEPES buffer (10 mM), 
MgCl2 (5 mM), ATP (2 mM), Apyrase (0.33 U), λexc 330 nm, 25 °C. 
4.2. Real time monitoring of enzyme activity with [Eu.2]+ 
and [Tb.2]+ 
For complex [Eu.2]
+
 the same process was performed to study its potential as a 
probe for real time monitoring of enzymatic reactions and again the first step was the study 
of the behaviour of the probe towards anions in the presence of Mg
2+
 ions. The following 
experimental work was conducted by Dr Sarah Hewitt, allowing my work to focus on 
developing [Eu.5]
+ 
for application
 
in cellular imaging (Chapter 5). The apparent binding 
constants for ATP and ADP in the presence of 3 mM Mg
2+
 were measured to be log Ka = 
3.7 (± 0.1) and log Ka = 4.1 (± 0.1) respectively. In the absence of magnesium(II) these 
values were log Ka = 4.4 (± 0.1) and log Ka = 4.6 (± 0.1) respectively, showing a greater 
decrease for ATP than for ADP due to the higher affinity of magnesium(II) for ATP.
173
 
Figure 4.12 presents the titration of Mg
2+
 ions in to a solution of 1 mM of each anion and 
[Eu.2]
+
. For [Eu.2]
+
, ADP induces a larger increase in emission intensity compared to 
ATP at the maximum emission (616.5 nm). This is fortuitous as in the case of enzymes 
transforming ATP into ADP, the intensity of the ΔJ=2 band will increase over the 
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enzymatic process. Generally, an increase of emission signal is preferable in bioassays or 
cellular imaging applications, as apposed to a decrease in emission that may be caused by 
other quenching processes, such as charge transfer to other biological species or 
photobleaching. In Figure 4.13 we can observe that the biggest difference between the two 
emission spectra of bound ATP and ADP is at approximately 3 mM MgCl2, which matches 
the concentration used in existing enzyme assays and was thus chosen as the ideal 
conditions for following enzyme reactions. 
 
Figure 4.13: Change in the emission intensity ratio of [Eu.2]
+
 at 616.5/599.5 nm (8 
μM) as a function of the concentration of MgCl2. Conditions: [ATP] and [ADP] = 
1 mM, HEPES buffer (10 mM), pH 7.0, λexc 330 nm, 25 °C. 
Figure 4.14 shows the difference in the emission spectral form and intensity of 
[Eu.2]
+
 for different anions in the presence and absence of the 3 mM of MgCl2. In the 
presence of Mg
2+
 the difference in intensity between ADP and ATP increases significantly. 
Even though the overall intensity diminishes on adding Mg
2+
 to the media, the 
discrimination of the probe for ADP is increased. This means that during an enzyme assay 
that converts ATP to ADP, the first and last emission recording will be further apart 
ensuring better resolution.  
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Figure 4.14: a) Change in the emission intensity ratio of [Eu.2]
+
 (8μM) for 
different anions in the absence of MgCl2. b). Change in the emission intensity ratio 
of [Eu.2]
+
 (8 μM) for different anions in the presence of 3 mM MgCl2. Conditions: 
[anion] = 1 mM, HEPES buffer (10 mM), pH 7.0, λexc 330 nm, 25 °C. 
From these results it was decided to study a kinase-catalysed phosphorylation 
reaction. Kinases are a major target in cancer drug discovery, and simple, reliable assays of 
kinase activity are needed for effective screening of new kinase inhibitors.
171,176–180
We 
chose to use the catalytic subunit protein kinase A (PKAc), a serine/threonine kinase that 
phosphorylates specific proteins. Figure 4.14 shows that the response of the probe towards 
phosphoserine (pSer) is minimal compared to ADP, as was the response to other 
components needed for the assay, including kemptide (H2N–LRRASLG–CO2H, 1 mM), 
DTT (1 mM) or PKAc (0.4 µM), which did not influence the emission of [Eu.2]
+
 in any 
significant manner. The Figure 4.15a show the change in the emission spectra of [Eu.2]
+
 as 
a function of the ratio of ADP/ATP. When the percentage of ADP was increased 
systematically (in the absence of enzyme), the emission intensity globally increased, 
particularly for the ΔJ = 2 (605–630 nm) band and the second component of the ΔJ = 1 
band. The ratio of 616.5 nm (the maximum of the ΔJ = 2 band) and 599.5 nm (the 
stationary point in the ΔJ = 1 band) was plotted against the mole fraction of ADP giving a 
linear increase. This data highlights our capacity to monitor in real time the transformation 
of ATP into ADP by following an increasing ratiometric luminescent signal. 
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Figure 4.15: a) Change in the emission intensity of [Eu.2]
+
 (5 μM) as a function of 
the ratio of ADP/ATP. b) Shows the linear increase of the ratio of 616.5/599.5 nm 
of [Eu.2]
+
 (5 μM) as a function of the mole fraction of ADP. Conditions: [anion] = 
1 mM, 3 mM Mg
2+
 HEPES buffer (10 mM), pH 7.0, λexc 330 nm, 25 °C. 
The next step was to monitor the enzymatic phosphorylation of kemptide by PKAc. 
Different concentrations of PKAc were added to ATP and Kemptide. Over the course of 
the enzyme reaction the peptide is phosphorylated and ATP is converted to ADP. Figure 
4.15a shows the variations of the maximum intensity for each concentration of PKAc 
studied. When no PKAc is present the intensity diminishes slightly due to photobleaching. 
In the presence of PKAc, the intensity rises, slowly for 0.05 µM enzyme but the rate 
increases each time the concentration of enzyme doubles. Figure 4.16b shows the potential 
to monitor initial enzyme reactions rates. The results show that within experimental error, 
when we double the concentration of enzyme, the rate of the reaction doubles also.  
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Figure 4.16: a) Variation of the intensity at 616.5 nm as a function of time when 
monitoring the activity of different amounts of PKAc. b) Linear change over the 
first ten minutes. Conditions: buffered aqueous solution (10 mM HEPES, pH 7.0), 
[Eu.2]
+
 (8 µM), PKAc (0–0.4 µM), kemptide (1 mM), ATP (1 mM), MgCl2 (3 mM), 
DTT (2 mM). λexc = 330 nm, 298 K. 
 
One of the major classes of new drugs is enzyme inhibitors, particularly kinase 
inhibitors.
171,181
 The inhibition of kinase activity by a potential new drug is usually 
monitored by complicated and lengthy processes. Often these assays are not capable of real 
time measurements (see section 1.3.5). [Eu.2]
+
 was able to efficiently monitor kinase 
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activity and assessing its ability to test inhibitors was the next step. Staurosporine, a well-
known inhibitor for many kinases, was added to the previously described enzymes assay 
(Figure 4.17). In the absence of staurosporine the enzymatic process occurs as before but 
upon addition, the process occurs much slower and the emission increases much slower. 
From 0.5 to 1 equivalent of staurosporine the inhibition of the enzyme is greater, as the rate 
of transformation of ATP to ADP decreases. Thus, [Eu.2]
+
 is able to monitor kinase 
activity in real-time and study the effect of inhibitors, by providing a long-lived 
luminescent signal. 
 
Figure 4.17: Time traces showing the change in emission intensity at 616.5 nm 
during the PKAc catalysed phosphorylation of kemptide, in the presence of 
staurosporine. Conditions: 10 mM HEPES, pH 7.0, [Eu.2]
+
 (8 µM), PKAc (0.4 
µM), kemptide (1 mM), ATP (1 mM), MgCl2 (3 mM), DTT (2 mM). λexc = 330 nm, 
298 K. 
In an extension of this work, we also showed that two probes [Eu.2]
+
 and [Tb.2]
+ 
can be used
 
in conjunction in order to obtain a ratiometric signal for enzyme monitoring. 
This work was done by Dr Sarah Hewitt and Miss Chloe Antonen (RSC summer student). 
Figure 4.18 shows the simulation of the transformation of GTP into GDP and phosphate, a 
reaction catalysed by GTPase, an important signalling enzyme in biology.
182
 The 
increasing intensity of the ΔJ = 2 band of [Eu.2]+ was divided by the stationary intensity of 
the ΔJ = 1 band of [Tb.2]+ leading to a linear ratiometric response proportional to the mole 
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fraction of GDP. This combination of Eu(III)/Tb(III) probes could thus be used to monitor 
another class of enzyme (GTPases) in real time, providing a ratiometric response that 
increases signal to noise. This work is ongoing and extends beyond the scope of this PhD 
study. 
 
Figure 4.18: Change in emission ratio of the [Eu.2]
+
 band (615–625 nm) / [Tb.2]+ 
(510–550 nm) as a function of the molar ratio of GDP. Conditions:[anion] = 8 μM 
of each probe, 1mM, MgCl2 5 mM,  HEPES buffer (10 mM), pH 7.0, λexc = 330 nm, 
25 °C. 
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4.3. Conclusion 
The application of probes [Eu.2]
+ 
and
 
[Eu.5]
+
 for real-time monitoring of enzyme 
reactions that consume ATP was studied. Initially, the emission response of probe [Eu.5]
+
 
towards adenosine phosphate anions in the presence of 5 mM magnesium chloride showed 
a reversal of sensing selectivity compared to buffered water. In this media, [Eu.5]
+
 showed 
a larger increase in emission for ATP compared to ADP, and monophosphate anions (AMP 
and phosphate) gave very small responses (as seen in buffered water). Unfortunately, it 
was not possible to determine an association constant between [Eu.5]
+
 and ATP due to 
multiple equilibria occurring in solution, which resulted in a ‘two-step’ binding isotherm. It 
is hypothesised that a highly emissive ternary complex forms between ATP, Mg and 
[Eu.5]
+
; this species was observed by high resolution mass spectrometry.  
The probe was then tested in simulated enzyme reaction conditions, which proved 
to reliably monitor the change in ATP/ADP ratio by a ratiometric luminescent signal. Next, 
the apyrase catalysed hydrolysis of ATP to ADP was monitored in real-time using [Eu.5]
+
 
.The reaction rate was found to be proportional to the amount of enzyme added, as 
expected. The more complex conversion of ATP to AMP via ADP hydrolysis was also 
successful and thus [Eu.5]
+
 is an efficient and stable sensor for discriminating ATP and 
ADP in competitive aqueous media.  
Following this success, other synthesised Ln(III) complexes where studied for 
different enzyme applications and further success was achieved. [Eu.2]
+
 was able to 
monitor kinase activity in real-time, providing a desirable increase-in-signal response as 
ADP is generated. Finally the combination of [Eu.2]
+
 and [Tb.2]
+
 was studied to provide a 
ratiometric readout of simulated GTPase activity. The ability to measure the red/green 
emission intensity of the two probes is a promising feature that could be utilised using a 
standard plate reader for more high throughput screening of enzyme activity and inhibitors. 
This work is ongoing and extends beyond the current PhD study.  
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 Cellular imaging of ATP levels Chapter 5:
 
The real time monitoring of ATP levels in cells would allow variations in energy in 
the cell to be monitored depending on stress, diseases or different type of cells.
142
 Owing to 
their unique photophysical properties, lanthanide complexes are being intensively used in 
cellular imaging applications. With the development of time–gated confocal microscopy 
the number of reported complexes has increased significantly in recent years.
119
 But to the 
best of our knowledge, no lanthanide–based probe for imaging of ATP in cells has been 
reported previously. Due to the current methods having significant drawbacks (section 1.3) 
it is necessary to develop new discrete europium complexes.
142
 The large Stokes’ shift, the 
long emission lifetimes, the capacity to tune the ligand to target a specific compartment of 
the cell, and their low toxicity makes them excellent candidates for cellular imaging. 
5.1. Intracellular media 
 
5.1.1. Proteins 
 
In this work, [Eu.2]
+
 and [Eu.5]
+
 were tested for applications in cells; the first step 
was to test their capacity to sense ATP in aqueous media containing proteins. Several 
literature examples have shown that emissive metal complexes can interact with proteins 
causing either enhancement or quenching of their emission.
35
 This is of course an 
unwanted feature when designing a probe that responds specifically to ATP.  
119 
 
 
Figure 5.1: Experiments showing the relative change in emission intensity, I(605–
630)/I0 (where I0 = Intensity (605–630 nm) of [Eu.2]
+
 or [Eu.5]
+
 in the absence of 
anions) of [Eu.2]
+
 and [Eu.5]
+
 (5 μM) in the presence of 0.4 mM HSA. Conditions: 
10 mM HEPES buffer, pH 7.0, λexc = 330 nm. 
A simple experiment involving the addition of human serum albumin (HSA) to 
both probes is displayed in Figure 5.1. HSA was chosen as the protein model because of its 
availability and abundance in the human body. For [Eu.5]
+
 only a small enhancement is 
observed, which can be attributed to the extra fluorescence of HSA tailing off into the 
Eu(III) luminescence. Whereas for [Eu.2]
+
 an over 2-fold increase in emission intensity 
was observed showing that probe [Eu.2]
+
 interacts with HSA and probably with other 
proteins.  
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Figure 5.2: Change in emission spectra of a) [Eu.2]
+
 and c) [Eu.5]
+
 (5 μM) as a 
function of added HSA (0–0.4 mM) in aqueous solution at pH 7.0. b and d) Plot of 
the emission intensity change (605–630 nm) versus HSA concentration and fitting 
of the data for b) log Ka = 4.8 (± 0.2) for [Eu.2]
+
 and d) log Ka = 3.5 (± 0.2) for 
[Eu.5]
+. Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
The titration of HSA into both probes confirmed these results (Figure 5.2), both 
probes seem to bind and interact with HSA but the resulting change in emission is very 
different. For [Eu.2]
+
 a substantial increase in emission is observed and a binding constant 
of log Ka = 4.8 (± 0.2) is observed, whereas for [Eu.5]
+
 a very small decrease in the 
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emission intensity is observed and the calculated binding constant is log Ka = 3.5 (± 0.2), 
more than two orders of magnitude less than ATP. Additionally, the luminescence 
lifetimes where measured for both probes in H2O and D2O yielding q values of 0 in both 
cases (Table 9.1 of the appendices), confirming that both probes interact with HSA but to 
different extents.  
The interaction between [Eu.5]
+
 and ATP was considered to be minimal and having 
only a small impact on the binding between ATP and the probe. This could be potentially 
attributed to the carboxylic acid bearing arms which constitute the difference between 
[Eu.5]
+
 and [Eu.2]
+
, which could be preventing the hydrophobic interactions between 
HSA and [Eu.5]
+
.  
 
 
Figure 5.3: a) Change in emission spectra of [Eu.5]
+
 upon addition of ATP in a 
fixed background of HSA (0.4 mM). b) Shows the fit to the experimental data, for 
log Ka = 3.8 (± 0.3). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
A titration of ATP into [Eu.5]
+
 in a fixed background of HSA (0.4 mM) is shown 
in Figure 5.3. The titration showed a 3-fold increase in emission intensity proving that the 
bound protein is displaced by ATP and showed an estimated apparent binding constant of 
log Ka of 4.0. This is approximately two orders of magnitude weaker binding to ATP 
compared to in the absence of protein. Under the same conditions [Eu.2]
+
 was unable to 
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sense a variation in the ATP concentration, illustrating the importance of considering the 
effects of protein binding when designing a probe for biological application. 
 
5.1.2. Recognition in simulated intracellular fluid 
 
Having demonstrated that [Eu.5]
+
 can detect ATP in the presence of physiological 
levels of magnesium(II) and human serum albumin, the next step was to simulate the 
intracellular environment and to measure the capacity of the probe for ATP sensing.  Prior 
to this, it was decided to determine the behaviour of the probe at different pH, as the probe 
must tolerate variations in pH inside the cell. A pH titration was performed with [Eu.5]
+
 in 
the presence of 2 mM ATP (Figure 5.4).  
 
Figure 5.4: Minimal change in emission spectra of [Eu.5]
+
 (20 μM) in the presence 
of 2 mM ATP, in water over the pH range 6.1–8.5,. λexc 330 nm, 25 °C. 
Over the range in which the pH can vary inside a cell (6.5 – 8.5) the change in 
emission intensity proved to be very small particularly around pH 7.3 and 8.0 which are 
mitochondrial and cytoplasmic pHs.
183
 What this implies is that any changes in cellular pH 
(e.g. due to stress) will have a minimal impact on the emission spectra of the probe, which 
is a considerable advantage over previously reported ATP probes, which are very sensitive 
to variations in intracellular pH.
15,184,185
 Additionally, stress to the cell can cause an 
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increase or a decrease in the level of dissolved oxygen in the cell, certain methods for ATP 
sensing also cause these variations (e.g. luciferase reaction).
186
 Figure 5.5 shows the 
response of [Eu.5]
+
 to dissolved O2 with and without the presence of 2 mM ATP. In each 
case, the variation of the luminescence signal is minimal (<5%). This data suggests that 
inside the cell a variation of O2 level is not going to impact the signal in any significant 
manner. 
 
Figure 5.5: Minimal (<5%) change in emission spectra of [Eu.5]
+
 (20 μM), alone 
and in the presence of 2 mM ATP, in air–equilibrated and degassed aqueous 
solution, λexc 330 nm, 25 °C. The solution was degassed by gentle bubbling of the 
sample with nitrogen gas for 10 minutes.  
Having verified that changes in pH and dissolved oxygen had a minimal 
interference on the emission response of [Eu.5]
+
, we next simulated the intracellular fluid 
of a healthy cell. Table 5.1 shows the solution the probe was tested on initially.  It is based 
on a modified Kreb’s buffer and contains a range of common cations, anions and 
biomolecules at their average cellular concentration. Cells contain nucleoside 
polyphosphates such as ATP (1–5 mM, 3 mM average), ADP (between 50–200 µM), GTP 
(average 0.5 mM) and UTP (average 0.5 mM).
14
 At this point it is important to note that 
the concentration of ATP is significantly higher, such that the. ATP/ADP ratios are 
maintained between 5 and 100 and the majority of the ADP is bound to proteins.
187
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crucial that an ATP sensor for cellular imaging purposes is able to work under these highly 
competitive conditions. 
 
 
Table 5.1: Composition of the initial simulated intracellular fluid (sodium salts). 
Compound Concentration / mM 
HEPES 25  
NaCl 110 
KCl 5.0 
CaCl2 2.5 
MgCl2 8.0 
Na2HPO4 0.90 
Lactate 2.3 
Citrate 0.13 
Pyrophosphate 0.05 
Glutathione 3.0 
HSA 0.4 
 
First, ATP was titrated in the absence of the nucleotides. Figure 5.6 shows the 
change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added aqueous ATP solution 
at pH 7.0. In this complex media, two binding events took place, like that observed in the 
presence of 5 mM Mg
2+
 ions. The overall emission intensity of [Eu.5]
+
 increased 3–fold, a 
detectable change that could be useful in cells.  
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Figure 5.6: a) Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. b) Data could not be fit to a 1:1 binding model 
due to multiple equilibria in solution. Conditions: Conditions: HEPES buffer (10 
mM, pH 7.4), NaCl (110 mM), KCl (5 mM), CaCl2 (2.5 mM), MgCl2 (8 mM), 
Na2SO4 (0.5 mM), sodium lactate (2.3 mm), sodium citrate (0.13 mM), Na2HPO4 
(0.9 mM), Na4P2O7 (0.05 mM), glutathione (3 mM), HSA (0.4 mM). λexc = 330 nm, 
25 °C. . 
The next step was to add biologically relevant amounts of NPPs to the media and to 
assess ATP binding behaviour. ADP (0.1 mM), GTP (0.5 mM), UTP (0.5 mM) were added 
to the simulated intracellular fluid and a titration of ATP was carried out (Figure 5.7). 
Under these conditions ATP was added, from 1 to 8 mM an increase in the emission 
intensity of the ΔJ = 2 band of 40% was observed. It is important to note that over this 
range the response was approximately linear over the biologically important ATP range 
(0.3 to 8.0 mM) (Figure 5.7b) indicating that [Eu.5]
+
 could be used to detect changes in 
ATP concentrations in intracellular fluid. 
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Figure 5.7: a) Detection of ATP in a simulated intracellular fluid, by monitoring 
the increase in emission intensity of [Eu.5]
+ (50 μM). b) shows the linear increase 
in Eu(III) emission intensity as a function of added ATP over the physiologically 
significant concentration range. Conditions: HEPES buffer (10 mM, pH 7.4), NaCl 
(110 mM), KCl (5 mM), CaCl2 (2.5 mM), MgCl2 (8 mM), Na2SO4 (0.5 mM), sodium 
lactate (2.3 mm), sodium citrate (0.13 mM), Na2HPO4 (0.9 mM), Na4P2O7 (0.05 
mM), glutathione (3 mM), HSA (0.4 mM), ADP (0.1 mM), GTP (0.5 mM) and UTP 
(0.5 mM). λexc = 330 nm, 25 °C.  
 
5.2. Cellular imaging of mitochondrial ATP 
 
During the life of a cell there are significant variations in energy levels. 
Considering that ATP is the primary energy source of the cell, being able to monitor ATP 
would allow the multiple energy requiring processes in the cell to be studied (e.g. muscle 
contraction, nerve impulses, protein transport, cell death). Moreover, if the imaging probe 
can resolve the sub-cellular compartments of cells it would be possible to monitor the 
production and consumption of ATP in the different organelles of the cell.   
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5.2.1. Probe design features 
 
For a probe to be viable for use in living cells it needs to have some key properties. 
It needs to cross the cell membrane; ideally it should exhibit a sub-cellular localisation 
profile in a particular organelle. It also needs to be non-toxic and to not perturb cellular 
homeostasis. Finally, over the time of study it should resist enzymatic degradation and 
photo bleaching.
188
 It was envisaged that the increased local positive charge of [Eu.5]
+
 and 
the intrinsic amphipathic nature of the surrounding ligand would help with the cellular 
uptake of the molecule and provide localization to the negatively charged inner membrane 
of the mitochondria. 
 
5.2.2. Subcellular localization 
 
The following cellular studies were conducted by Dr Robert Pal at Durham 
University. Cellular studies were conducted using NIH-3T3 cells and images were 
collected using fluorescence and laser scanning confocal microscopy (LSCM).
189
 
[Eu.5]
+ (50 μM) was incubated in NIH-3T3 cells for 2 hours resulting in the uptake 
of the Eu(III) complex. The localisation of [Eu.5]
+ 
inside the cell has been analysed using 
colocalization studies with MitoTracker Green (Pearson’s correlation coefficient, P = 0.91) 
(Figure 5.8). The predominant localisation was found to be in the mitochondria. The reason 
why [Eu.5]
+ 
tends to localise to the mitochondria could be due to the overall positive 
charge of the Eu(III) complex and the amphipathic nature of the molecule.
76
  
ICP-MS confirmed this localisation profile and after incubating 4 × 10
6
 NIH-3T3 
cells for 2 hours the concentration of Eu(III) in a given cell was found to be 69 µM (± 5%). 
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Figure 5.8: LSCM images showing (left) localisation of [Eu.5]
+ (50 μM) in the 
mitochondria of NIH–3T3 cells (exc 355 nm, em 605–720 nm); (middle) 
MitoTracker Green (exc 488 nm, em 500–530 nm); (right) RGB merged image 
verifying colocalization (P = 0.91). 
 
5.2.3. Stability and cytotoxicity 
 
In terms of stability of the Eu(III) probe, LSCM images were recorded over a 
period of 8 hours and showed very little quenching (±10%) of emission and the cells 
appeared to be healthy and growing during this timeframe (Figure 5.9). An assay was 
conducted over 24 hours to determine the cytotoxicity of [Eu.5]
+
 and was found to be 
greater than 200 μM (Figure 5.9). The incubation concentration used in the assays was 50 
µM, which means that under these conditions and on this time frame the probe can be 
considered non–toxic. 
 
 
[Eu.3]+	 MTG	 Merge	
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Figure 5.9: (Upper) Time–lapsed LSCM images of NIH–3T3 cells stained with 
[Eu.5]
+  (50 μM, λexc 355 nm, λem 605–720 nm) recorded at 0, 60, 120 and 160 
minutes post-incubation; (Lower) Graph showing minimal fluctuation (±10%) in 
the observed emission intensity of cells stained with [Eu.5]
+  
over 180 minutes.  
 
5.2.4. Intracellular performance 
 
5.2.4.1. Visualising elevated ATP levels in the mitochondria of living 
cells   
 
To artificially elevate ATP levels in cells we used staurosporine, a broad-spectrum 
inhibitor of kinase activity. Inhibiting kinase activity will have the short-term effect to 
increase the ATP levels as it reduces the enzymatic consumption of ATP. In the long term 
it will induce cell apoptosis as kinases are essential enzymes for normal cell function. 
Figure 5.10a (left) shows representative images of the change in the emission intensity 
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produced by cells. Before treatment with staurosporine (0 min) the low level of ATP 
induces low emission intensity but after 1.5 h with 10 nM staurosporine an increase in the 
emission intensity of each cell is visible. Figure 5.10b shows the plot of the overall 
brightness of the cells in the range (em 605–720 nm) over a period of 2.5 hours. We can 
observe that after treatment with staurosporine the increase in emission intensity is around 
65%, consistent with our in vitro experiments. After that time the signal reached a 
maximum and no obvious signs of cell apoptosis were evident during the timeframe of the 
experiment. To verify that the probe is not responsible for some modification of the cell’s 
behaviour (which causes increased probe uptake and thus an increase in the signal) the 
emission intensity was recorded over the same time frame without any addition of 
staurosporine. This experiment resulted in a variation of emission intensity of less than 10 
%.  
 
Figure 5.10: Real–time monitoring of elevated levels of ATP in mitochondria. (a) 
Time–lapsed LSCM images of NIH-3T3 cells stained with [Eu.5]+ (50 μM, exc 355 
nm, em 605–720 nm) before (0 min) and after treatment with staurosporine (10 
nM), a potent inhibitor of protein kinases; (b) Time-dependent increase in emission 
intensity (605–720 nm) of cells stained with [Eu.5]+ following treatment with 
staurosporine (10 nM).  
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The ICP-MS study of the cells with incubated staurosporine for 2 hours (Figure 
5.11) showed a very small variation in the concentration of europium(III) inside the cells 
compared to the experiment with no staurosporine, showing that the increase in intensity 
cannot be caused by an increase in probe uptake. 
 
Figure 5.11: ICP-MS data showing minimal variation in the accumulation of 
[Eu.5]
+
 within NIH-3T3 cells, grown under different conditions. For 4 × 10
6
 NIH-
3T3 cells incubated with [Eu.5]
+
 (50 μM) for 2 hours, the effective concentration of 
Eu(III) metal in a given cell is 69 μM (±5%), versus 65 μM (±10%) after treatment 
with staurosporine for 2 hours, and 62 μM (±8%) of Eu(III) after treatment with 
KCN for 30 minutes. 
The conclusion of this experiment is that [Eu.5]
+
 can detect cellular augmentation 
of ATP levels caused by the addition of staurosporine, over the first 2 hours an increase of 
the luminescence signal was observed in the mitochondria and after that time the cell 
started to enter apoptosis. This is consistent with previously reported work that showed that 
upon addition of staurosporine the ATP levels increased in the cytosol
185
 and the 
mitochondria
30
 before the cells died. 
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5.2.4.2. Monitoring depleted ATP levels in cells upon treatment with 
KCN  
 
 
 
Figure 5.12: (Upper) Comparison of LSCM images of NIH-3T3 cells stained with 
[Eu.3]
+ (50 μM, λexc 355 nm, λem 605–720 nm) in the presence and absence of 
glucose; (Lower) Time dependent decrease in emission intensity of cells stained 
with [Eu.3]
+ 
following treatment with KCN (0.1 mM) under glucose starvation 
conditions, referenced against cells grown in the presence of glucose (showing 
100% probe brightness). 
 
The next step was to see if it is possible to use [Eu.5]
+ 
 to monitor decreases in ATP 
levels in the cell. To do so potassium cyanide was used, it is a known inhibitor of oxidative 
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production via other mechanisms (glycolysis) the cells were incubated in glucose–free 
growth medium. In this media the observed decrease in emission intensity was of 20% 
compared to cells grown in media containing glucose. KCN was then added as shown in 
Figure 5.12. An important 80% decrease in emission intensity was observed in about 20 
minutes. This indicates that the decrease of ATP levels upon addition of KCN is fast and 
that the probe [Eu.5]
+ 
can detect rapid variations of ATP levels in living cells. This rapid 
depletion shows that upon addition of KCN, the level of ATP decrease very quickly due to 
the inhibition of oxidative phosphorylation consistent with previously reported work.
15
 
Once again ICP-MS analysis showed a variation of less than 10% of the accumulated metal 
in comparison to the untreated cells.  
A possibility that could explain this depletion in the emission intensity is that upon 
addition of KCN and inhibition of oxidative phosphorylation, the bicarbonate 
concentration might vary. Bicarbonate is involved in the regulation of the production of 
cyclic AMP, which is involved in the regulation of ATP production.
190
 It has already been 
proven that the probe binds to bicarbonate 100 times less than to ATP in aqueous buffered 
solution (Table 3.1) but it is necessary to show that a variation in the intracellular level of 
bicarbonate would not have a significant influence on the emission intensity. Following the 
procedure reported by Pal ,
191
 the cells were loaded with [Eu.5]
+
 and the atmospheric CO2 
level was modified in the imaging chamber from 2% to 7%. The total emission intensity 
after incubation of 1 hour under those conditions was measured and compared to the 
constant atmospheric pressure of 5% of CO2. The variation observed was of less than 10% 
(Figure 5.13) and thus could not explain the variations observed upon incubation with 
KCN. 
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Figure 5.13: Comparison of LSCM images of NIH-3T3 cells stained with [Eu.5]
+ 
(50 μM, λexc 355 nm, λem 605–720 nm) after incubation for 60 minutes at 2–7% 
atmospheric CO2. The graph shows less than 5% variation in the intensity of 
Eu(III) emission as a function of pCO2.  
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5.3. Conclusion 
 
Probes [Eu.5]
+ 
and [Eu.2]
+ 
bearing quinoline amide groups showed different 
binding behaviour towards human serum albumin; [Eu.2]
+ 
interacts
 
more strongly with 
HSA such that the emission signal is saturated and cannot signal the presence of ATP, 
whereas [Eu.5]
+ 
showed minimal interaction with HSA and could detect
 
ATP in a 
competition experiment.. The behaviour of [Eu.5]
+ 
in a simulated biological fluid was 
assessed and it was discovered that even in a highly competitive medium the probe could 
detect an increase in ATP levels within the physiologically relevant range, providing an 
increase in the emission intensity of about 65%. This result was then reproduced in living 
cells and upon addition of staurosporine, a broad spectrum kinase inhibitor, the emission 
intensity also increased by around 65%, consistent with an increase of intracellular ATP 
level. The probe was revealed to be cell permeable and localized preferentially to the 
mitochondria. Its cytotoxicity was shown to be minimal making it the first example of a 
luminescent lanthanide probe for the detection of ATP in living cells.  
The chemically induced reduction of ATP level in cells was achieved by addition of 
potassium cyanide and the emission intensity of [Eu.5]
+
 decreased to almost zero upon 
within 20 minutes, consistent with rapid depletion of ATP. These cellular imaging studies 
show that the probe [Eu.5]
+
 can detect changes in the concentration of ATP inside the 
mitochondria of living cells and could provide a versatile imaging tool for studying cell 
metabolism and other ATP requiring processes in real time. 
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 Conclusion and future work Chapter 6:
  
The synthesis of eight europium complexes and one terbium complex for the 
purpose of detecting polyphosphate anions has been reported. A convergent synthetic 
strategy was primarily employed: a number of 7-substituted quinoline units was 
synthesised containing different hydrogen bond donor (amide and phenyl urea) groups 
aimed to strengthen the interaction with ATP. At the same time different cyclen scaffolds 
were prepared, presenting different moieties to modulate the metal donor groups (and thus 
local positive charge) or the physical properties such as water solubility. After 
optimisation, the ligands thus obtained were complexed with europium(III) forming [Eu.1–
6]
+
 and [Eu.cis2]
+
 and terbium(III) to form [Tb.2]
+
. The efficient synthesis of these 8 
complexes via a convergent method allowed the fabrication of a small library of 
compounds. However, this strategy needed to be planned and seen through to the end 
before obtaining results and feedback for subsequent probe optimisation. A divergent 
strategy would allow a complex to be obtained and studied, in a short time, enabling a  
modified complex to be prepared based on these results. The disadvantage of a divergent 
strategy is that it only allows modifications on two of the moieties at a time, but it is a 
rapid method using a feedback loop to produce optimised compounds. Following this 
approach, complex [Eu.7]
+
 was prepared bearing two quinoline amine groups. Using this 
building block, the aromatic amines were functionalised with phenylboronic acid groups 
via amide linkages to give complex [Eu.8]
+
 , allowing the ribose component of ATP to be 
targeted. This convergent approach shows promise for the future preparation of this class 
of complexes. 
The photophysical properties of each complex were studied in buffered aqueous 
solution. Complexes [Eu.3]
+
 and [Eu.6]
+
 showed the longest absorption wavelength that 
was desirable for biological applications as the excitation of biomolecules will be less 
likely to interfere. In terms of the capacity of the probes to absorb light, [Eu.1]
+
 and 
[Eu.4]
+
 had the highest extinction coefficients, likely due to the lack of functionalisation of 
the quinoline units. They also have the highest quantum yield making them overall 
relatively bright europium complexes All synthesised complexes showed long 
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luminescence lifetimes (0.5 to 1 ms in water) with a particular mention for [Eu.3]
+
 and 
[Eu.6]
+
 with lifetimes of 1.08 and 1.16 ms, respectively. The luminescence lifetimes in 
deuterated water was also studied and allowed determination of the hydration state of the 
complexes. We discovered that the long lifetimes of [Eu.3]
+
 and [Eu.6]
+
 is due to the lack 
of bound water molecule, which is necessary for anion binding and sensing. All the other 
complexes possess a bound water molecule that could be displaced upon binding to target 
nucleoside polyphosphates anions. 
The anion binding properties of six europium complexes were studied in buffered 
aqueous solution at pH 7.0. Urea containing complexes [Eu.3]
+
 and [Eu.6]
+
 were ruled out 
as anion receptors for biological applications, because of their low solubility in water and 
lack of a bound water molecule. Quinoline amide containing complexes [Eu.2]
+
 and 
[Eu.5]
+
 showed high potential for sensing ATP and ADP as the increase in emission 
intensity observed for these anions was much greater than for all other anions tested. 
[Eu.1]
+
 and [Eu.4]
+
, on the other hand, did not show any selectivity between mono-, di- 
and triphosphate anions, nor did they display a strong enhancement in the emission 
intensity for any studied anion, confirming the requirement for some hydrogen-bonding 
functionality at the 7-position on the quinoline ring. The binding of the probes to anions 
was shown to fit to a 1:1 binding model and apparent binding constants were calculated 
from luminescence titration experiments. Complexes [Eu.1]
+
 and [Eu.4]
+
 showed no 
selectivity and low binding affinities ruling them out for further sensing applications. The 
terbium complex [Tb.2]
+ 
did not show changes in its emission spectrum in the presence of 
any studied anions, due primarily to the much lower sensitivity of the complex to 
quenching by bound water.  
Complexes [Eu.2]
+
 and [Eu.5]
+
 were identified as key candidates for biological 
applications, such as monitoring enzyme activity and cellular imaging. They showed strong 
binding and high selectivity for nucleoside di- and triphosphate anions over all other 
studied species. The increase in emission intensity in the presence of target polyphosphate 
anions (ATP for [Eu.5]
+
, ADP for [Eu.2]
+
) is substantial (around 10-14 times) and they are 
soluble in water and stable over the physiological pH range. The emission response of 
[Eu.5]
+
 towards ATP in the presence of 5 mM magnesium(II) ions is significantly higher 
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than that observed for ADP, whereas monophosphate anions (AMP and phosphate) give 
very small responses. Unfortunately, it was not possible to determine an association 
constant between [Eu.5]
+
 and ATP due to multiple equilibria occurring in solution, which 
resulted in a ‘two-step’ binding isotherm. It is hypothesised that a highly emissive ternary 
complex forms, ATP:Mg:[Eu.5]
+
, and this species was observed by high resolution mass 
spectrometry..The discrimination between ATP and ADP by [Eu.5]
+
 allowed the apyrase 
catalysed hydrolysis of ATP to ADP to be monitored in real-time, by providing a decrease 
in emission intensity that was proportional to the amount of enzyme added. Following this 
success in enzyme activity monitoring, other complexes where studied for similar 
applications and even greater success was achieved with [Eu.2]
+
. For this Eu(III) complex, 
a much higher emission response was observed for ADP in the presence of Mg(II) ions, 
compared to that of ATP. This was exploited to monitor kinase catalysed phosphorylation 
reactions in real-time, by measuring an increase in emission signal against the ADP/ATP 
ratio. Finally, the combined use of [Eu.2]
+
 and [Tb.2]
+
 was studied and allowed a 
ratiometric measurement of the ATP/ADP ratio (in a simulated enzyme reaction), by 
comparing the stationary emission of [Tb.2]
+
 with the increasing emission of [Eu.2]
+
 
Complex [Eu.5]
+ 
can detect ATP in the presence of human serum albumin whereas 
probe [Eu.2]
+ 
proved to interact too strongly with this protein for in vivo applications. The 
sensing behaviour of [Eu.5]
+ 
in a simulated biological fluid was assessed and it was 
discovered that even in a complex medium containing many potentially competing anions 
(GTP, UTP, pyrophosphate, bicarbonate) the probe could detect an increase of ATP levels 
within the physiological (millimolar) range. The probe was used in live-cell imaging 
experiments to detect ATP fluctuations as a function of time. The probe was shown to 
localise to the mitochondria and respond to changes in ATP levels upon treatment of the 
cells with staurosporine and potassium cyanide, which caused the emission intensity of the 
probe to increase and decrease, respectively. Its cytotoxicity was shown to be minimal 
making it the first example of a luminescent lanthanide probe for the detection of ATP in 
living cells. This Eu(III) probe could provide a versatile imaging tool for studying cell 
metabolism and other ATP requiring processes in real time. 
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The results that have been discussed are very encouraging and demonstrate the  
ability of this new class of lanthanide(III) complexes to detect nucleoside polyphosphate 
anions in biological media and in cells. Further research should be pursued to create anion 
receptors with even better properties. Firstly, the overall brightness of the probes could be 
improved in several ways, one possible approach could be to introduce an electron 
donating group (e.g. a methoxy group) at the 5-position of the quinoline unit. The impact 
on the Eu(III) complex should be to increase the extinction coefficient and thus increase 
the overall brightness, a property that is desirable for cellular imaging applications. An 
extra property of such functionalisation would be to increase the maximum absorption 
wavelength of the complex, which would better match the excitation wavelength of 
common lasers (355 nm) used in fluorescence microscopy and reduce the energy of the UV 
irradiation employed.  
Secondly, the utility of [Eu.2]
+
 for in vitro enzyme assays is very promising, 
however an unwanted feature of [Eu.2]
+
 is its strong interaction with proteins such as 
HSA. Based on the fact that [Eu.5]
+
 does not interact strongly with protein, and its main 
difference in structure is the two terminal carboxylate arms, it is proposed that the new 
complex [Eu.9]
+
 would show minimal binding to protein  but otherwise retain the desired 
anion binding and sensing properties of [Eu.2]
+
 (Figure 6.1). 
Finally, the development of terbium and europium complexes of a common ligand 
is potentially useful for future cellular applications. As demonstrated with [Tb.2]
+
 and 
[Eu.2]
+
 in vitro, it may be possible to detect ATP using the ratio of green/red emission 
from the complex pair. The stationary emission intensity of the terbium complex would 
serve as an internal calibration, making the measurement independent of probe 
concentration. This approach would require careful examination of probe uptake behaviour 
to confirm that both Eu(III) and Tb(III) complexes exhibit the same localisation inside the 
cell.  
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Figure 6.1: Next generation of Europium complex for ATP sensing. 
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 Experimental Chapter 7:
 
7.1. General procedures 
 
NMR spectroscopy  
1
H, 
13
C, 
31
P, COSY and HMQC NMR spectra were recorded in the stated 
deuterated solvent on a JEOL ECS-400 spectrometer (
1
H at 399.782 MHz, 
13
C at 100.525 
MHz, 
31
P 161.835 MHz), or a Bruker Advance Ultra-Shield 400 spectrometer (
1
H at 
400.134 MHz, 
13
C at 100.624 MHz, 
31
P 161.976 MHz) at 293 K. Chemical shifts are 
expressed in ppm and are adjusted to the chemical shift of the residual NMR solvent 
resonances (CDCl3: 
1H δ = 7.26 ppm, 13C δ = 77.16 ppm, CD3OD: 
1H δ = 3.31 ppm, 13C δ 
= 49.00 ppm or D2O:
 1H δ = 1.56 ppm). The coupling constants are expressed in Hz.  
Mass spectrometry 
Liquid Chromatography Electrospray Mass spectra were recorded on a Waters 
micromass LC system with a Waters 996 Photodiode Array Detector, a Waters 600 
controller and a Waters 2700 Manager sampler controlled using MassLynx version 3.2 
software. The system operates in positive or negative ion mode, with acetonitrile as the 
carrier solvent. The flow rate was maintained at 1.5 mL/min over a gradient of 5 to 95% 
acetonitrile (0.1% formic acid) in water (0.1% formic acid) for 8 minutes. High resolution 
mass spectra were recorded using a Thermofisher Q-Exactive orbitrap mass spectrometer. 
Ternary adducts were analysed by injected solutions of ~50 μM Eu(III) complex with ~500 
µM ATP, ADP or GTP and 500µM of MgCl2 in a mixture of methanol/water (1:1 v/v) and 
the spectrum recorded.  
Chromatography 
Column chromatography was performed using flash silica gel 60 (particle size 40–
63 microns) purchased from Apollo scientific. Thin layer chromatography (TLC) was 
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performed on aluminium sheet silica gel plates with 0.2 mm thick silica gel 60 F254 using 
the stated mobile phase. 
Preparative RP-HPLC was performed using a Waters 2489 UV/Visible detector 
performed at 254 nm, a Waters 1525 Binary HPLC pump controlled by the Waters Breeze 
2 HPLC system software. Separation was achieved using a semi-preparative XBridge C18 
(5 µm OBD 19 × 100 mm) column at a flow rate maintained at 17 mL/min. A solvent 
system composed of either water (0.1% formic acid) / methanol (0.1% formic acid) or 
water (50 mM NH4HCO3) / acetonitrile was used over the stated linear gradient (usually 0 
to 100% organic solvent over 10 min). Analytical RP-HPLC was performed using a 
XBridge C18 5 µm 4.6 × 100 mm at a flow rate maintained at 2.0 mL/ min using the same 
gradient and solvents. 
pH measurements 
Measurements of pH were carried out using a Jenway 3510 pH/mV meter with a 
Jenway combination electrode or a Jenway 3020 pH meter with an Aldrich glass 
combination pH electrode, both calibrated using buffer solutions of pH 4.00 ± 0.01, 7.00 ± 
0.01 and 10.00 ± 0.01.  
Optical spectroscopy 
Emission spectra were obtained using a 3 mL Kartell PMMA cuvettes, unless stated 
otherwise. With excitation at λmax for [Eu.1-4]
+
, reading emission in the range 550 – 720 
nm (for titrations) or 570 – 635 nm (for enzyme assays). Emission spectra were recorded 
on an SPEX Fluoromax luminescence spectrometer using dM300 version 3.12 software. 
An integration time of 0.5 seconds, increment of 0.5 nm and excitation and emission slits 
of 0.5 nm were used.  
UV/Vis absorbance spectra were measured on an GENESYS 10S UV/Vis 
spectrophotometer (Thermo Scientific) using VISIONlite version 5.2 software. Molar 
extinction coefficients were determined by first dissolving a known amount of Eu(III) 
complex in a known amount of solvent to give a bulk solution. Four solutions of known 
concentration, with absorbance values ranging between 0.1 and 1.0, were made up by 
dilution of the bulk solution. Molar extinction coefficients, ε, were calculated in 
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accordance with the Beer-Lambert law, by plotting absorbance, A, against complex 
concentration, c. Quantum yields were measured using a previously reported bis-
azaxanthone europium(III) complex, [Eu.L
1
(OH2)], in water as a standard (em= 0.018).
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Quantum yield values have an error of ±20%. 
Lifetime measurements were performed using a Perkin Elmer LS55 luminescence 
spectrometer with FL Winlab Molecular Spectroscopy version 4.00.02 software. Lifetime 
measurements were typically obtained by indirect excitation of the Eu(III) ion via the 
chromophore using a short pulse of light (at λmax) followed by monitoring the integrated 
intensity of the light emitted at 615 nm during a fixed gate time, tg, after a delay time, td. 
Measurements were made for a minimum of 20 delay times, covering 3 or more lifetimes. 
A gate time of 0.1 ms was used, and the excitation and emission slits were set to 10 and 5 
nm respectively. The obtained decay curves were plotted in Microsoft Excel and fitted to 
the equation:  
I = A0 + A1e
-kt
 
I: intensity at time t following excitation; A0: intensity when decay has ceased 
A1: pre-exponential factor; k: rate constant for the depopulation of the excited state 
General procedure for titrating [Eu.1–4]+ with anions 
A stock solution of Eu(III) complex was prepared in deionized water. Stock 
solutions of the anion (sodium salt, usually 0.001 M, 0.01 M, 0.1 M) were also prepared in 
10 mM HEPES buffer at pH 7.0. To a 1 cm cuvette containing 1 mL of 10 mM HEPES 
(unless stated otherwise), was added a solution of the probe so that the concentration of 
probe reaches 5 µM and the Eu(III) emission spectrum was recorded. Aliquots of the anion 
solution were then added, ensuring that the total added volume did not exceed 50 µL. After 
each addition, the solution was mixed with a pipette and the emission spectrum was 
recorded. Typically, 200 equivalents of the anion were added to the solution for titrations 
in 10 mM HEPES and up to 1000 equivalents for more complex aqueous media. Each 
titration was repeated at least twice. To determine apparent binding constants (reported as 
log Ka values) for the bound anion, two wavelength bands were selected (typically ΔJ = 
2/ΔJ = 1) and the emission intensity ratio was plotted as a function of anion concentration. 
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The titration data was analysed using a nonlinear least-squares curve fitting procedure, 
based on a 1:1 binding model described by the equation below: 
𝐹𝐵 =
1
𝐾𝑎
+ [𝑋] + [𝐸𝑢] − √(
1
𝐾𝑎
+ [𝑋] + [𝐸𝑢])2 + 4[𝑋][𝐸𝑢]
2[𝐸𝑢]
 
FB: fraction bound, calculated by (I-I0)/(I1-I0), where I = intensity at [X], I0 = initial 
intensity and I1 = final intensity 
[X]: total concentration of anion in solution 
[Eu]: total concentration of Eu(III) complex 
Ka: apparent binding constant 
 
pH titration 
The emission spectrum of 1 mL of 2 mM ATP and 25 µM [Eu.1–8]+ in deionized 
water at pH ̴ 5 was recorded (λexc = 330–340 nm, λem = 550–720 nm). A solution of NaOH 
(1 M or 100 mM) was added 2 µL at a time to the solution, increasing the pH by ~0.2 units 
until pH  ̴9 and an emission spectrum (λexc = 330 nm, λem = 550–720 nm) was collected 
after each addition. 
ATP to ADP titration: simulating apyrase activity  
Variable amounts of a solution of 2 mM ADP, 5 mM MgCl2 and 5 µM [Eu.5]
+
 in 
10 mM HEPES (pH 7.0) was added to 50 µL of 1 mM ATP, 5 mM MgCl2 and 5 µM 
[Eu.5]
+
 in 10 mM HEPES (pH 7.0), and the emission spectra (λexc = 330 nm, λem = 550 – 
720 nm) recorded after each addition. The ratio of the intensity at 614/594 nm was 
followed. Similar procedure was followed for [Eu.2]
+
.
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Apyrase activity assay 
Apyrase (ATPase:ADPase ratio, 10:1) was purchased from Sigma Aldrich as a 
lyophilised powder of ≥200 units/mg protein, and was used without further purification. 
Apyrase was added to ATP, MgCl2 and [Eu.5]
+
 in 10 mM HEPES (pH 7.0) to a final 
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volume of 90 µL and concentration of 2 mM ATP, 5 mM MgCl2 and 5 µM [Eu.5]
+
. 
Emission spectra (λexc = 330 nm) were obtained over the range 570–630 nm, with an 
average of 90 s between each recording. The ratio of the intensity at 614/594 nm was 
followed. Similar procedure was followed for [Eu.2]
+
.
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Cell culture 
An investigation of the cellular behaviour of complex [Eu.5]
+ 
was conducted using 
mouse skin fibroblast (NIH-3T3) cells using fluorescence and laser scanning confocal 
microscopy. Cells were maintained in exponential growth as monolayers in F-12/DMEM 
(Dulbecco’s Modified Eagle Medium) 1:1 that was supplemented with 10% foetal bovine 
serum (FBS). Cells were grown in 75 cm
2
 plastic culture flasks, with no prior surface 
treatment. Cultures were incubated at 37 °C, 20% average humidity and 5% (v/v) CO2. 
Cells were harvested by treatment with 0.25% (v/v) trypsin solution for 5 min at 37 ºC. 
Cell suspensions were pelleted by centrifugation at 1000 rpm for 3 min, and were re-
suspended by repeated aspiration with a sterile plastic pipette. Microscopy cells were 
seeded in 12-well plates on 13mm 0.17mm thick standard glass cover-slips or un-treated 
iBibi 100 uL live cell channels and allowed to grow to 40% – 60% confluence, at 37 ºC in 
5% CO2. At this stage, the medium was replaced and cells were treated with complex 
[Eu.5]
+
 (50 μM) and co-stains for the stated duration of loading time (please refer to main 
text and Figures 5.9 and 5.10). MitoTracker Green (MTG) was used as the co-stain of 
choice, due to matching the localisation profile of [Eu.5]
+ (Pearson’s correlation 
coefficient, P = 0.91). This stain was introduced to the Eu(III) complex containing media at 
the last 30 minutes of incubation, as a 100-fold diluted DMSO stock solution, resulting in a 
100 nM final concentration of MTG.   
For Eu(III) complex loading, co-staining and imaging, DMEM media (10% FBS) 
lacking phenol red (live-cell medium) was used. Following incubation as detailed above, 
the cover slips were washed with phosphate-buffered saline (PBS; pH 7.4) three times, in 
quick succession, and mounted on slides using live-cell medium. When glass coverslips 
were used, the edges were sealed with colourless, quick-dry nail varnish to prevent drying 
out of the sample. In the case of un-treated iBidi channels, all loading and washing 
experiments were carried out with gravitational 10 degree tilt. 
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Confocal microscopy  
Cell images were obtained using the PhMoNa system based on a Leica SP5 II 
microscope operating with a fiber-coupled 355 nm Coherent laser (Nd:YAG 3rd 
Harmonic, 80mW) for sensitised Eu(III) emission. Steady state fluorescence images were 
recorded using the PhMoNa enhanced Leica SP5 II LSCM confocal microscope equipped 
with a HCX PL APO 63x/1.40 NA LambdaBlue Oil immersion objective. Data were 
collected using 2x digital magnification at 100 Hz/line scan speed (4-line average, 
bidirectional scanning) at 355 nm (3rd harmonic NdYAG laser, set at 20 mW, 400 nJ/voxel 
total dwell time).  
The modular PhMoNa technique used in this work harnesses spatially modulated 
illumination intensities, using an in situ generated raster-scanned standing wave excitation 
beam optical grid pattern. Such an approach allows experimental resolution in both lateral 
and axial domains to be improved by at least a factor of 2 (x,y = 62 nm, z = 188 nm @ 355 
nm Ex 63x 1.40NA, 100 Hz/line, 200 nJ/voxel dwell time) and is free from time-
consuming post-image processing deconvolution algorithms.  
In order to achieve excitation with maximal Eu(III) complex emission, the 
microscope was equipped with a triple channel imaging detector, comprising a 
conventional PMT systems and two HyD hybrid avalanche photodiode detectors. The latter 
parts of the detection system, when operated in the BrightRed mode, is capable of 
improving imaging sensitivity by 25%, reducing signal to noise by a factor of 5. Frame size 
was determined at 1024 x 1024 pixel, with x2 digital magnification to ensure illumination 
flatness of field and 0.6 airy disc unit determining the applied pinhole diameter rendering 
on voxel to be corresponding to 62 x 62 nm
2
 (frame size 125 x 125 μm2) with a section 
thickness set at 188 nm (at 355 nm excitation). A HeNe or Ar ion laser was used to aid 
transmission image capture and when commercially available organelle-specific stains (e.g. 
MitotrackerGreen
TM
) were used to corroborate cellular compartmentalization.  
All imaging parameters are kept constant across experiments. This includes voxel 
size, laser power, line speed and averaging sequences. The threshold algorithm to control 
brightness automated by the Leica SP5 II software is calculated by the image specific 
signal-to-noise ratio or it is accessible post image-processing via imageJ 1.49h. 
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Analysis of probe brightness  
Probe brightness was determined relative to control cells incubated with [Eu.5]
+ 
alone. All imaging parameters such as image resolution, voxel size, laser power, detector 
gain, field of view (FOV), emission window and scan speed were kept constant throughout 
and a zero contrast value was established using blank unloaded cells. To allow sufficient 
signal-to-noise ratio and variation of contrast to monitor brightness increase or decrease as 
a function of modulated ATP levels the maximum overall brightness of each image using 
complex only was set at 150 (±5%) contrast value (from the maximum 255 mean grey 
value). Each image was analysed using Leica Advanced Fluorescence software. Each 
experiment was carried out on a full FOV containing up to 5 cells, with their brightness 
monitored as a function of time. Each experiment was repeated at least 5 times. Therefore, 
each time point shown in Figures 5.9 and 5.10 (main text) is an averaged representation of 
5 individual microscope slides with up to 5 cells/FOV using 5 predetermined perinuclear 
regions of each cell. The mean grey values of these 5 sample areas in the perinuclear 
region of the cell, with area of approximately 45 μm2 (45.243 ± 0.005 μm2) were recorded 
for each whole cell visible in the image. The mean of all values for each treatment (of at 
least 45 sample areas per treatment) was calculated and compared to the reference mean 
(120 sample areas).  
As localisation of [Eu.5]
+ 
was determined to be mitochondrial, 5 sample areas per 
cell were selected that were >75% occupied with mitochondria (example shown in Figure 
7.1). The voxel dimensions were chosen to minimise variation in the organelle content, 
both within and in the focal planes above and below each sample area, thus the axial 
dimension was at least 5 % of the total cell thickness. Regions were also selected with 
minimal time dependent cellular movement and organelle rearrangement in mind. To 
summarise, to determine an intensity value for each image, 5 small (about 500 pixels) areas 
were taken, representing a mitochondrial region of the cell.  The values observed in each 
case were averaged, giving the Eu(III) emission intensity (within the  window 600-720 nm) 
for that image. 
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Figure 7.1: Example of 5 sample areas, showing >75% occupancy by stained 
organelles. 
 
Cellular uptake and toxicity studies 
Cell toxicity measurements were conducted using a ChemoMetec A/S 
NucleoCounter3000-Flexicyte instrument with Via1-cassette cell viability cartridge. The 
cellular stain Acridine Orange was used for cell detection and the nucleic acid stain DAPI 
was used to detect non-viable cells. The experiments were carried out in triplicate.  
In cellular uptake studies, cells were seeded in 6-well plates and allowed to grow to 
80% – 100% confluence, at 37 ºC in 5% CO2. At this stage, the media was replaced with 
media containing [Eu.5]
+
 and total cellular europium was determined using inductively 
coupled plasma mass spectrometry (ICP-MS), by Dr. C. Ottley in the Department of Earth 
Sciences at Durham University. 
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X-Ray studies 
Data collection: CrysAlis PRO 1.171.39.46b (Rigaku OD, 2018); cell refinement: 
CrysAlis PRO 1.171.39.46b (Rigaku OD, 2018); data reduction: CrysAlis PRO 
1.171.39.46b (Rigaku OD, 2018); program(s) used to solve structure: SHELXT 2014/5 
(Sheldrick, 2014); program(s) used to refine structure: SHELXL2018/1 (Sheldrick, 2018); 
molecular graphics: Bruker SHELXTL; software used to prepare material for publication: 
Bruker SHELXTL. Radiation type: Mo Kα; μ (mm-1):1.63; Diffractometer: Rigaku FRE+ 
equipped with VHF Varimax confocal mirrors and an AFC12 goniometer and HyPix 6000 
detector diffractometer. Absorption correction: Gaussian CrysAlis PRO 1.171.39.46b 
(Rigaku Oxford Diffraction, 2018) Numerical absorption correction based on gaussian 
integration over a multifaceted crystal model. Empirical absorption correction using 
spherical harmonics,   implemented in SCALE3 ABSPACK scaling algorithm. 
 
Synthesis 
All reagents were purchased and used as received. Analytical and anhydrous 
solvents were purchased from Fischer Scientific and were laboratory grade. Water was 
purified by the ‘puritestillplus’ system, with conductivity of 0.04 µS cm-1. 
Computational modelling 
All DFT calculations were carried out using the QChem 5.1 package27, at room 
temperature and generally with a water solvent model unless otherwise stated. Initial 
calculations were carried out to identify the optimal method for the calculations being 
conducted on the molecules, which proved to be a B3LYP hybrid functional with a DFT-
BJ (Becke-Jonson)28 method ,Stuttgart-Bonn Large Core (SRLC) effective core potential 
(ECP) and def2-sv(p) basis for all atoms other than europium (III). The following methods 
were also attempted and were either unsuccessful or made little difference to the 
calculations: B3LYP with Stuttgart-Bonn Small Core (SRSC) ECP, PBEO hybrid 
functional with SRLC ECP and B3LYP hybrid functional with def2-tzvp basis. In 
calculations requiring a solvent, a PCM method was used with the following dielectric 
constants (ɛ) where necessary: H2O (78.39), Methanol (36.64). Additional single-point 
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calculations were carried out to generate orbital calculations to identify the highest 
occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LOMO) of 
the investigated molecules to gain further insight into the behaviour of the molecule. 
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7.2. Synthetic procedures 
 
7-Bromoquinaldine (2.4)
27
 
3-Bromoaniline (9.4 mL, 86 mmol) was added to aqueous HCl (5 M, 60 mL) and 
the mixture was stirred at 110 °C, until the solid had fully dissolved. Crotonaldehyde (8.6 
mL, 103 mmol) was added as a solution in toluene (6 mL) over a period of 30 min. The 
reaction mixture was heated for a further 1 h, and then the solution was allowed to cool 
down to 60 °C. ZnCl2 (11.7 g, 86 mmol) was added slowly over 10 minutes. The reaction 
mixture was cooled in an ice bath, causing a precipitate to form, which was isolated by 
decanting the liquid which was filtered and the solid added back. The brown coloured solid 
was dissolved in a mixture of dichloromethane (150 mL) and aqueous ammonia (29%, 150 
mL) and stirred until complete dissolution had been achieved. The organic layer was 
separated and the aqueous layer extracted with dichloromethane (3 × 150 mL). The 
combined organic fractions were dried (MgSO4) and concentrated under reduced pressure. 
The crude material was purified by column chromatography (silica gel; neat 
dichloromethane, then dichloromethane/methanol 98/2 v/v) to give 7-Bromoquinaldine 2.4 
as a white solid (6.22 g, 33%); m.p. 77–79 °C (lit27: m.p. 77–79 °C); 1H NMR (400 MHz, 
CDCl3) δ 8.21(1H, H
8
), 8.01 (d,
 3
J = 8.5 Hz,1H, H
4
), 7.63 (d,
 3
J = 8.5 Hz, 1H, H
5
), 7.56 
(dd, 
 4
J =  2 Hz,
 3
J = 8.5 Hz, 1H, H
6
), 7.30 (d,
 3
J =  8.5 Hz, 1H, H
3
), 2.74 (3H, H
9
); 
13
C 
NMR (100 MHz, CDCl3) δ 160.3 (C
2
),148.5 (C
8’
), 136.2 (C
4
), 131.2 (C
8
), 129.4 (C
6
), 
128.9 (C
5
), 125.2 (C
4’
), 123.7 (C
7
), 122.5 (C
3
) 25.5 (C
9
); m/z (ESI
+
) 221.9918 [M+H]
+
 
(C10H9NBr requires 221.9918); Rf = 0.50 (silica, CH2Cl2/CH3OH, 98/2 v/v). The spectral 
data were consistent with those reported previously.
27
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7-Aminoquinaldine (2.5)
27
 
7-bromoquinaldine 2.4 (1.80 g, 8.1 mmol) was dissolved in degassed dimethyl 
sulfoxide (16 mL) and K2CO3 (3.36 g, 24.3 mmol), L-proline (0.373 g, 3.2 mmol), CuI 
(0.309 g, 1.6 mmol) were added sequentially. The resulting mixture was stirred under 
nitrogen for 15 min. Degassed ammonium hydroxide (6.5 mL, 28%) was added and the 
solution was stirred under argon at 90 °C for 48 h. The mixture was cooled to rt and then 
partitioned between dichloromethane (60 mL) and saturated NH4Cl (60 mL). The aqueous 
layer was extracted with dichloromethane (3 × 60 mL) and the combined organic layers 
were washed with water (60 mL), dried (MgSO4) and the solvent removed under reduced 
pressure. The crude material was subjected to column chromatography (silica gel; hexane: 
ethyl acetate, 50/50 v/v, then ethyl acetate: methanol, 90/10 v/v) to give compound 2.5 as a 
light brown solid (0.654 g, 51%); m.p. 144–146 °C (lit.192 m.p. 143–145 °C); 1H NMR 
(400 MHz, CDCl3) δ 7.86 (d, 
3
J = 8.5 Hz, 1H, H
4
), 7.55 (d,
 3
J = 8.5 Hz, 1H, H
5
), 7.14 (d,
 
4
J = 2.5 Hz, 1H, H
8
), 7.02 (d, 
3
J = 8.5 Hz, 1H, H
3
), 6.91 (dd ,
 4
J =  2.5 Hz,
 3
J  8.5 Hz, 1H, 
H
6
), 4.03 (br 2H, NH2), 2.66 (3H, H
10
); 
13
C NMR (100 MHz, CDCl3) δ 159.3 (C
2
),149.5 
(C
8’
), 147.9 (C
7
), 136.2 (C
4
),128.8 (C
5
), 120.6 (C
4’
), 118.7 (C
3
), 117.8 (C
6
), 108.9 (C
8
), 
25.6 (C
9
); m/z (ESI
+
) 159.0916 [M+H]
+
 (C10H11N2 requires 159.0922); Rf = 0.20 (silica, 
ethyl acetate). The spectral data were consistent with those reported previously.
27
 
 
 
7-(t-Butoxycarbonylamino)quinaldine (2.6) 
27
 
To a solution of 7-aminoquinaldine 2.5 (0.829 g, 5.2 mmol) in 1,4-dioxane (15 mL) 
was added a solution of di-t-butyl dicarbonate (1.42 g, 6.5 mmol) in 1,4-dioxane (5 mL) 
and the mixture was stirred under argon at 85 °C for 48 h. Solvent was removed under 
reduced pressure and the crude oil was purified by column chromatography (silica gel; neat 
hexane to neat ethyl acetate) to give compound 2.6 as a white solid (1.22 g, 90%); m.p. 
140–142 °C (lit.27 m.p. 140–142 °C); 1H NMR (400 MHz, CDCl3) δ 7.93 (1H, d, 
3
J = 8.5 
153 
 
Hz, H
4
), 7.83 (1H, d, 
3
J = 8.5 Hz, H
6
), 7.74 (d,
 4
J = 2.0 Hz,  1H, H
8
), 7.67 (d,
 3
J = 8.5 Hz, 
1H, H
5
), 7.14 (d,
 3
J = 8.5 Hz, 1H, H
3
), 7.01 (br 1H, NH), 2.69 (3H, H
9
), 1.52 (9H, H
12
); 
13
C 
NMR (100 MHz, CDCl3) δ 159.6 (C
3
), 152.7 (C
10
), 148.5 (C
8’
), 139.8 (C
7
), 135.9 (C
4
), 
128.3 (C
5
), 122.9 (C
4’
), 120.7 (C
3
), 118.8 (C
6
), 115.1 (C
8
), 81.1 (C
11
), 28.4 (C
12
), 25.4 (C
9
); 
m/z (ESI
+
) 249.1448 [M+H]
+
 (C15H19N2O2 requires 249.1447); Rf=0.38 (silica, ethyl 
acetate/hexane, 50/50 v/v). The spectral data were consistent with those reported 
previously.
27
 
 
7-(t-Butoxycarbonylamino)-2-quinaldine carbaldehyde (2.7) 
27
 
To a solution of 7-(t-Butoxycarbonylamino)quinaldine 2.6 (1.10 g, 4.3 mmol) in 
1,4-dioxane (25 mL) was added SeO2 (0.712 g, 6.4 mmol) and the mixture was stirred at 
85 °C under argon for 12 h. The reaction mixture was evaporated under reduced pressure 
and partitioned between dichloromethane (50 mL) and water (50 mL). The aqueous layer 
was extracted with dichloromethane (3 × 50 mL) and the combined organic layers were 
dried (MgSO4) and evaporated under reduced pressure to give compound 2.7 (1.05 g, 89%) 
as a yellow solid; m.p. = 208–210 °C (lit.27 m.p. 208–210 °C); 1H NMR (400 MHz, 
CDCl3) δ 10.2 (br. s, 1H, H
9
), 8.23 (d, 
3
J = 8.5 Hz, 1H, H
4
 ), 8.14 (d, 
4
J = 2.0 Hz, 1H, H
8
), 
7.92 (d,
 3
J = 8.5 Hz,  1H, H
3
), 7.89 (dd,
 3
J = 8.5 Hz,
 4
J = 2.0 Hz, 1H, H
6
), 7.83 (d,
 3
J = 8.5 
Hz, 1H, H
5
), 6.84 (br. s, 1H, NH), 1.57 (s, 9H, H
12
);
 13
C NMR (100 MHz, CDCl3) δ 194.0 
(C
9
), 153.1 (C
8’
), 152.5 (C
10
), 148.8 (C
2
), 140.7 (C
7
), 137.2 (C
4
), 128.7 (C
5
), 126.5 (C
4’
), 
122.4 (C
6
), 116.1 (C
8
), 116.0 (C
3
), 81.6 (C
11
), 28.5 (C
12
); Rf=0.60 (silica, ethyl acetate : 
hexane, 50/50 v/v). The spectral data were consistent with those reported previously.
27
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7-(t-Butoxycarbonylamino)-2-quinolinylmethanol (2.8) 
27
 
NaBH4 (0.272 g, 7.2 mmol) was added to a stirred solution of aldehyde 2.7 (1.02 g, 
3.6 mmol) in methanol (20 mL). The mixture was stirred under argon for 15 h. Water (40 
mL) was added and the organic solvent was removed under reduced pressure. The resulting 
mixture was extracted with dichloromethane (3 × 40 mL). The combined organic layers 
were dried (MgSO4) and evaporated under reduced pressure and the crude material was 
purified by column chromatography (silica gel; hexane/ethyl acetate 1/1  to neat ethyl 
acetate v/v) to give compound 2.8 (0.857 g, 83%) as a yellow solid; m.p. 123–125 °C (lit.27 
m.p. 125–127 °C); 1H NMR (400 MHz, CDCl3) δ 8.05 (d, 
3
J = 8.5 Hz, 1H, H
4
), 8.02 (d, 
4
J 
= 2.0 Hz, 1H, H
8
), 7.74 (d,
 3
J = 8.5 Hz, 1H, H
5
), 7.67 (dd,
 3
J = 8.5 Hz,
 4
J 2.0 Hz,  1H, H
6
), 
7.16 (d,
 3
J = 8.5 Hz, 1H, H
3
), 6.81 (br. s, 1H, NH), 4.89 (s, 2H, H
9
),1.57 (s, 9H, H
12
);
 13
C 
NMR (150 MHz, CDCl3) δ 159.5 (C
2
), 152.6 (C
10
), 147.7 (C
8’
), 140.1 (C
7
), 136.7 (C
4
), 
128.6 (C
5
), 124.0 (C
4’
), 119.4 (C
6
), 117.0 (C
3
), 114.9 (C
8
), 81.3 (C
11
), 64.1 (C
9
), 28.5 (C
12
); 
m/z (ESI
+
) 275.1394 [M+H]
+
 (C15H19N2O3 requires 275.1396); Rf = 0.18 (silica, ethyl 
acetate/hexane, 50/50 v/v). The spectral data were consistent with those reported 
previously.
27
 
 
(7-Aminoquinolin-2-yl)methanol (2.9) 
HCl in dioxane (4 mL, 1 M) was added to a suspension of 7-(t-
Butoxycarbonylamino)-2-quinolinylmethanol 2.8 (0.200 g, 0.730 mmol) in water (1 mL). 
The resulting mixture was stirred under nitrogen at room temperature for 2 hours and the 
solvent was removed under reduced pressure to give compound 2.9 (0.173 g, 96%) as an 
orange solid; m.p. 108–110 °C;  1H NMR (400 MHz, CD3OD) δ 8.57 (d, 
3
J = 8.0 Hz, 1H, 
H
4
), 7.86 (d, 
3
J = 9.0 Hz, 1H, H
5
), 7.38 (d, 
3
J = 8.0 Hz, 1H, H
3
), 7.22 (dd, 
3
J = 9.0, 
4
J = 
2.0 Hz, 1H, H
6
), 7.07 (d, 
4
J = 2.0 Hz, 1H, H
8
), 4.95 (s, 2H, H
9
), NH signal not observed; 
13
C NMR (CD3OD) δ 155.7 (C
2
), 153.4 (C
8’
), 145.1 (C
4
), 140.2 (C
7
), 130.5 (C
5
), 122.1 
(C
4’
), 121.0 (C
6
), 113.5 (C
3
), 96.98 (C
8
), 60.1 (C
9
);  m/z (ESI+) 175.0867 [M+H]
+
 
(C10H11N2O requires 175.0866). 
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2-(((tert-Butyldimethylsilyl)oxy)methyl)quinolin-7-amine (2.15) 
(7-Aminoquinolin-2-yl)methanol 6 (0.349 g, 1.41 mmol) and imidazole (0.410 g, 
7.00 mmol) were dissolved in dichloromethane (15 mL). tert-Butyldimethylsilyl chloride 
(0.568 g, 3.50 mmol) in dichloromethane (1 mL) was added and the reaction mixture 
stirred for 3hoursunder an atmosphere of nitrogen. The solvent was removed under reduced 
pressure and the residue was partitioned between dichloromethane (20 mL) and brine (20 
mL). The aqueous layer was extracted with dichloromethane (2 × 20 mL) and the 
combined organic layers were evaporated under reduced pressure. The resulting solid was 
purified by column chromatography (silica gel; neat petroleum ether to petroleum 
ether/ethyl acetate 1/1, v/v) to give the silyl ether 2.15 (0.336 g, 83%) as an orange oil; 
1
H 
NMR (CDCl3) δ 8.02 (d, 
3
J = 8.5 Hz, 1H, H
5
), 7.62 (d, 
3
J = 8.5 Hz, 1H, H
4
), 7.46 (d, 
3
J = 
8.5 Hz, 1H, H
3
), 7.15 (d, 
4
J =  2.0 Hz, 1H, H
8
), 6.96 (dd, 
3
J = 8.5, 
4
J = 2.0 Hz, 1H, H
6
), 
4.96 (s, 2H, H
9
), 4.07 (s, 2H, NH), 0.97 (s, 9H, H
12
), 0.16 (s, 6H, H
10
); 
13
C NMR (CDCl3) δ 
162.2 (C
2
), 149.2 (C
8’
), 147.9 (C
7
), 136.5 (C
4
), 129.0 (C
5
), 121.6 (C
4’
), 118.1 (C
6
), 115.1 
(C
3
), 108.9 (C
8
), 66.9 (C
9
), 26.1 (C
12
), 18.54(C
11
), -5.2 (C
10
); m/z (ESI+) 289.1725 [M+H]
+
 
(C16H26N2OSi requires 289.1731); Rf = 0.46 (silica, ethyl acetate/hexane, 50/50 v/v).  
 
 
1-(2-(((tert-Butyldimethylsilyl)oxy)methyl)quinolin-7-yl)-3-phenylurea (2.16) 
To a solution of 2-(((tert-Butyldimethylsilyl)oxy)methyl)quinolin-7-amine 2.15 (78 
mg,0.27 mmol) in dry acetonitrile (2 mL) was added phenyl isocyanate (30 µL, 0.27 
mmol) and triethylamine (56 µL, 0.41 mmol) and the reaction mixture was stirred at r.t. 
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overnight under a nitrogen atmosphere. The solution was evaporated under reduced 
pressure and the resulting crude solid purified by column chromatography (silica gel; neat 
petroleum ether to petroleum ether/ethyl acetate, 7/3 v/v) to give compound 2.16 (82 mg, 
75%) as a light yellow solid; 
1
H NMR (CDCl3) δ 8.51 (s, 1H, NH), 7.96 (d, 
3
J = 8.0 Hz, 
1H, H
4
), 7.87 (s, 1H, NH), 7.82 (dd, 
3
J = 9.0,
 4
J = 2.0 Hz, 1H, H
6
), 7.59 (d, 
4
J = 2.0, 1H, 
H
8
), 7.55 (d, 
3
J = 9.0 Hz, 1H, H
5
), 7.44 (d, 
3
J = 8.0 Hz, 1H, H
3
), 7.19 (d,
 3
J = 7.0 Hz, 2H, 
H
15
), 7.12 (t,
 3
J = 7.0 Hz, 2H, H
16
), 6.93 (t, 
3
J = 7.0 Hz, 1H, H
17
), 4.86 (2H, H
9
), 0.89 (s, 
9H, H
12
), 0.05 (s, 6H, H
10
); 
13
C NMR (CDCl3) δ 162.1 (C
13
), 153.6 (C
2
), 147.7 (C
8’
), 140.6 
(C
7
), 138.2 (C
14
), 136.8 (C
4
), 129.1 (C
16
), 128.7 (C
17
), 124.0 (C
4’
), 123.7 (C
5
), 120.6 (C
6
), 
120.4 (C
15
), 117.2 (C
8
), 115.7 (C
3
), 66.6 (C
9
), 26.1 (C
12
), 18.5 (C
11
), -5.2 (C
10
) ; m/z (ESI
+
) 
408.2102 [M+H]
+
 (C23H30N3O2Si requires 408.2102); Rf = 0.67 (silica, ethyl 
acetate/hexane, 50/50 v/v). 
 
 
1-(2-(Hydroxymethyl)quinolin-7-yl)-3-phenylurea (2.11) 
To a solution of 1-(2-(((tert-Butyldimethylsilyl)oxy)methyl)quinolin-7-yl)-3-
phenylurea 2.16 (0.155 g, 0.380 mmol) in dry tetrahydrofuran (2 mL) was added 
tetrabutylammonium fluoride solution in tetrahydrofuran (0.76 mL, 0.76 mmol, 1 M) and 
the reaction mixture was stirred for 1 h at r.t. under a nitrogen atmosphere. The resulting 
mixture was evaporated under reduced pressure and the crude material thus obtained was 
partitioned between dichloromethane (50 mL) and water (50 mL). The aqueous layer was 
extracted with dichloromethane (25 mL) and the organic layers were combined and dried 
(MgSO4) and evaporated under reduced pressure. The resulting crude solid was purified by 
column chromatography (silica gel; neat dichloromethane to dichloromethane/methanol, 
96/4 v/v) to give compound 2.11 (96 mg, 86%) as a light yellow solid; m.p. 215–217 °C; 
1
H NMR (400 MHz, CD3OD) δ 8.26 (d, 
3
J = 8.0 Hz, 1H, H
4
), 8.15 (d, 
4
J = 2.0 Hz, 1H, 
H
8
), 7.85 (d, 
3
J = 9.0 Hz, 1H, H
5
), 7.69 (dd, 
3
J = 9.0,
 4
J = 2.0 Hz, 1H, H
6
), 7.57 (d, 
3
J = 
8.0 Hz, 1H, H
3
), 7.46 (d, 
3
J = 7.0 Hz, 2H, H
12
), 7.30 (t,
 3
J = 7.0 Hz, 2H, H
13
), 7.05 (t,
 3
J = 
7.0 Hz, 1H, H
14
), 4.83 (s, 2H, H
9
); 
13
C NMR (100 MHz, CD3OD) δ 163.4 (C
2
), 155.0 (C
10
), 
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149.1 (C
8’
), 142.6 (C
7
), 140.3 (C
11
), 138.4 (C
4
), 129.9 (C
13
), 129.5 (C
14
), 125.1 (C
4’
), 124.1 
(C
5
), 121.3 (C
6
), 120.5 (C
12
), 118.3 (C
3
), 115.1 (C
8
), 66.0 (C
9
); m/z (ESI
+
) 294.1232 
[M+H]
+
 (C17H16N3O2 requires 294.1237); Rf = 0.42 (silica, dichloromethane/methanol, 
95/5 v/v).  
 
N-(2-(((tert-Butyldimethylsilyl)oxy)methyl)quinolin-7-yl)acetamide (2.17) 
To a solution of amine 2.15 (0.167 g, 0.580 mmol) in anhydrous acetonitrile (4 mL) 
was added triethylamine (150 µL, 1.09 mmol) and acetic anhydride (86 µL, 0.91 mmol). 
The reaction mixture was stirred under an atmosphere of nitrogen at room temperature for 
48 h. The solvent was removed under reduced pressure and the crude mixture was purified 
by column chromatography (silica gel; neat dichloromethane to dichloromethane/methanol, 
98/2 v/v) to give compound 2.17 (0.172 g, 90%) as an orange oil; 
1
H NMR (400 MHz, 
CDCl3) δ 9.27 (s, 1H, NH), 8.06 (d,
 4
J = 1.0 Hz, 1H, H
8
), 8.04 (d, 
3
J = 8.5 Hz, 1H, H
4
), 
7.86 (dd, 
3
J = 9.0,
 4
J = 1.0 Hz, 1H, H
6
), 7.62 (d, 
3
J = 9.0 Hz, 1H, H
5
), 7.55 (d, 
3
J = 8.5 Hz, 
1H, H
3
), 4.91 (2H, H
9
), 2.12 (s, 3H, H
14
), 0.92 (s, 9H, H
12
), 0.08 (s, 6H, H
10
); 
13
C NMR 
(400 MHz, CDCl3) δ 169.5 (C
13
), 162.2 (C
2
), 147.5 (C
8’
), 140.0 (C
7
), 136.7 (C
4
), 128.4 
(C
5
), 124.4 (C
4’
), 120.4 (C
6
), 117.5 (C
3
), 116.0 (C
8
), 66.3 (C
9
), 26.0 (C
12
), 24.5 (C
14
), 18.4 
(C
11
), -5.3 (C
10
); m/z (ESI
+
) 331.1836 [M+H]
+
 (C18H27N2O2Si requires 331.1836); Rf = 
0.42 (silica, dichloromethane/methanol, 95/5 v/v). 
 
N-(2-(Hydroxymethyl)quinolin-7-yl)acetamide (2.12) 
To a solution of N-(2-(((tert-butyldimethylsilyl)oxy)methyl)quinolin-7-
yl)acetamide 2.17 (0.160 g, 0.480 mmol) in anhydrous tetrahydrofuran (2 mL) was added a 
solution of tetrabutylammonium fluoride in tetrahydrofuran (0.96 mL, 0.96 mmol, 1 M) 
and the solution was stirred under an atmosphere of nitrogen for 1hoursat room 
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temperature. The solvent was removed under reduced pressure and the crude mixture 
purified by column chromatography (silica gel; neat dichloromethane to 
dichloromethane/methanol 94/6, v/v) to give compound 2.12 (85 mg, 82%) as a light 
yellow solid; m.p. 176–178 °C; 1H NMR (CD3OD) δ 8.35 (d, 
4
J = 2.0 Hz, 1H, H
8
), 8.20 (d, 
3
J = 8.0 Hz, 1H, H
4
), 7.78 (d, 
3
J = 9.0 Hz, 1H, H
5
), 7.66 (dd, 
3
J = 9.0,
 4
J = 2.0 Hz, 1H, 
H
6
), 7.57 (d, 
3
J = 8.0 Hz, 1H, H
3
), 4.83 (s, 2H, H
9
), 2.20 (s, 3H, H
11
); 
13
C NMR (CD3OD) 
δ 172.0 (C10), 163.4 (C2), 148.7 (C8’), 141.5 (C7), 138.2 (C4), 129.4 (C5), 125.7 (C4’), 121.4 
(C
6
), 118.9 (C
3
), 117.0 (C
8
), 66.0 (C
9
), 24.0 (C
11
); m/z (ESI
+
) 217.0972 [M+H]
+
 
(C12H13N2O2 requires 217.0972); Rf = 0.34 (silica, dichloromethane/methanol, 95/5, v/v).  
 
 
(7-(3-Phenylureido)quinolin-2-yl)methyl methanesulfonate (2.18) 
To a solution of 1-(2-(hydroxymethyl)quinolin-7-yl)-3-phenylurea 2.11 (30 mg, 
0.10 mmol) in dry tetrahydrofuran (2 mL) was added triethylamine (17 µL, 0.12 mmol) 
and methansulfonyl chloride (8 µL, 0.11 mmol). The reaction mixture was stirred for 2 h at 
r.t. under a nitrogen atmosphere and evaporated under reduced pressure to give compound 
2.18 (37 mg, quant.) as a yellow solid. The crude material was used immediately without 
any further purification. 
1
H NMR (400 MHz, CDCl3) δ 9.42 (s, 1H, NH), 8.93 (s, 1H, NH), 
8.21 (s, 1H, H
8
), 8.11 (d, 
3
J =  8.0 Hz, 1H, H
4
), 7.93 (d, 
3
J = 8.5 Hz, 1H, H
5
), 7.66 (t, 
3
J = 
8.5 Hz, 1H, H
6
), 7.53 (d, 
3
J = 8.0 Hz, 2H, H
12
), 7.36 (d, 
3
J = 8.0 Hz, 1H, H
3
), 7.22 (t, 
3
J = 
8.0 Hz, 2H, H
13
), 6.95 (t, 
3
J = 7.4 Hz, 1H, H
14
), 5.46 (s, 2H, H
9
), 2.85 (s, 3H, H
15
); m/z 
(ESI
+
) 372.1 [M+H]
+
 (C18H18N3O4S requires 372.1). 
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(7-Acetamidoquinolin-2-yl)methyl methanesulfonate (2.19) 
To a solution of the primary alcohol 2.12 (84 mg, 0.38 mmol) in anhydrous 
tetrahydrofuran (1 mL) was added diisopropylethylamine (100 µL, 0.58 mmol) and 
methanesulfonyl chloride (32 µL, 0.40 mmol). The reaction mixture was stirred for 2 hours 
at room temperature under a nitrogen atmosphere and evaporated under reduced pressure. 
The resulting material was partitioned between water (10 mL) and dichloromethane (10 
mL). The aqueous layer was extracted with dichloromethane (2 × 10 mL) and the organic 
layers were combined, dried (MgSO4) and the solvent was removed under reduced pressure 
to give 2.19 (100 mg, 89%) as a yellow oil. The crude material was used immediately 
without any further purification. 
1
H NMR (400 MHz, CDCl3) δ 9.41 (s, 1H, NH), 8.29 (br 
s, 1H, H
8
), 8.01 (d, 
3
J= 9.0, 1H, H
4
), 7.81 (br d, 
3
J= 8.5 Hz, 1H, H
6
), 7.60 (d, 
3
J= 8.5 Hz, 
1H, H
5
), 7.34 (d, 
3
J= 9.0 Hz, 1H, H
3
), 5.36 (s, 2H, H
9
), 3.05 (s, 3H, H
12
), 2.19 (s, 3H, H
11
); 
13
C NMR (400 MHz, CDCl3) δ 169.8 (C
10
), 153.9 (C
2
), 149.0 (C
8’
), 140.5 (C
7
), 137.1 (C
4
), 
128.12 (C
5
), 124.4 (C
4’
), 121.5 (C
6
), 118.2 (C
3
), 116.7 (C
8
), 46.7 (C
66
), 24.6 (C
11
), 8.6 
(C
12
); LCMS: m/z (ESI
+
) 295.1 [M+H]
+
 (C13H15N2O4S requires 295.1); Rf = 0.24 (silica, 
ethyl acetate/hexane, 50/50 v/v). 
 
Dibenzyl 1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate (2.21)
131
 
To a solution of 1,4,7,10-tetraazacyclododecane (2.80 g, 16.3 mmol) in a mixture 
of water/1,4-dioxane (50/20 mL) was added Na2HPO4 (7.8 g, 55.2 mmol) and the pH was 
adjusted to 2.5 by careful additions of conc. HCl. Benzyl chloroformate in dioxane (10 
mL) was added dropwise over a period of 30 min and the reaction left to stir for a further 
18 h at rt under nitrogen. The solvent was evaporated under reduced pressure and the 
residue dissolved in water (100 mL), followed by adjustment of the pH to 7 by addition of 
conc. KOH. The aqueous phase was extracted with diethyl ether (2 × 100 mL), followed by 
CH2Cl2 (2 × 100 mL). The organic phases were combined, dried over (MgSO4), filtered, 
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and the solvent removed under reduced pressure to give compound 2.21 as a white solid. 
The solid was dissolved in CH2Cl2 (10 mL) and cold Et2O (100 mL) was added, causing a 
white solid to precipitate (6.00 g, 82 %); m.p. 118–120 °C (lit.27 m.p. 113–116 °C); 1H 
NMR (CDCl3) δ 7.35 (m, 10H, H
4 
and H
5 
and H
6
), 5.17 (s, 4H, H
2
), 3.68 and 2.97 (m, 16H, 
ring CH2); 
13
C NMR (CDCl3) δ 156.3 (C
1
), 136.0 (C
3
), 128.5 (C
4 
and C
5 
and C
6
), 68.0 (C
2
), 
49.8 (m, 8C, ring CH2); m/z (ESI
+
) 441.2483 [M+H]
+
 (C24H33N4O4 requires 441.2496); Rf 
= 0.64 (silica, dichloromethane/methanol, 95/5 v/v). The spectral data were consistent with 
those reported previously.
131
 
 
Dibenzyl 4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,7-
dicarboxylate (2.22)
143
 
 
 The bis-amine 2.21 (4.5g, 10.2 mmol) and potassium carbonate (10 g, 30.6 mmol) 
were dissolved in anhydrous acetonitrile (60 mL), followed by addition of tert-butyl 
bromoacetate (3.5 mL, 23.5 mmol). The mixture was heated and stirred at 60°C for 24 
hours. Salts were filtered off, and the solvent removed under reduced pressure to obtain a 
yellow viscous oil. The recovered residue was purified by flash column chromatography 
(silica gel, neat CH2Cl2 to CH2Cl2/MeOH, 98/2 v/v, with an increment of 0.5%) to yield 
compound 2.22 as a clear yellow viscous oil (5.2 g, 76%). The obtained oil was used in the 
next step without further purification. IR (νmax.cm
-1
, neat): 2978, 2932, 2924, 1689, 1458, 
1420, 1242, 1142, 748, 694. 
1
H NMR (400 MHz, CDCl3) δ (ppm): 7.3 (10H, m, H
4,5,6
), 
5,08 (4H, s, H
5
), 3.1–3.5 (12H, broad m, H7 and ring CH2), 2.7–2.9 (8H, broad m, ring 
CH2), 1.39 (18H, s, H
10
). 
13
C NMR (100 MHz, CDCl3) δ (ppm): 170.4 (C
8
), 156.3 (C
1
), 
136.8 (C
3
), 128.4 (C
4
), 127.8 (C
5
), 127.9 (C
6
), 80.8 (C
9
), 66.9 (2C, C
2
), 56.0 (2C, C
7
), 54.3, 
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54.0 (ring CH2), 46.9 (C
10
), 46.6 (ring CH2), m/z (ESI
+
) (C36H52N4O8) requires 669.3858 
[M+H]
+
 = 669.3848. Data in accordance with literature.
143
 
 
Di-tert-butyl 2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (2.23)
143
 
Intermediate 2.22 (5.2 g, 7.8 mmol) was dissolved in methanol (30 mL) to which 
Pd(OH)2/C (130 mg, 0.1 eq) was added. The atmosphere was first purged with Argon and 
then the inert gas was replaced by hydrogen. The reaction mixture was stirred at room 
temperature for 3 days. The catalyst was removed by filtration through a pad of 
Celite®.  The solvent was then removed under reduced pressure. The product was then 
solubilised in acidic water (pH=3, 150 mL). The aqueous layer was washed with ethyl 
acetate (2 × 50 mL) and dichloromethane (2 × 50 mL) to get rid of organic impurities 
(remaining starting material, over-alkylated product, side products). The pH of the water 
phase was then adjusted to pH=6 and washed again with dichloromethane (3 × 50 mL) to 
eliminate other impurities. Finally, the pH was adjusted to pH=9–10 and the product was 
extracted back from the water phase by extraction with dichloromethane (5 × 50 mL) to 
recover the product. The organic layers were combined, dried over MgSO4 and the solvent 
was evaporated by reduce pressure, to yield compound 2.23 as a clear viscous oil (2.65 g, 
85%). IR (νmax.cm
-1
, neat): 3456, 3281, 3222, 1721, 1473, 1145; 
1
H NMR (400 MHz, 
CDCl3) δ (ppm): 3.26 (2H, s, H
1
), 2.9–2.7 (8H, ring CH2), 2.7–2.5 (8H, ring CH2), 1.31 
(18H, s, H
4
); 
13
C NMR (100 MHz, CDCl3) δ (ppm): 170,9 (C2), 80.9 (C3), 56.8 (C1), 51.3 
(ring CH2), 46.6 (ring CH2), 27.9 (C
4
);  m/z (ESI+) 401.3120 [M+H]+ (C20H41N4O4 
requires 401.3122); Data in accordance with literature.
143 
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Ethyl 3-(2-bromoacetamido)propanoate (2.24)
193
 
To a solution of ethyl 3-aminopropanoate (0.500 g, 3.2 mmol) in dichloromethane 
(12 mL) was added triethylamine (0.862 mL, 6.4 mmol) and the solution was cooled to 0 
°C. Bromoacetyl bromide (285 µL, 3.2 mmol) was added dropwise and the solution was 
allowed to warm up to rt and stirred for 3 h under nitrogen. The reaction mixture was 
partitioned between sat. aqueous Na2CO3 (50 mL) and dichloromethane (50 mL), the 
aqueous layer was extracted with dichloromethane (2 × 50 mL) and the combined organic 
layers were dried (MgSO4) and evaporated under reduced pressure. The crude material was 
purified by column chromatography (silica gel; ethyl acetate/ petroleum ether 1/1 v/v) to 
give compound 2.24 (0.546 g, 76%) as a transparent oil; 
1
H NMR (400 MHz, CDCl3) δ 
6.97 (s, 1H, NH), 4.07 (q, 
3
J 7.0 Hz, 2H, H
6
), 3.93–3.76 (2H, H1), 3.46 (t, 3J 7.0 Hz, 2H, 
H
3
), 2.46 (t,
 3
J 7.0 Hz, 2H, H
4
), 1.18 (t,
 3
J 7.0 Hz, 3H, H
7
); 
13
C NMR (400 MHz, CDCl3) δ 
172.5 (C
2
), 165.6 (C
5
), 61.1 (C
6
), 35.7 (C
3
), 33.8 (d, C
4
), 29.2 (C
1
), 14.3 (C
7
); m/z (ESI
+
) 
755.3948 [M+H]
+
 (C38H55N6O10 requires 755.3974). Rf = 0.50 (silica, ethyl 
acetate/petroleum ether, 50/50 v/v). The spectral data were consistent with those reported 
previously.
193
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Dibenzyl 4,10-bis(2-((3-ethoxy-3-oxopropyl)amino)-2-oxoethyl)-1,4,7,10-
tetraazacyclododecane-1,7-dicarboxylate (2.25) 
 
To a solution of dibenzyl 1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate 2.21 
(0.343 g, 0.780 mmol) in anhydrous acetonitrile (10 mL) was added potassium bicarbonate 
(0.538 g, 3.90 mmol) and ethyl 3-(2-bromoacetamido)propanoate 2.24 
 
(0.526 g, 2.34 
mmol) and the reaction mixture was stirred at 60 °C for 18 hours under a nitrogen 
atmosphere. The reaction mixture was decanted to remove potassium salts and the filtrate 
was reduced under vacuum. The crude material was purified by column chromatography 
(silica gel; dichloromethane neat to dichloromethane/methanol 8/2 v/v) to give compound 
2.25 (0.500 g, 88%) as a colourless oil; 
1
H NMR (400 MHz, CDCl3) δ 7.33 (m, 10H, H
11
,
 
H
12 
and H
13
), 5.11 (s, 4H, H
9
), 4.11 (q, 
3
J = 7.0 Hz, 4H, H
6
), 3.54–2.30 (m, 28H, ring CH2 
,H
1
 ,H
3
 and H
4
), 1.23 (t, 
3
J = 7.0 Hz, 6H, H
7
); 
13
C NMR (100 MHz, CDCl3) δ 172.2 (C
2
), 
171.2 (C
5
), 156.9 (C
8
), 136.6 (C
10
), 128.7 (C
12
), 128.4 (C
13
), 128.3 (C
11
), 67.6 (C
9
), 60.7 
(C
6
), 55.1 (ring C), 53.6 (C
1
), 48.9 (ring C), 34.9 (C
3
), 34.2 (C
4
), 14.3 (C
7
); m/z (ESI
+
) 
755.3972 [M+H]
+
 (C38H55N6O10 requires 755.3974); Rf = 0.28 (silica, 
dichloromethane/methanol, 95/5 v/v). 
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Diethyl 3,3'-((2,2'-(1,4,7,10-tetraazacyclododecane-1,7-
diyl)bis(acetyl))bis(azanediyl))dipropionate (2.26) 
To a solution of dibenzyl 4,10-bis(2-((3-ethoxy-3-oxopropyl)amino)-2-oxoethyl)-
1,4,7,10-tetraazacyclododecane-1,7-dicarboxylate 2.25 (0.488 g, 0.670 mmol) in methanol 
(10 mL) was added Pd(OH)2 / C(49 mg, 0.07 mmol) and the reaction mixture was stirred 
under an atmosphere of hydrogen for 18 h. The resulting mixture was filtered over Celite, 
rinsed with methanol (3 × 10 mL) and evaporated under reduced pressure to give 
compound 2.26 as a colourless oil (0.315 g, 97%); 
1
H NMR (400 MHz, CDCl3) δ 7.67 (s, 
2H, NH), 4.10 (q, 
3
J = 7.0 Hz, 4H, H
6
), 3.52 (q, 
3
J = 6.5 Hz, 4H, H
4
), 3.19 (t, 
3
J = 6.5 Hz, 
4H, H
3
), 2.67 (m, 16H, ring CH2), 2.57 (s, 4H, H
1
), 1.25 (t,
 3
J = 7.0 Hz, 6H, H
7
), ring NH 
signals not observed; 
13
C NMR (100 MHz, CDCl3) δ 172.7 (C
2
), 171.6 (C
5
), 60.7 (C
6
), 
60.3 (C
1
), 53.4 (ring C), 46.2 (ring C), 35.1 (C
3
), 34.0 (C
4
), 14.3 (C
7
); m/z (ESI
+
) 487.3228 
[M+H]
+
 (C22H34N6O6 requires 487.3239); Rf = 0.37 (silica, dichloromethane/methanol, 
95/5 v/v). 
 
165 
 
 
 
Di-ter.t.-butyl 2,2'-(4,10-bis((7-(3-phenylureido)quinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate (2.31) 
To a solution of the bis-amine 2.23 (19 mg, 0.046 mmol) in dry acetonitrile (3 mL) 
was added potassium carbonate (40 mg, 0.29 mmol) and (7-(3-phenylureido)quinolin-2-
yl)methyl methanesulfonate 4 (37 mg, 0.10 mmol). The reaction was stirred overnight at 
60 °C under a nitrogen atmosphere and the resulting mixture was centrifuged (1500 rpm, 3 
min) and the filtrate was evaporated under reduced pressure. The crude material was 
purified by column chromatography (silica gel; neat dichloromethane to 
dichloromethane/methanol, 90/10 v/v) to give compound 2.31 (24 mg, 55%) as a yellow 
solid;
1
H-NMR (400 MHz, CDCl3) δ 9.36 (s, 2H, NH), 8.79 (s, 2H, NH), 8.18 (s, 2H, H
8
), 
7.94 (d, 
3
J = 8.0 Hz, 2H, H
4
), 7.73 (d, 
3
J = 9.0 Hz, 2H, H
6
), 7.57 (d, 
3
J = 8.0 Hz, 1H, H
3
), 
7.45 (d, 
3
J = 9.0 Hz, 2H, H
5
), 7.38 (d, 
3
J = 8.0 Hz, 4H, H
12
), 7.12 ( br t, 
3
J = 8.0 Hz, 6H, 
H
13
 and H
14
), 5.29 (s, 2H, H
9
), 2.72 (s, 2H, H
15
), 1.16 (d, 18H, H
18
), ring NH signals not 
observed; 
13
C NMR (400 MHz, CDCl3) δ 171.1 (C
16
), 157.8 (C
2
), 153.3 (C
10
), 149.3 (C
8’
), 
142.0 (C
7
), 141.8 (C
11
), 137.0 (C
4
), 128.7 (C
4’
), 128.6 (C
13
), 127.8 (C
5
), 122.2 (C
14
), 121.4 
(C
6
), 119.7 (C
3
), 119.2 (C
12
), 115.6 (C
8
), 77.3 (C
17
), 56.5 (C
9
), 46.2 (C
15
), 27.9 (C
18
), 
Signals for ring CH2 are hidden in the baseline; m/z (ESI
+
) 951.5261 [M+H]
+
 
(C54H67N10O6 requires 951.5240); Rf = 0.36 (silica, dichloromethane/methanol, 90/10 v/v). 
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2,2'-(4,10-bis((7-(3-phenylureido)quinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetic acid (L3) 
Macrocycle 2.31 (25 mg, 0.026 mmol) was added to a mixture of TFA (0.25 mL) 
and dichloromethane (0.75 mL). The resulting mixture was stirred for 36 h at r.t.. The 
solvents were evaporated under reduced pressure and the resulting oil purified by 
preparative RP-HPLC [gradient: 0 − 100% methanol in water (0.1% formic acid), over 10 
min; tR = 8.0 min] to give product L3 as a light yellow solid (10 mg, 45%); 
1
H NMR (400 
MHz, D2O) δ 7.82 (d, 
3
J = 8.0 Hz, 2H, H
4
), 7.59 (d, 
4
J = 2.0 Hz, 2H, H
8
), 7.44 (d, 
3
J = 9.0 
Hz, 2H, H
5
), 7.39 (dd, 
3
J = 9.0 Hz,
 4
J = 2.0 Hz, 2H, H
6
), 7.04 (t, 
3
J = 7.5 Hz, 6H, H
13
H
14
), 
6.87 (t, 
3
J = 7.5 Hz, 4H, H
12
), 6.65 (t, 
3
J = 8.0 Hz, 2H), 2.18 (s, 4H, H
9
), 0.84 (s, 4H, H
15
); 
m/z (ESI
+
) 839.3945 [M+H]
+
 (C46H51N10O6 requires 839.3988); 
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Analytical RP-HPLC trace of 9; [[gradient: 0 − 100% methanol in water (0.1% 
formic acid), over 10 min; tR = 8.0 min]. 
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Diethyl 3,3'-((2,2'-(4,10-bis(quinolin-2-ylmethyl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)bis(acetyl))bis(azanediyl))dipropionate (2.32) 
 
To a solution of the macrocyclic bis amine 2.26 (35 mg, 0.072 mmol) in anhydrous 
acetonitrile (3 mL) was added potassium carbonate (47 mg, 0.34 mmol) and 2-
(chloromethyl)quinoline (2.28) (31 mg, 0.14 mmol). The reaction mixture was stirred at 60 
°C under an atmosphere of nitrogen for 18 h. The resulting mixture was centrifuged (1500 
rpm, 3 min) and the filtrate was separated from potassium salts and evaporated under 
reduced pressure. The crude material was purified by column chromatography (silica gel; 
neat dichloromethane to dichloromethane/methanol, 95/5 v/v) to give compound 2.32 (18 
mg, 33%) as a colourless oil; 
1
H NMR (400 MHz, CDCl3) δ 8.00 (d,
 3
J = 8.0 Hz, 2H, H
4
), 
7.87 (d,
 3
J = 8.5 Hz, 2H, H
8
), 7.63 (d,
 3
J = 8.5 Hz, 2H, H
5
), 7.53 (t,
 3
J = 8.5 Hz, 2H, H
7
), 
7.37 (m, 4H, H
6
 and H
3
), 6.75 (s, 2H, NH), 3.93 (q, 4H, H
15
), 3.83 (t,
 3
J = 6.0 Hz, 4H, H
12
), 
2.35 (t,
 3
J = 6.0 Hz, 4H, H
13
), 1.80 (s, 2H, H
9
), 1.78 (s, 2H, H
10
), 1.01 (t, 6H, H
16
); m/z 
(ESI
+
) 769.4398 [M+H]
+
 (C42H57N8O6 requires 769.4396); Rf = 0.76 (silica, 
dichloromethane: methanol, 95/5, v/v). 
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Diethyl 3,3'-((2,2'-(4,10-bis((7-acetamidoquinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(acetyl))bis(azanediyl))dipropionate (2.33) 
To a solution of the bis amine 2.26 (39 mg, 0.080 mmol) in anhydrous acetonitrile 
(3 mL) was added potassium carbonate (50 mg, 0.37 mmol) and mesylate ester 2.19 (88 
mg, 0.30 mmol). The reaction mixture was stirred at 60 °C under an atmosphere of 
nitrogen for 18 h. The resulting mixture was centrifuged (1500 rpm, 3 min) and the filtrate 
was separated from potassium salts and evaporated under reduced pressure. The crude 
material was purified by column chromatography (silica gel; dichloromethane/methanol, 
95/5, to dichloromethane/methanol, 84/16 v/v) to give compound 2.33 (46 mg, 65%) as a 
white solid; 
1
H NMR (400 MHz, CDCl3) δ 9.37 (2H, NH), 8.00 (d, 
3
J = 8.0 Hz, 2H, H
4
), 
7.87 (br s, 4H, H
8
 and NH), 7.64 (d, 
3
J = 8.5 Hz, 2H, H
5
), 7.43 (d, 
3
J = 8.5 Hz, 2H, H
6
), 
7.14 (d, 
3
J = 8.0 Hz, 2H, H
3
), 3.96 (q, 
3
J = 7.0 Hz, 4H, H
17
), 3.14 (t, 
3
J = 6.0 Hz, 4H, H
14
), 
3.05 (s, 4H, H
9
), 2.72 (s, 4H, H
12
), 2.18 (t, 
3
J = 6.0 Hz, 4H, H
15
), 1.96 (s, 6H, H
11
), 1.11 (t, 
3
J = 7.0 Hz, 6H, H
18
) signals for ring CH2 are obscured, ring NH signals not observed; 
13
C 
NMR (400 MHz, CDCl3) δ 172.3 (C
16
), 170.8 (C
13
), 169.6 (C
10
), 159.3 (C
2
), 148.3 (C
8’
), 
139.9 (C
7
), 136.6 (C
4
), 127.5 (C
5
), 124.2 (C
4’
), 122.0 (C
6
), 120.2 (C
3
), 118.8 (C
8
), 60.5 (C
9
 
and C
17
), 56.2 (C
12
), 50-55 (ring C), 35.0 (C
14
), 34.0 (C
15
), 24.3 (C
11
), 14.2 (C
18
); m/z 
(ESI
+
) 883.4832 [M+H]
+
 (C46H63N10O8 requires 883.4835) Rf = 0.25 (silica, 
dichloromethane/methanol, 9/1 v/v). 
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Diethyl 3,3'-((2,2'-(4,10-bis((7-(3-phenylureido)quinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(acetyl))bis(azanediyl))dipropionate (2.34) 
To a solution of the bis-amine 2.26 (35 mg, 0.072 mmol) in dry acetonitrile (3 mL) 
was added potassium carbonate (50 mg, 0.36 mmol) and (7-(3-phenylureido)quinolin-2-
yl)methyl methanesulfonate 2.20 (67 mg, 0.18 mmol). The reaction was stirred overnight 
at 60 °C under a nitrogen atmosphere and the resulting mixture was centrifuged (1500 rpm, 
3 min) and the filtrate was evaporated under reduced pressure. The crude material was 
purified by column chromatography (silica gel; neat dichloromethane to 
dichloromethane/methanol, 90/10 v/v) to give compound 2.34 (27 mg, 36%) as a white 
solid; 
1
H NMR (400 MHz, CDCl3) δ 8.90 (s, 2H, NH), 8.20 (s, 2H, NH), 8.00 (2H, H
4
), 
7.70 (d, 
3
J = 7.8 Hz, 2H, H
5
), 7.43 (d, 
3
J = 7.4 Hz, 2H, H
6
), 7.17 (m, 10H, H, H
3
, H
8
, H
13 
and H
14
), 6.96 (d, 4H, H
12
), 6.85 (s, 2H, NH), 3.93 (q, 
3
J = 7.0 Hz, 4H, H
20
), 3.32–2.45, 
2.15, 1.83, 1.24, (The total amount of proton needed is present (32H) but could not be 
assigned), 1.08 (t, 
3
J = 7.0 Hz, 6H, H
21
), ring NH signals not observed; 
13
C NMR (400 
MHz, CDCl3) δ 172.4 (C
19
), 170.7 (C
16
), 158.7 (C
2
), 152.3 (C
10
), 148.9 (C
8’
), 140.9 (C
7
), 
139.9 (C
11
), 136.8 (C
4
), 128.5 (C
13
), 127.8 (C
5
), 123.2 (C
4’
), 121.9 (C
14
), 121.1 (C
6
), 118.9 
(C
12
), 118.0 (C
3
), 114.9 (C
8
), 60.5 (C
9
), 55.7 (C
20
), 39.8 (C
15
), 34.9 (C
17
), 34.0 (C
18
), 14.2 
(C
21
), Signals for ring C are hidden in the baseline; m/z (ESI
+
) 1037.5356 [M+H]
+
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(C56H69N12O8 requires 1037.5356); Rf = 0.30 (silica, dichloromethane/methanol, 90/10 
v/v). 
 
 
3,3'-((2,2'-(4,10-bis((7-acetamidoquinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(acetyl))bis(azanediyl))dipropionate (L5) 
Macrocycle 2.30 (30 mg, 0.03 mmol) was added to a mixture of aq. NaOH (2 mL, 
0.5M) and methanol (0.5 mL). The resulting mixture was stirred for 36 hours at room 
temperature under a nitrogen atmosphere. LCMS analysis showed complete conversion of 
starting material and the mixture was purified by preparative RP-HPLC [gradient: 0 − 
100% methanol in water (0.1% formic acid), over 10 min; tR = 6.3 min] to give product L2 
as a white solid (19 mg, 68%); 
1
H NMR (D2O) δ 8.29 (d, 
3
J = 9.0 Hz, 2H, H
3
), 8.26 (s, 2H, 
NH), 7.74 (d, 
3
J = 9.0 Hz, 2H, H
4
), 7.69 (s, 2H, H
8
), 7.36 (d, 
3
J = 8.5 Hz, 2H, H
5
), 6.88 (d, 
3
J = 8.5 Hz, 2H, H
6
), 5.01 (s, 4H, ring CH2), 3.62 (s, 12H, ring CH2), 3.37 (m, 8H, H
12
 and 
H
9
), 3.05 (t, 
3
J = 6.0 Hz, 4H, H
14
), 2.09 (t, 
3
J = 6.0 Hz, 4H, H
15
), 1.60 (s, 6H, H
11
) ring NH 
signals not observed; 
13
C NMR (D2O) δ 177.9 (C
16
), 171.3 (C
13
), 171.1 (C
10
), 170.1 (C
2
), 
150.5 (C
8’
), 145.8 (C
7
), 138.1 (C
4
), 128.30 (C
5
), 124.7 (C
4’
), 120.2 (C
6
), 118.4 (C
3
), 117.4 
(C
8
), 57.0 (C
9
), 54.9 (C
12
), 50-53 (ring C), 35.3 (C
14
), 34.9 (C
15
), 22.8 (C
9
); m/z (ESI
+
) 
827.4180 [M+H]
+
 (C42H55N10O8 requires 827.4199). 
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Analytical RP-HPLC trace of deprotected ligand L5; [gradient: 0 − 100% 
methanol in water (0.1% formic acid), over 10 min; tR = 6.3 min] 
 
 
3,3'-((2,2'-(4,10-bis((7-(3-phenylureido)quinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(acetyl))bis(azanediyl))dipropionate (L6) 
Macrocycle 2.31 (24 mg, 0.020 mmol) was added to a mixture of aq. NaOH (2 mL, 
0.5 M) and methanol (0.5 mL). The resulting mixture was stirred for 36 h at r.t.. LCMS 
analysis showed complete conversion of starting material and the resulting crude material 
was purified by preparative RP-HPLC [gradient: 0 − 100% methanol in water (0.1% 
formic acid), over 10 min; tR = 7.3 min] to give product L6 as a light yellow solid (14 mg, 
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61%); m.p. 186–188 °C;  1H NMR (D2O) δ 8.23 (br s, 2H, H
4
), 8.00 (br s, 2H, H
5
), 7.71 (br 
s, 2H, H
6
), 7.34 (br s, 4H, H
13
), 7.15 (br s, 4H, H
12
), 7.06 (m, 4H, H
3
 and H
14
), 6.94 (s, 2H, 
H
8
), 3.72 (s, 4H, H
9
), 3.38 (s, 4H, H
15
), 3.18 (br s, 4H, H
17
), 2.21 (br s, 4H, H
18
), ring NH 
signals not observed; m/z (ESI
+
) 981.4724 [M+H]
+
 (C52H61N12O8 requires 981.4730); 
 
Analytical RP-HPLC trace of L6; [gradient: 0 − 100% methanol in water (0.1% 
formic acid), over 10 min; tR = 7.3 min]. 
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Di-tert-butyl 2,2'-(7,10-bis((7-acetamidoquinolin-2-yl)methyl)-1,4,7,10-
tetraazacyclododecane-1,4-diyl)diacetate (2.35) 
 
To a solution of the bis amine 2.27 (63 mg, 0.16 mmol) in anhydrous acetonitrile (8 
mL) was added potassium carbonate (110 mg, 0.80 mmol) and mesylate ester 2.19 (103 
mg, 0.35 mmol). The reaction mixture was stirred at 60 °C under an atmosphere of 
nitrogen for 18 h. The resulting mixture was centrifuged (1500 rpm, 3 min) and the filtrate 
was separated from potassium salts and evaporated under reduced pressure. The crude 
material was purified by column chromatography (silica gel; neat dichloromethane, to 
dichloromethane/methanol, 88/12 v/v) to give compound 2.35 (87 mg, 68%) as a white 
solid; 
1
H NMR (400 MHz, CDCl3) δ 8.15 (br s, 2H, H
4
), 7.98 (s, 2H, H
8
) , 7.79 (d, J = 8.0 
Hz, 2H, H
5
), 7.42 (d, J = 8.0 Hz, 2H, H
6
), 7.00 (br s, 2H, H
3
), 3.41 (s, 4H, H
9
), 2.82 (br s, 
4H
12
), 2.18 (s, 6H, H
11
), 1.33 (s, 18H, H
15
), signals for ring CH2 are obscured, NH signals 
not observed; 
13
C NMR (400 MHz, CDCl3) δ 171.9 (C
13
), 170.3 (C
10
), 158.0 (C
2
), 148.2 
(C
8’
), 140.6 (C
7
), 136.5 (C
4
), 127.7 (C
5
), 123.8 (C
4’
), 121.9 (C
6
), 120.7 (C
3
), 117.9 (C
8
), 
82.4 (C
14
), 60.0 (ring CH2), 56.5 (C
9
), 50.6 (C
12
), 49.6 (ring CH2), 28.09 (C
15
), 24.4 (C
11
); 
m/z (ESI
+
) 797.4709 [M+H]
+
 (C44H61N8O6 requires 797.4693) Rf = 0.5 (silica, 
dichloromethane/methanol, 9/1 v/v). 
 
2,2'-(7,10-bis((7-acetamidoquinolin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4-
diyl)diacetic acid (cis-L2) 
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To the macrocycle 2.35 (87 mg, 0.11 mmol) was added trifluoroacetic acid (5 mL). 
The reaction mixture was stirred at room temperature under an atmosphere of nitrogen for 
18 h. The resulting mixture was purified by preparative RP-HPLC [gradient: 0 − 100% 
methanol in water (0.1% formic acid), over 10 min; tR = 6.0 min] to give product cis-L2 as 
a yellow solid (62 mg, 84%); 
1
H-NMR (MeOD) δ 8.31 (s, 2H, H8), 7.92 (d, J = 8.0 Hz, 2H, 
H
4
), 7.73 (d, J = 8.5 Hz, 2H, H
5
), 7.65(d, J = 8.5 Hz, 2H, H
6
), 7.42 (d, J = 8.0 Hz, 2H, H
3
), 
4.19 (s, 4H, H
9
), 3.64 (s, 4H, H
12
), 2.24 (s, 6H, H
11
), signals for ring CH2 are obscured, NH 
signals not observed; 
13
C-NMR (MeOD) δ 171.6 (C13), 170.7 (C10), 166.3 (C2), 147.2 (C8’), 
140.2 (C
7
), 137.1 (C
4
), 127.91 (C
5
), 124.25 (C
4’
), 120.7 (C
6
), 120.2 (C
3
), 116.3 (C
8
), 56.0 
(C
9
), 50.6 (C
12
), 22.7 (C
11
), ring CH2 difficult to determine. m/z (ESI
+
) 685.3441 [M+H]
+
 
(C36H45N8O6
+
 requires 685.3457); 
 
[Eu.1]
+  
Ligand L1 (21 mg, 0.029 mmol) was dissolved in a mixture of methanol/water (2 
mL, 1:1 v/v) and the pH of the solution was raised to 8.5 by the addition of KOH (1 M). 
EuCl3.6H2O (11.6 mg, 0.032 mmol) was added and the solution was stirred at 60 °C under 
argon for 24 h. The mixture was cooled to room temperature and the crude material was 
purified by preparative RP-HPLC [gradient: 2 − 100% acetonitrile in 25 mM NH4CO3 over 
10 min], to give [Eu.1]
+ 
as a colourless solid (10 mg, 48%); 
1
H NMR (400 MHz, D2O) 
spectral range of 76 ppm (47.0 to -29.2 ppm), 46.9, 29.4, 17.8, 16.5, 15.1, 14.7, 12.8, 11.2, 
11.0, 9.4, 9.1, 7.0, 6.0, 3.9, 3.6, 3.2, 3.0, 2.7, 2.2, 2.1, 0.2, -1.9, -2.5, -5.9, -6.2, -7.4, -11.9, -
12.5, -13.5, -17.2, -18.6, -27.3, -27.4, -27.9, -29.2; m/z (ESI
+
) 719.2000 [M+H]
+
 
(C32H36N6O4Eu
 requires 719.1997); εH2O = 11800 M
-1
 cm
-1
;  H2O  23%, ν(H2O) = 0.51 ms, 
ν(D2O) = 1.37 ms, hydration state q = 1.1. 
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Analytical RP-HPLC trace of [Eu.1]
+
; tR = 6.84 min [gradient: 2 − 100% 
acetonitrile in 25 mM NH4CO3 over 15 min] 
 
1
H NMR (400 MHz) spectrum of [Eu.1]
+ 
recorded in D2O. 
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[Eu.2]
+  
To a solution of pure deprotected ligand L2 (16 mg, 0.021 mmol) in a mixture of 
water (20 mL) and methanol (26 mL) was added europium(III) chloride (8.3 mg, 0.023 
mmol). The pH was adjusted to 8.0 by addition of NaOH (0.5 M) and the reaction mixture 
was stirred at 60°C for 18 h. The methanol was removed under reduced pressure and the 
water by lyophilisation, to give [Eu.2]
+ 
as a white solid. 
1
H NMR (400 MHz, D2O) spectral 
range of  77 ppm (+47.2 to -30.0 ppm), 47.3, 29.6, 17.8, 16.4, 16.0, 15.2, 14.7, 13.1, 11.8, 
11.0, 9.4, 9.1, 7.0, 6.0, 4.0, 3.4, 2.8, 2.4, 1.9, 1.7, -0.5, -2.1, -2.2, -5.6, -6.5, -7.3, -12.0, -
12.4, -14.0, -17.4, -18.7, -27.8, -28.1, -30.0, two signals obscured or overlapping, N-H 
signals not observed; m/z (ESI
+
) 833.2444 [M+H]
+
 (C36H42N8O6Eu 
 
requires 833.2426); 
εH2O = 12500 M
-1
 cm
-1
;  H2O  5%, ν(H2O) = 0.45 ms, ν(D2O) = 1.54 ms, hydration state q = 
1.2. 
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Analytical RP-HPLC trace of [Eu.2]
+
; tR = 6.75 min [gradient: 2 − 100% 
acetonitrile in 25 mM NH4CO3 over 15 min] 
 
1
H NMR (400 MHz) spectrum of [Eu.2]
+ 
recorded in D2O. 
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[Eu.3]
+ 
To a solution of ligand L3 (5 mg, 0.006 mmol) in methanol (3 mL) was added 
europium triflate (4.3 mg, 0.007 mmol). The reaction mixture was stirred at 60 °C 2 hours 
in the microwave. The organic solvent was removed under reduced pressure to give 
product [Eu.3]
+
 as a light yellow solid (0.8 mg, 14%); m/z (ESI
+
) 989.2993 [M+H]
+
 
(C52H58EuN12O8 requires 989.2965); λmax = 342 nm; εH2O = 6000 M
-1
 cm
-1
; ν(H2O) = 1.08 
ms, ν(D2O) = 1.72 ms, hydration state, q = 0.0. Due to the limited amount of sample no 
NMR data could be recorded. 
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[Eu.4]
+
 
The protected ligand L4 (107 mg, 0.140 mmol) was dissolved in methanol (1 mL) 
and added to a mixture of aqueous NaOH (2 mL, 0.5M) and methanol (0.5 mL). The 
resulting mixture was stirred for 24 h at room temperature under a nitrogen atmosphere to 
give the deprotected ligand in quantitative yield; m/z (ESI
+
) 713.3772 [M+H]
+
 
(C38H49N8O6
 
requires 713.3770). Half of the deprotected ligand (0.068 mmol) was 
dissolved in water and the pH of the solution was adjusted to 7 by addition of HCl (1 M) 
and europium chloride (25 mg, 0.068 mmol) was added. The reaction mixture was stirred 
at 60°C for 18 h. The methanol was removed under reduced pressure and the resulting 
mixture was lyophilised to give a white solid, which was purified by preparative RP-HPLC 
[gradient: 0 − 100% acetonitrile in 50 mM NH4HCO3 over 10 min; tR = 5.3 min] to give 
[Eu.4]
+ 
as a white solid (20 mg, 17 %); 
1
H NMR (400 MHz, MeOD) spectral range of 54 
ppm (33.6.0 to -20.8 ppm), 33.6, 28.3, 24.9, 19.4, 14.6, 12.8, 12.7, 12.4, 11.8, 11.3, 10.8, 
10.7, 10.4, 10.0, 9.7, 9.5, 9.1, 8.9, 8.5, 8.3, 8.0, 7.8, 7.6, 6.2, 5.4, 4.0, 3.2, 3.0, 2.5, 2.2, 2.1, 
1.9, 1.6, 1.4, 1.2,0.9, 0.8, 0.2, 0.1, -0.6, -1.1, -1.6, -2.0, -2.2, -2.5, -3.2, -3.7, -4.5, 5.4, -5.6, 
-6.4, -6.6, -7.1, -7.4, -7.8, -8.1, -8.9, -9.6, 10.4, -11.4, -13.4, -14.6, -15.6, -15.9, -17.9, -
18.12, -19.7, -20.8; m/z (ESI
+
) 863.2740 [M+H]
+
 (C38H46EuN8O6
 requires 863.2747); λmax 
= 318 nm; εH2O = 21000 M
-1
 cm
-1
;  H2O  18%, ν(H2O) = 0.60 ms, ν(D2O) = 1.29 ms, 
hydration state q = 0.7. 
 
Analytical RP-HPLC trace of [Eu.4]
+
; tR = 4.93 min [gradient: 2 − 100% 
acetonitrile in 50 mM NH4CO3 over 15 min] 
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1
H NMR (400 MHz) spectrum of [Eu.4]
+ 
recorded in CD3OD. 
 
[Eu.5]
+
 
To a solution of pure deprotected ligand L5 (17 mg, 0.021 mmol) in a mixture of 
water (20 mL) and methanol (26 mL) was added europium(III) chloride (8.5 mg, 0.023 
mmol). The pH was adjusted to 8.0 by addition of NaOH (0.5 M) and the reaction mixture 
was stirred at 60°C for 18 h. The methanol was removed under reduced pressure and the 
water by lyophilisation, to give [Eu.5]
+ 
as a white solid. m/z (ESI
+
) 977.3165 [M+H]
+
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(C42H52EuN10O8
+
 requires 977.3176); λmax = 328 nm; εH2O = 7700 M
-1
 cm
-1
;  H2O  6.5%, 
ν(H2O) = 0.56 ms, ν(D2O) = 1.22 ms, hydration state, q = 0.8. 
 
 
Analytical RP-HPLC trace of [Eu.5]
+
; tR = 4.78 min [gradient: 2 − 100% 
acetonitrile in 50 mM NH4CO3 over 15 min] 
 
 
[Eu.6]
+ 
To a solution of ligand 7 (34 mg, 0.035 mmol) in methanol (3 mL) was added 
europium triflate (25 mg, 0.042 mmol). The reaction mixture was stirred at 60 °C 2 hours 
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in the microwave. The organic solvent was removed under reduced pressure to give 
product [Eu.6]
+
 as a light yellow solid (6 mg, 15%); m/z (ESI
+
) 566.1938 [M+H]
2+
 
(C52H59EuN12O8 requires 566.1890); more than 5 ppm; λmax = 344 nm; ν(H2O) = 1.16 ms, ν(D2O) 
= 3.03 ms, hydration state, q = 0.2. 
 
 
[Eu.cisL2]
+
 
To a solution of pure deprotected ligand cisL2 (20 mg, 0.0291 mmol) in a mixture 
of water (4 mL) and methanol (4 mL) was added europium(III) chloride (11 mg, 0.029 
mmol). The pH was adjusted to 8.0 by addition of NaOH (0.5 M) and the reaction mixture 
was stirred at 60°C for 18 h. The methanol was removed under reduced pressure and the 
water by lyophilisation, to give [Eu.cisL2]
+ 
as a white solid; m/z (ESI
+
) 825.2422 [M+H]
+
 
(C36H42EuN8O6
+
 requires 825.2434); λmax = 328 nm; εH2O = 14000 M
-1
 cm
-1
;  H2O  9.6%; 
ν(H2O) = 0.65 ms, ν(D2O) = 1.39 ms, hydration state, q = 0.7. 
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[Tb.2]
+ 
To a solution of pure deprotected ligand L2 (10 mg, 0.015 mmol) in a mixture of 
water (2 mL) and methanol (2 mL) was added Terbium(III) chloride (6 mg, 0.016 mmol). 
The pH was adjusted to 8.0 by addition of NaOH (2 M) and the reaction mixture was 
stirred at 60°C for 18 h. The methanol was removed under reduced pressure and the water 
by lyophilisation, to give [Tb.2]
+ 
as a white solid.  
 
7-(t-Butoxycarbonylamino)-2-((methylsulfonyloxy)methyl)quinoline (2.36) 
27
 
7-(t-Butoxycarbonylamino)-2-quinolinylmethanol 2.8 (0.410 g, 1.5 mmol) was 
dissolved in anhydrous tetrahydrofuran (15 mL) and cooled to 5 °C. Triethylamine (300 
µL, 2.25 mmol) and methanesulfonyl chloride (139 µL, 1.8 mmol) were added and the 
mixture was stirred under argon at rt for 30 min. Solvent was removed under reduced 
pressure and the residue was partitioned between dichloromethane (40 mL) and brine (40 
mL). The aqueous layer was extracted with dichloromethane (3 × 40 mL) and the 
combined organic layers were dried (MgSO4), filtered and evaporated under reduced 
pressure to give compound 2.36 as a yellow oil (0.486 g, 92%), which was used in the next 
step without further purification; 
1
H NMR (400 MHz, CDCl3) δ 8.18 (d, 
3
J 8.0Hz, 1H, H
4
), 
7.96 (d,
 4
J 2.0Hz, 1H, H
8
), 7.84 (d, 
3
J 9.0 Hz, 1H, H
5
), 7.78 (d, 
3
J 9.0 Hz,
 4
J 2.0Hz, 1H, 
H
6
), 7.49 (d,
 3
J 8.0Hz, 1H, H
3
), 6.83 (s, 1H, NH), 5.50 (s, 2H, H
9
), 3.12 (s, 3H, H
13
), 1.55 
(s, 9H, H
12
); m/z (ESI
+
) 353.1171 [M+H]
+
 (C16H21N2O5 requires 353.1171); Rf = 0.55 
(silica, ethyl acetate: hexane, 50/50 v/v). The spectral data were consistent with those 
reported previously.
27
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Di-tert-butyl 2,2'-(4,10-bis((7-((tert-butoxycarbonyl)amino)quinolin-2-yl)methyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (2.37) 
To a solution of the bis amine 2.23 (182 mg, 0.450 mmol) in anhydrous acetonitrile 
(10 mL) was added potassium carbonate (311 mg, 2.25 mmol) and mesylate ester 2.36 
(352 mg, 1.00 mmol). The reaction mixture was stirred at 60 °C under an atmosphere of 
nitrogen for 18 h. The resulting mixture was centrifuged (1500 rpm, 3 min) and the filtrate 
was separated from potassium salts and evaporated under reduced pressure. The crude 
material was purified by column chromatography (silica gel; neat dichloromethane, to 
dichloromethane/methanol, 92/10 v/v) to give compound 2.37 (214 mg, 52%) as a white 
solid; m/z (ESI
+
) 913.5527 [M+H]
+
 (C50H73N8O8 requires 913.5546); Rf = 0.6 (silica, 
dichloromethane/methanol, 9/1 v/v). 
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2,2'-(4,10-bis((7-aminoquinolin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)diacetic acid (L7) 
To the macrocycle 2.37 (52 mg, 0.057 mmol) was added trifluoroacetic acid (1 
mL). The reaction mixture was stirred at room temperature under an atmosphere of 
nitrogen for 18 h. The resulting mixture was purified by preparative RP-HPLC [gradient: 0 
− 100% methanol in water (0.1% formic acid), over 10 min; tR = 4.8 min] to give product 
L7 as a white solid (28 mg, 82%); 
1
H NMR (400 MHz, D2O) δ 8.31 (d, J = 8.0 Hz, 2H, 
H
4
), 7.53 (d, J = 9.0 Hz, 2H, H
5
), 7.36 (d, J = 8.0 Hz, 2H, H
3
), 6.89 (d, J = 9.0 Hz, 2H, H
6
), 
6.61 (s, 2H, H
8
), 3.99 (s, 4H, H
12
), 3.44 (br s, 12H, ring CH2), 2.98 (br s, 4H, H
9
), 2.87 (br 
s, 4H, ring CH2);
13
C NMR (400 MHz, D2O) δ 168.4 (C
11
), 154.7 (C
2
), 149.2 (C
8’
), 145.0 
(C
4
), 141.7 (C
4’
), 130.6 (C
5
), 122.8 (C
7
), 121.9 (C
6
), 117.2 (C
3
), 96.1 (C
8
), 56.4 (C
9
), 54.5 
(C
10
), 51.1 (ring C), 47.4 (ring C); m/z (ESI
+
) 601.3236 [M+H]
+
 (C32H41N8O4 requires 
601.3245); 
 
Analytical RP-HPLC trace of compound L7; [gradient: 0 − 100% methanol in 
water (0.1% formic acid), over 10 min; tR = 4.8 min] 
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[Eu.7]
+ 
To a solution of pure deprotected ligand L7 (20 mg, 0.029 mmol) in a mixture of 
water (4 mL) and methanol (4 mL) was added europium(III) chloride (11 mg, 0.030 
mmol). The pH was adjusted to 8.0 by addition of NaOH (0.5 M) and the reaction mixture 
was stirred at 60°C for 18 h. The methanol was removed under reduced pressure and the 
water by lyophilisation, to give [Eu.7]
+ 
as a white solid. m/z (ESI
+
) 751.2206 [M+H]
+
 
(C32H38N8O4 requires 751.2223); 
 
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl chloride (2.38)
194
 
To a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (10 
mg, 0.039 mmol) in dichloromethane (2 mL) was added oxalyl chloride dropwise (4 µL, 
0.047 mmol) and a drop of dimethylformamide. The resulting mixture was stirred at room 
temperature for one hour and gas formation was observed. The solvent was evaporated and 
the residue used in the next step without further purification. 
1
H-NMR (400 MHz, CD3CN) 
8.36 (s, 1H, H
7
), 8.18 (dd, J = 7.8, 1.2 Hz, 1H, H
5
), 8.02 (s, 1H, H
3
), 7.58 (t, J = 7.6 Hz, 
1H, H
4
), 1.31 (s, 12H, H
9
); 
13
C-NMR (400 MHz, CD3CN) δ 168.4 (C
1
), 141.4 (C
7
), 137.1 
(C
5
), 133.8 (C
3
), 132.6 (C
2
), 129.1 (C
4
), 84.6 (C
8
), 24.3 (C
9
), the carbon 6 attached to the 
boron is hidden in the baseline; Low resolution mass spectrometry: m/z (ESI
+
) 267.1 
188 
 
[M+H]
+
 (C13H17BClO3 requires 267.1); The spectral data were consistent with those 
reported previously.
194
 
 
[Eu.8]
+ 
To the macrocycle [Eu.7]
+
 (13 mg, 0.016 mmol) in dry acetonitrile (3 mL) and 
diisopropylamine (14 µL, 0.08 mmol) was added 3-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)benzoyl chloride 2.38 (10.4 mg, 0.039 mmol) and the reaction was left 
to react over 18 h at room temperature. LCMS analysis showed complete conversion of 
starting material and the mixture was purified by preparative RP-HPLC [gradient: 0 − 
100% methanol in water (0.1% formic acid), over 10 min; tR = min] to give product 
[Eu.8]
+
 as a white solid (1 mg, 6%); m/z (ESI
+
) 1047.2875 [M+H]
+
 (C46H48B2EuN8O10
+
 
requires 1047.2886); λmax = 333 nm;  H2O  4.6%; ν(H2O) = 0.92 ms, ν(D2O) = 2.42 ms, 
hydration state, q = 0.5.  
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 Appendices Chapter 9:
Spectroscopic studies of [Eu.1–4]+  
 
Figure 9.1: Change in absorption spectra of [Eu.1]
+
 as a function of concentration. 
Inset shows the fit to the experimental data, with a molar extinction coefficient, ε = 
11,800 M
-1
.cm
-1
, 318 nm. Conditions: 10 mM HEPES buffer, pH 7.0. 
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Figure 9.2: Change in absorption spectra of [Eu.2]
+
 as a function of concentration. 
Inset shows the fit to the experimental data, with a molar extinction coefficient, ε = 
12,500 M
-1
.cm
-1
, 332 nm. Conditions: 10 mM HEPES buffer, pH 7.0. 
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Figure 9.3: Change in absorption spectra of [Eu.4]
+
 as a function of concentration. 
Inset shows the fit to the experimental data, with a molar extinction coefficient, ε = 
21,000 M
-1
.cm
-1
, 318 nm. Conditions: 10 mM HEPES buffer, pH 7.0. 
 
 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
260 280 300 320 340 360 380 400 420 440
A
b
s
o
rb
a
n
c
e
  
Wavelength / nm 
y = 21084x + 0.014 
R² = 0.9999 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0 0.01 0.02 0.03
A
b
s
o
rb
a
n
c
e
 
Concentration / mM 
202 
 
 
Figure 9.4: Change in absorption spectra of [Eu.5]
+
 as a function of concentration. 
Inset shows the fit to the experimental data, with a molar extinction coefficient, ε = 
7,700 M
-1
.cm
-1
, 330 nm.  Conditions: 10 mM HEPES buffer, pH 7.0. 
 
Table 9.1: Lifetime measurements and hydration state, q, of complexes [Eu.1–4]+ 
in the presence and absence of ATP and HSA. [a] Values of hydration state, q, 
(±20%) are derived using the methods reported in reference 
110
.  
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Lifetime in D2O (ms) q
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Figure 9.5: Change in emission spectra of [Eu.1]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.0 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 °C. 
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Figure 9.6: Change in emission spectra of [Eu.1]
+
 (5 μM) as a function of added 
ADP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.3 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 
°C. 
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Figure 9.7: Change in emission spectra of [Eu.1]
+
 (5 μM) as a function of added 
AMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.3 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.8: Change in emission spectra of [Eu.1]
+
 (5 μM) as a function of added 
PPi in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 2.4 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 °C 
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Figure 9.9: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 4.4 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 °C. 
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Figure 9.10: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
ADP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.6 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.11: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
AMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.4 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.12: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
GTP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 4.4 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 °C. 
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Figure 9.13: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
GDP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.6 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.14: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
GMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.4 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
 
0
10
20
30
40
50
60
550 570 590 610 630 650 670 690 710
In
te
n
s
it
y
 
Wavelength / nm 
1.3
1.5
1.7
2.0
2.2
0 0.0005 0.001
6
0
5
-6
3
0
 /
 5
8
0
-6
0
0
 
[GMP] / M 
213 
 
 
Figure 9.15: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
UTP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.6 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 °C. 
0
10
20
30
40
50
60
550 570 590 610 630 650 670 690 710
In
te
n
s
it
y
 
Wavelength / nm 
1.25
1.53
1.80
2.07
2.35
0 0.001 0.002
6
0
5
-6
3
0
 /
 5
8
0
-6
0
0
 
[UTP] / M 
214 
 
 
Figure 9.16: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
UDP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.2 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.17: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
UMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 2.7 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.18: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
PPi in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.5 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 °C. 
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Figure 9.19: Change in emission spectra of [Eu.2]
+
 (5 μM) as a function of added 
HPO4
2-
 in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 2.1 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 332 nm, 25 
°C. 
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Figure 9.20: Change in emission spectra of [Eu.4]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 °C. 
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Figure 9.21: Change in emission spectra of [Eu.4]
+
 (5 μM) as a function of added 
ADP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 
°C. 
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Figure 9.22: Change in emission spectra of [Eu.4]
+
 (5 μM) as a function of added 
AMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 3.5 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 
°C. 
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Figure 9.23: Change in emission spectra of [Eu.4]
+
 (5 μM) as a function of added 
PPi in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.3 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 318 nm, 25 °C. 
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Figure 9.24: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ATP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 5.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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Figure 9.25: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
ADP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 5.7 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.26: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
AMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.8 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.27: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
GTP in aqueous solution at pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 5.3 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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Figure 9.28: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
GDP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 5.2 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.29: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
GMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.2 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.30: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
UTP in aqueous solution pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 4.9 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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Figure 9.31: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
UDP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 5.3 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.32: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
UMP in aqueous solution at pH 7.0. The inset shows the fit to the experimental 
data, for log Ka = 4.3 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 
°C. 
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Figure 9.33: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
PPi in aqueous solution pH 7.0. The inset shows the fit to the experimental data, for 
log Ka = 4.7 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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Figure 9.34: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
HPO4
2-
 in aqueous solution pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 2.7 (± 0.1). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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Figure 9.35: Change in emission spectra of [Eu.5]
+
 (5 μM) as a function of added 
HCO3
-
 in aqueous solution pH 7.0. The inset shows the fit to the experimental data, 
for log Ka = 3.0 (± 0.2). Conditions: HEPES buffer (10 mM), λexc 330 nm, 25 °C. 
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High Resolution Mass Spectra of Ternary Adducts 
 
Figure 9.36: High resolution mass spectral data for [Eu.5+GTP+5H]
2+
 
(EuC52H69N15O21P3). 
 
Figure 9.37: High resolution mass spectral data for [Eu.4+ATP+3H]
2+
 
(EuC48H63N13O19P3). 
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Figure 9.38: High resolution mass spectral data for [Eu.4+GTP+3H]
2+
 
(EuC48H63N13O20P3). 
 
Figure 9.39: High resolution mass spectral data for [Eu.2+ATP+2H]
-
 
(EuC46H56N13O19P3) and high resolution mass spectral data for [Eu.2+ADP+H]
-
 
(EuC46H55N13O16P2). Data collected by Dr. Sarah Hewitt. 
Calculated 
Observed 
236 
 
X-Ray 
 
Figure 9.40: Projective view of the unit cell on the direction of a of the complex 
[Eu.2]
+
. 
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Figure 9.41: 
31
P NMR spectra of [Eu.2]
+
 with 1 equivalent of ATP. 
 
Figure 9.42: 
31
P NMR spectra of [Eu.2]
+
 with 1 equivalent of ATP irradiating at -
60 ppm. 
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Figure 9.43: 
31
P NMR spectra of [Eu.2]
+
 with 1 equivalent of ATP irradiating at -
36 ppm. 
 
Figure 9.44: 
31
P NOESY spectra of [Eu.2]
+
 with 1 equivalent of ATP. 
